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Since its application by Dr Edward Jenner in the 18th century, vaccination has 
revolutionized medicine. Large scale vaccination campaigns have resulted in the eradication of 
smallpox and the World Health Organization has set targets to eradicate polio, rubella and 
measles using a world wide vaccination strategy [1]. The goal of vaccination is to prime an 
individuals’ immune system against a specific pathogen, so on second encounter the immune 
system is capable of quickly removing the threat. The classical approach is to use a non-
pathogenic strain that closely resembles the pathogen (live-attenuated vaccines), or an 
inactivated pathogen. These vaccines generally provide good protection as they resemble the 
original pathogen the most. This approach, however, also brings safety risks. Vaccines based 
on live-attenuated or whole inactivated bacteria or viruses can contain a variety of biologically 
active compounds (e.g. toxins, bacterial cell membrane products) that can cause symptoms 
like fever and nausea. In the case of live-attenuated vaccines, reassortment with a wildtype 
virus could lead to regaining their pathogenicity. Moreover, in immuno-compromised patients 
these types of vaccines can cause disease symptoms, as these individuals are not capable of 
clearing the vaccines. Finally, most of these vaccines are injected intramuscularly or 
subcutaneously, as generally the large size and instability of the antigen does not allow 
application via mucosal routes. Injectable vaccines often cause pain/discomfort, local swelling 
(inflammation) and stiffness.  
Vaccine coverage in the Western world is not optimal, as the turn up of the various state 
vaccination programs hardly ever passes 70% [2-5]. Although part of the vaccination refusals is 
of religious nature, an increasing population does not want to be immunized fearing the side 
effects of the vaccine and the discomfort upon injection [6]. This has prompted governments 
and health organizations to enlarge their funds for research and development of (safer) 
subunit and non-invasive vaccines (e.g. dermal, nasal, oral, pulmonary) [7-9] as better patient 









Adverse effects can be reduced by stripping the virulence factors from a pathogen, leaving 
only the part to which the immune system has to make antibodies or a T-cell response. 
Subunit vaccines only contain this antigenic part of the pathogen (often only a single protein) 
and are therefore safer and pharmaceutically better defined [10]. Although some subunit 
vaccines have been applied very successfully (e.g. diphtheria toxoid, pertussis toxoid and 
tetanus toxoid), most of them do not completely protect the vaccinated population [11]. 
Paradoxically, because of the lack of co-stimulatory factors, the immunogenicity of these types 
of vaccines is reduced. This is a direct consequence of the nature of the immune system; it will 
only develop a response if the encountered material is considered dangerous [12]. Antigen 
presenting cells (APCs; e.g. macrophages, dendritic cells) play a crucial role in the decision 
making by the immune system whether or not to respond and are therefore the key target in 
vaccination (Figure 1). On encounter with a pathogen APCs engulf it and break it down into 
small fragments (epitopes). Meanwhile various constituents of the pathogen contribute to 
activation of the APC (Figure 1a), making the cell capable of initiating an adaptive (T- and B-
cell mediated) immune response [13]. These constituents are evolutionary conserved motives 
that are shared by many pathogens, so called pathogen associated molecular patterns 
(PAMPs), making it possible for the APC to distinguish between dangerous and innocuous 
antigens, via pathogen recognition receptors (PRR) [14, 15]. Plain subunit antigen will also be 
sampled by APCs, but because of the lack of PAMPs will be considered harmless and will not 
induce maturation of the APC (Figure 1b). It is therefore imperative to formulate the antigen 
in such a way that APCs do get activated e.g. by addition of PAMPs or the use of vaccine 
delivery systems [16]. 
 
Non-invasive vaccination 
Currently, most vaccines are injected subcutaneously or intramuscularly as it is a simple 
procedure and allows accurate dosing. This does not mean however that muscle and 
subcutaneous tissue are sites that provide the best environment for inducing an immune 
response. Before the introduction of the hollow needle in the 19th century, vaccines were 
usually applied nasally or scratched into the skin [17]. As the exterior of the body is under 
constant attack by invading pathogens, the skin and the mucosal linings are densely equipped 




Not surprisingly, studies comparing the antibody response after intramuscular and 
intradermal vaccination clearly show superior antibody titers after intradermal injection [19-
21]. Nonetheless intradermal vaccination did not establish itself as the standard 
administration method, because of poor protection in the elderly population but most of all 
















Similarly, very encouraging results were obtained by pulmonary vaccination against measles in 
Mexico [23], but the need for a delivery device (nebulizer) whereas intramuscular vaccination 
was just as effective, prohibited the widespread use of the pulmonary vaccine [24]. In this 
respect nasal and oral vaccination provide a more promising alternative. Oral application (e.g., 
as a tablet or capsule) may seem easy and convenient for the vaccinee, but the harsh gastro-
intestinal conditions compromises the vaccines’ stability. Currently, 1 inactivated and 4 live-
Figure 1: a) A bacterium is encountered by the APC (1) and subsequently engulfed (2). 
In the endosome the pathogen is degraded into epitopes (red) (3). Co-stimulatory  
factors (brown, green) on the bacterium activate the APC and make it express various 
co-stimulatory factors (4) enabling it to activate T- and B-cells. b) Plain subunit 
antigens encountered by a DC (1) are also taken up (2) and degraded into epitopes 
(3), but lack of virulence factors prohibits the activation of the APC (4). 
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attenuated oral vaccines have been licensed (the polio vaccine already being administered 
over 1 billion times!), but no oral subunit vaccine has been marketed yet, illustrating the 
difficulty of making effective oral vaccines.  
 




The nasal cavity is easily accessible (e.g., nasal spray or nose drops) and the low enzymatic 
activity compared to the gastro-intestinal tract provides better antigen stability, making nasal 
administration very promising. Nonetheless, only 1 live attenuated flu vaccine (Flumist®) is on 
the market, showing that nasal vaccination is possible, but also challenging  
Although the nasal flu vaccine has been well perceived by the public [25], because of the 
live attenuated nature of the vaccine, it only recommended for use in a population between 




and the elderly. A subunit vaccine would be preferable, but until now only 1 nasal subunit 
vaccine had been licensed which had to be withdrawn from market because of presumed side 
effects of the adjuvant [26].   
The poor efficacy of nasally administered vaccines is caused by the physiology of the nasal 
cavity. Compared to muscle or subcutaneous tissue, the nasal cavity has a different 
immunologic build up, as it is a mucosal site. Moreover, the antigen has to find its way 
through several barriers (mucus, epithelium), in a limited time frame (nose cleared every 20 
minutes removing all constituents trapped in its mucus), before it is absorbed into the body. 
So, if nasal vaccination is to be successful, the vaccine’s formulation should be adapted to the 
challenges the physiology of the nasal cavity provides. Indeed, in the literature a wide variety 
of vaccine formulations are described (mainly tested in mice) that increase the efficacy of 
nasally administered antigen [27-32]. Although these studies are very encouraging and 
provide valuable information on the use of absorption enhancers and adjuvants, an integral 
approach combining the positive characteristics of these various formulations is hardly 
described. Increasing knowledge on the pathways and bottlenecks involved in nasal 
vaccination will make it possible to optimize the formulations and rationally design nasal 
vaccines. 
 
Aim and outline of this thesis 
Nasal vaccination has the potential to provide protection combined with more patient 
comfort and a higher safety profile than classical injectable vaccines. However, the nasal 
physiology and immunological aspects of the nasal epithelium hamper the efficacy of nasally 
administered vaccines.  
The aim of this thesis is therefore three-fold:  
• to identify the principal hurdles to successful nasal vaccine delivery;  
• to develop preclinical model systems to investigate these hurdles;  




In Chapter 2 the main physiological hurdles that have to be overcome to render nasal 
vaccination successful are reviewed. The progress made in the field of nasal delivery of 
subunit vaccines is described and emerging opportunities for improving nasal vaccines are 
discussed. 
Throughout this thesis ovalbumin (OVA), a 45-kDa protein purified from chicken eggs and 
widely used in immunology, was used as a model subunit antigen. As nasal administration of 
plain OVA does not result in effective seroconversion, the effectiveness of a nasal vaccine 
formulation can be easily assessed using this antigen. A model system to investigate one of 
the main physiological hurdles, penetration of the mucosal epithelium, is discussed in Chapter 
3. A cell culture system based on an intestinal epithelial cell line (Caco-2) including M-cells is 
introduced as tool to assess the transport of vaccine delivery systems through the mucosal 
epithelium. Moreover, monocyte derived human dendritic cells (DC) are explored to 
investigate the role of DC uptake and maturation. The predictive value of these in vitro assays 
is studied by intraduodenal vaccination with OVA encapsulated in two potential mucosal 
vaccine delivery systems, chitosan and N-trimethyl chitosan (TMC) nanoparticles. 
To address the mechanistics behind nasal vaccination, the characteristics of 3 nasal 
delivery systems, based on nanoparticles composed of PLGA, TMC, or both, are correlated to 
their capacity to induce antibody production (Chapter 4) and CD4+ T-cell activation (Chapter 5) 
or tolerance (Chapter 5) after nasal administration in mice. Moreover, a new method to assess 
the residence time of an antigen in the nasal cavity is introduced (Chapter 4). 
The effectiveness of cationic liposomes, a promising delivery system for injectable 
vaccines, as carriers for nasal vaccines is investigated in mice (Chapter 6) and compared to 
other application routes, i.e. epidermal, intradermal and intranodal administration. 
Furthermore, this chapter describes investigations on the usefulness of (1) encapsulating 
antigen in vesicles and (2) co-encapsulation or co-administration of an adjuvant. 
In Chapters 7-10 the knowledge gained from the first chapters on the mechanistics behind 
nasal vaccination is applied to improve the most promising delivery system tested, being 
nanoparticles based on TMC. In an attempt to make smaller TMC/antigen entities, TMC-
antigen conjugates are developed and characterized physicochemically and immunologically in 
Chapter 7. Nasal application of these conjugates and their interaction with various 




  Chapter 9 concerns the replacement of tripolyphosphate, a physical crosslinker used to 
prepare TMC nanoparticles, with the adjuvant CpG, acting as a crosslinking agent as well as an 
immune modulator, and the effect on particle characteristic and immunogenicity. In Chapter 
10 a variety of other adjuvants described in the literature are encapsulated in TMC 
nanoparticles and their effectiveness as immune potentiators as are assessed in mice. 
Chapter 11 summarizes the results and conclusions in this thesis. Moreover, future 
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Nasal vaccination is a promising alternative to classical parental vaccination, as it is non-
invasive and, in principle, capable of eliciting strong systemic and local immune responses. 
However, the protective efficacy of nasally administered antigens is often impaired because of 
delivery problems: free antigens are readily cleared from the nasal cavity, poorly absorbed by 
nasal epithelial cells and generally have low intrinsic immunogenicity. In this review paper, we 
describe the main physiological hurdles to nasal vaccine delivery, survey the progress made in 
technological approaches to overcome these hurdles and discuss emerging opportunities for 
improving nasal vaccines. According to current insights, encapsulation of the antigen into 
bioadhesive (nano)particles is a promising approach towards successful nasal vaccine delivery. 
These antigen-loaded particles can be tailor made by supplying them with targeting ligands, 
adjuvants or endosomal escape mediators to form the desired vaccine that provides long-



























Vaccination is the most cost effective way of fighting infectious diseases. Although some 
vaccination strategies have been very successful, novel approaches are needed to develop 
safe and effective vaccines against diseases like HIV/AIDS, malaria, influenza and cancer. 
Additionally, adverse reactions, like pain, fever, headaches, nausea and allergic reactions have 
led to declined patient compliance [1-6] and have prompted governments and health 
organizations to enlarge their funds for research and development of non-invasive vaccines [7-
9]. Among the potential needle free routes, nasal vaccination is particularly attractive. The 
nasal cavity had been the preferred delivery site until the introduction of the hollow needle in 
the 19th century [10]. In the search for alternatives to the needle, the interest in nasal 
vaccination has reemerged. This paper will review the main physiological hurdles that have to 
be overcome to render nasal vaccination successful, describe the progress made in the field of 






Nasal vaccination has several interesting advantages. The nose is easily accessible and the 
nasal cavity is equipped with a high density of dendritic cells (DC) that can mediate strong 
systemic and local immune responses against pathogens that invade the human body through 
the respiratory tract [11-13]. Mucosal immunity is mediated by secretory immunoglobulin A 
(sIgA) antibodies, which prevent pathogens from colonizing mucosal epithelia (e.g. respiratory 
tract, gastro intestinal tract) and hence clear the organisms before they invade the underlying 
tissue.  
Local immunity in the upper airways, as well as systemic immunity, is mainly mediated by 
the lymphoid tissue referred to as nasal associated lymphoid tissue (NALT). NALT is comprised 
of agglomerates of cells involved in the initiation and execution of an immune response, like 
DC, T-cells and B-cells [14], situated underneath the nasal epithelium. NALT is most 
pronounced in the nasopharynx and the Waldeyer’s ring, which includes the nasopharyngeal, 
tubal, palatine and lingual tonsils, making the adenoids an important part of the NALT. Indeed 
some studies have shown that sIgA excretion is dependent on these areas and tonsillectomy 
has been associated with decreased immunity [15, 16]. Moreover, Zuercher et al [17] showed 
the presence of germinal centers (places where plasma cells are located) in the NALT after 
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challenge with a reovirus, and Shimoda et al [18] showed that B-cells in the subepithelial 
region of the nose are prone to switch from IgM to IgA, indicating a role for the NALT as 
inductive site for immune responses. Mucosal immunity after nasal vaccination is, however, 
not restricted to the upper airways. Via a system called the common mucosal immune system, 
after nasal immunization sIgA antibodies also can be detected also in other mucosal 
secretions.  
In spite of the large effort that has been directed to developing nasal vaccines, only one 
nasal vaccine is currently on the market (Table I). Furthermore, nasal vaccine delivery may be 
compromised in patients with respiratory infections and the need for an effective delivery 
device should not be overlooked. In attempts made to improve the immunogenicity of nasal 
subunit vaccines, the vaccine formulation plays a crucial role, as will be further discussed 
below.  
 





*Based on [19] and [20] 
 
 
Roadmap to successful nasal vaccine delivery 
 
After nasal administration of a vaccine, a number of successive steps should lead to a 
protective immune response (Fig. 1). In this section we will describe these steps and discuss 
how a vaccine delivery system can enhance the immune response by promoting these steps. 
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Prolonging the nasal residence time 
After intranasal (i.n.) administration, the first step in the trajectory towards an immune 
response is that the antigen reaches the NALT. In principle, there is no direct contact between 
DC in the subepithelial regions of the nose and the antigen in the lumen, although it has been 
suggested that DC can partially penetrate the epithelium making them capable of sampling 
the mucosal surface [21]. Therefore, during the limited nasal residence time of the vaccine, 
the antigen must cross the nasal epithelium. Increasing the residence time of the vaccine 
(normally ca. 20 minutes), with use of mucoadhesive substances, may therefore be a possible 
approach to improve the efficacy of a vaccine (Fig. 1).  
 
M-cell targeting 
The mechanism of antigen uptake through the epithelium is somewhat controversial. The 
epithelium is composed of only a thin layer of pseudostratified epithelial cells, connected by 
tight junctions. Since the diameter of tight junctions is only a few Ångstroms [22], it is very 
unlikely that (killed) bacteria or viruses, bulky antigens, or particulate vaccine delivery systems 
are able to penetrate this barrier by paracellular transport even if the tight junctions are 
widened up [23]. Transcellular transport is a more likely route by which (particulate) antigens 
reach the NALT. In particular, microfold cells (M-cells) serve as a portal for particulate antigens 
to enter the subepithelial region [12, 24-26]. M-cells are part of the NALT and cover the 
subepithelial dome containing DC, B-cells and T-cells. M-cells do not contain cilia and have 
relatively high concentrations of cytoskeleton protein vimentin [27, 28], making M-cells easily 
accessible and flexible, respectively, to be involved in transmembranous transport [29]. 
Indeed, after recognition and internalization, M-cells can transport particulate antigens to the 
NALT, by transcytosis [30]. Unlike epithelial cells, M-cells have been reported to efficiently 
take up antigens with a particulate nature and deliver them to a lymphatic environment rather 
than to the systemic circulation. This may explain why the increased efficiency of particulate 
antigens is undisputed, whereas increased drug transport using particles is still under 
discussion [31]. Hence, improving the uptake of a vaccine through M-cells would target the 
antigen to the underlying immune cells, and may thereby contribute to higher immune 
responses (Fig. 1). 
 
DC signaling 
After antigen uptake, DC mature and migrate to the nearby cervical lymph nodes, where 
they present the peptides on MHC class 2 (MHC II) molecules to helper T (Th) cells. Upon 
recognition of the MHC II-peptide complex and costimulation from APC, naïve Th cells 
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differentiate into effector Th cells, which can be divided in two major subtypes: Th1 and Th2 
cells. Th1 cells are mainly involved in activation and proliferation of the cellular immune 
system, whereas Th2 cells are involved in stimulation and increase of the humoral immune 
responses. The DC signaling determines the fate of the naïve Th cell and can be influenced by 
the use of delivery systems and adjuvants. So, not only can delivery systems and adjuvants 
increase immune responses, they can also influence the Th1/Th2 balance, i.e. the type of 
immune response. Since the optimal balance of the immune reaction is dependent on the 
pathogen in question, induction of the desired type of immune response should be tailored 




























Schematic overview of 
the consecutive steps 
towards successful nasal 
vaccine delivery: 1) 
mucoadhesion; 2) 
antigen uptake, by M-
cell transport; 3) delivery 
to and subsequent 
activation/maturation of 
DC; 4) induction of B-cell 
and T-cell responses. DC 
= dendritic cell, M-cell = 
microfold cell, Th cell = 
helper T cell. 
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Induction of CTL immune responses.  
Obtaining immunity against intracellular pathogens like intracellular bacteria and viruses 
often requires the induction of CTL responses. The induction of CTL with a vaccine can only be 
achieved when a number of requirements are fulfilled. Firstly, the vaccine should contain class 
1 (MHC I) epitopes. Secondly, an MHC II epitope must be present in the vaccine, since a strong 
induction of CTL responses is only possible when Th cells are co-activated. Thirdly, the MHC I 





























Figure 2:  
Various mechanisms a 
vaccine formulation can 
exploit to induce the 
desired immune response. 
1) cytosolic delivery for 
targeting the antigen to 
MHC class I presentation; 
2) targeting the innate 
immune system through 
pathogen recognition 
receptors (PRR); 3) the use 
of toxin-based adjuvants; 
4) incorporation of 
cytokines or other 
costimulatory molecules. 




DC copulsed with a Th1 and a Th2 inducing antigen were shown to direct these antigens to 
distinct compartments, leading to different, antigen dependent polarization of the immune 
response [32]. Presentation of exogenous antigens by MHC I molecules is called cross 
presentation [33, 34]. Recently, it was described that the mechanism of antigen uptake, which 
dictates the intracellular destination compartment, is not only involved in the activation and 
polarization of Th cells, but also determines whether the antigen is presented to either CD4+ 
Th cells or CD8+ CTL. This would suggest that a DC itself is not polarized upon ingestion of an 
antigen; rather, each intracellular compartment can prepare different instructions that can be 
presented to different T cells by one DC [35, 36]. Targeting mediators in the vaccine 
formulation could be employed to facilitate the delivery of endocytosed antigens to the 
desired intracellular compartments and thereby promote cross presentation (Figure 2). 
 
Adjuvant targets. Adjuvants can be classified according to their mechanisms of action. One 
group of adjuvants acts through binding to pathogen recognition receptors (PRR) on cells. The 
binding of PAMP to PRR activates an intracellular signaling cascade in the innate immune cells, 
which eventually leads to DC maturation, cytokine production and costimulatory signaling to 
Th cells (Fig. 2). 
The Toll-like receptor (TLR) family is a group of PRR that has been characterized in detail 
[37]. TLR are expressed by DC and recognize PAMP (Fig. 2) like lipopolysaccharide (LPS), 
dsRNA, CpG motifs and bacterial lipoproteins [38, 39]. Simultaneous stimulation of these 
innate immune receptors and antigen delivery to the DC generally leads to Th1 responses and 
Th1 dependent antibody isotypes [37], but some TLR ligands induce Th2 cytokines upon 
activation of the TLR [40]). 
 Another group of adjuvants are toxin based adjuvants. Enterotoxins like the cholera 
toxin (CT) and the Escherichia coli heat labile toxin (LT) are strong mucosal adjuvants that 
induce mucosal as well as serum antibody responses [41, 42]. LT and CT consist of a toxic A 
subunit with ADP-ribosyltransferase activity, which is linked non-covalently to a pentamer of B 
subunits that bind to ganglioside GM-1 receptors found on most cells [43]. Since the use of LT 
has been associated with neurological toxicity, efforts have been made to develop non-toxic 
mutants of LT and CT. The exact mechanism of adjuvanticity of toxin-based adjuvants is not 
fully understood, but the toxins CT and LT induce expression of B7 molecules on DC that can 
subsequently deliver costimulatory signals to Th cells (Fig. 2) [44].  
 Cytokines are probably the critical communication molecules of most classical 
adjuvants [45]. Therefore cytokines and other costimulatory molecules have been evaluated 
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as adjuvants to promote T-cell activation (Fig. 2). Similary, antibodies mimicking the binding of 
these molecules to receptors on the T-cells have been tested as adjuvants. 
 
 
Approaches to improve nasal vaccine delivery 
 
In this section we discuss, based on the roadmap described in the previous section, several 
approaches that have been described in the literature to improve the delivery and 




Subunit antigens, having little affinity for the nasal epithelium, are generally cleared within 
minutes. Prolonging the residence time is commonly accomplished by coadministering the 
antigen with mucoadhesives, usually polymers. The term mucoadhesive does not discriminate 
between the interaction with either the mucosal cell surface or the mucus covering this 
surface. If the adhesive also interacts with the antigen, both interactions can lead to a 
decreased mucociliary clearance of antigens. 
Recently, Smart gave an overview of the basics and mechanisms of mucoadhesion [46]. 
Briefly, properties like hydrophilicity, crosslinking, charge, molecular weight and the presence 
of acidic or alkaline functional groups influence the mucoadhesion of a polymer. 
Mucoadhesive polymers can be divided in 3 categories according to their mechanism of 
interaction. The first category includes hydrophilic polymers that adsorb to the mucus by 
forming hydrogen bonds, like sodium alginate, sodium carboxymethylcellulose, hydroxypropyl 
methylcellulose and carbopol. The second class comprises cationic polymers, like chitosan-
derived polymers interacting with the negatively charged mucin mainly by ionic interactions, 
although hydrogen bonds could also play a role [47, 48]. Additionally, chitosan derivatives can 
open tight junctions and thereby can increase the permeability of the epithelium [49], but its 
significance for improved antigen delivery is questionable. The third class of mucoadhesives 
involves thiolated polymers, thiomers, that can form covalent disulfide bonds with the cystein 
groups in mucin [50]. Recent studies show that thiomers are the strongest mucoadhesives 
[51].  
Antigens coadministered with mucoadhesive polymers, like hyaluronic acid [52], chitosan 
[53] and carboxylmethylcellulose [54] have indeed shown increased antibody responses as 
compared to application of the antigen without any additives. However, serum antibody levels 
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reached by coadministration of Bordetella pertussis hemagglutinin vaccine [55], diphtheria 
toxoid [56], tetanus toxoid [57], anthrax protective protein [57], inactivated influenza virus 
[58] or herpesvirus 1 glycoprotein [59] with chitosan never exceeded levels reached by 
intramuscular (i.m.) injection, despite the capability of chitosan to increase the nasal residence 
time [60]. Clearly, a prolonged residence time is not the sole determinant for a successful 
vaccine.  
 
Particulate antigen carriers  
Uptake of antigens through the nasal epithelium can be increased by incorporation into 
particles [61]. For instance, i.n. administration in mice of antigens incorporated in 
nanoparticles composed of poly lactide-co-glycolide (PLGA), a biodegradable polymer, led to 
over 100 fold increased antibody responses in comparison with aqueous solution of 
parainfluenza virus proteins [62], hepatitis B soluble antigen [63], Bordetella bronchiseptica 
dermonecrotoxin [64] and recombinant HIV proteins [65]. Polystyrene beads loaded with 
hemagglutinin led to increased protection against influenza in mice [66], probably due to 
enhanced antigen uptake [67]. Nasal application of liposomes loaded with killed measles virus 
[68], formaldehyde-killed Yersinia pestis [69], or influenza A hemagglutinin [70] even elicited 
superior IgG antibody levels than i.m. administered alum adsorbed antigen.  
 Mucoadhesive particles. Particles composed of mucoadhesive polymers are even more 
effective antigen carriers, as they combine prolonged residence time in the nasal cavity with 
the beneficial properties of particulate systems. Chitosan particles are well-known 
mucoadhesive antigen carriers. Coadministration of soluble chitosan with cholera toxoid or 
ovalbumin (OVA) induced higher immune responses than administration of antigen alone, but 
incorporation of the CT or OVA antigen into chitosan nanoparticles resulted in superior serum 
antibody levels in rats [71]. Similarly, Amidi et al showed that nasally applied influenza 
antigens incorporated in trimethylated chitosan (TMC) nanoparticles elicited superior IgG and 
sIgA antibody response as compared to naked antigen or antigen coadministered with TMC 
[72]. 
Alternatively, particulate antigen carriers can be rendered mucoadhesive by coating them 
with mucoadhesive polymers. Intranasal vaccination with hepatitis B surface antigen (HBsAg) 
encapsulated in chitosan coated PLGA particles resulted in a 30 fold increase of serum IgG 
levels in comparison with uncoated HBsAg loaded PLGA particles [73]. Vila et al showed that 
chitosan coating of tetanus toxoid-containing PLA particles increases transport through the 
nasal epithelium in comparison with uncoated particles [74]. The increased transport was 
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accompanied by higher IgG responses against tetanus toxoid, indicating a positive effect of 
epithelial transport on vaccine efficacy. 
 Particle characteristics. The physicochemical properties of the particles most likely are 
critical to the effectiveness of the vaccine. For instance, particle size and zeta potential can 
impact the transport by M-cells as well as subsequent events, but the ideal particle 
characteristics are still under discussion.  
The effect of particle size has not been thoroughly investigated for nasal vaccination. It has 
been determined that M-cells in Peyer’s patches in the gut selectively take up particles with a 
diameter up to 10 μm [75] and that the particle size influences the type of immune response 
[76]. Xiang et al stated that particles resembling the size of viruses (20-200 nm) will be 
handled by the immune system as being a virus and elicit a cellular biased response, whereas 
particles with the size of a bacterium (between 0.5-5 μm) will favor a humoral response [77]. 
For nasal vaccination, several studies pointed to small (nano)particles being more rapidly 
absorbed by nasal M-cells [61, 71, 78-80], but no boundaries have been determined. Fujimura 
et al [81] showed that particles coated with the cationic polymers chitosan or poly-L-lysine 
were taken up by the NALT in a size range from 0.2 μm to 2 μm, with an increased uptake of 
smaller particles. Unfortunately, these particles did not carry an antigen, making it impossible 
to determine the effect of increased uptake on resulting immune responses.  
As the cell membrane of M-cells is negatively charged, one can argue that a positive zeta 
potential is beneficial for M-cell transport. However, mucus and epithelial cells carry a 
negative charge as well, making electrostatic interactions very unspecific. Still, nasal 
application of a Yersinia pestis antigen in positively charged liposomes induced significantly 
stronger antibody responses than the same antigen in negatively charged liposomes [70, 82]. 
Likewise, nasal administration of HBsAg in positively charged PLGA microparticles resulted in 
significantly higher antibody levels than the same antigen in negatively charged PLGA 
microparticles (Jaganathan et al 2006). Although negatively charged or neutral particles have 
been reported to drastically increase antibody response after nasal immunisation [78, 83], 
positively charged particles seem to be superior to their negatively charged counterparts.  
Improved mechanistic insight into the role of particle characteristics on antigen uptake will 
be necessary to resolve the ideal characteristics of a particulate carrier for uptake by the nasal 
epithelium.  
 
M-cell targeting approaches 
Specific M-cell targeting could further enhance vaccine efficacy. A variety of 
microorganisms, e.g. influenza viruses and group A streptococci, have been found to target 
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themselves to M-cells [12, 24, 25]. Complete bacteria can be used as vaccine carrier, exploiting 
their M-cell targeting mechanisms. Expression of Streptococcus pneumoniae antigens on live 
lactobacillus led to high IgG and sIgA titers in mice after i.n. administration [84]. Since live and 
inactivated lactobacilli induced similar protective immunity after nasal administration [85], the 
positive effect of lactobacillus is likely not due to prolonged residence time, but rather to 
increased bioadhesion or (M-cell mediated) uptake.  
Virosomes are reconstituted virus envelopes, including a lipid bilayer and surface proteins. 
For instance, influenza virosomes (containing hemagglutinin and neuraminidase surface 
antigen) can be used as carriers to transport antigens to the cytosol of cells that overexpress 
sialic acid residues [86, 87] and might be exploited to target DC [88], but could target M-cells 
by the same mechanism. Virosomes have been shown to be excellent nasal carriers for several 
antigens like the F-protein of RSV [89] and DNA vaccines [90]. 
M-cells express several adhesion molecules on their cell surface that can bind pathogens. 
However, most work has been done on intestinal M-cells [91-93] and regional differences 
between M-cells exist [94, 95]. For instance, the plant lectin Ulex europaeus 1 lectin (UEA-1) 
[96] as well as lectins from other species [97-99] have been successfully used for targeting 
particles to intestinal M-cells in mice, but the specificity of UEA-1 for nasal M-cells is lower, as 
it also has affinity for nasal epithelial and goblet cells [100]. Despite this shortcoming, UEA-1 
has been shown to increase M-cell transport and able to raise serum antibody levels when 
coadministered i.n. with DNA encoding HIV envelope protein [101]. 
Putative ligands that selectively target nasal M-cells include isolectin B4 and Maackia 
amurensis I lectin [100], which recognize α-(1-3)-linked galactose and sialic acid, respectively 
[102]. Interestingly, sialic acid and galactose residues are involved in the initial binding of 
influenza virion to the host cell [103] and influenza A type viruses adhere efficiently to nasal 
M-cells in vitro [24]. Adherence of Streptococcus pneumoniae to the tracheal epithelium in 
chinchillas is dependent on the expression of sialic acid [104], showing the importance of 
these carbohydrate residues on the nasal epithelium for the entrance of these airborne 
pathogens. Nasal application of the model antigen HRP with isolectin B4 significantly enhanced 
the antibody (IgG and sIgA) response to HRP in comparison with administration of HRP alone 
[102]. Recently it has been established that the Fc part of sIgA (and IgG alike) may also target 
M-cell, thereby creating a positive feedback loop [105]. Consequently coating particles with 
sIgA or IgG can increase M-cell transport [106] and have been show to increase the 
immunogenicity of liposomal HBsAg formulation after nasal administration [107].  
Finally, several other receptors have recently been identified as potential M-cell targeting 
ligands, especially β1-integrin [108]. Several pathogens use β1-integrins to cross the intestinal 
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epithelium, such as Yersinia pestis [109] and Escherichia coli [110, 111]. Recently Gullberg et al 
showed that uptake of latex particles by human intestinal M-cells in vitro was increased when 
the particles were coated with a β1-integrin ligand [112]. Hicks et al [113] showed that β1-
integrin is also readily expressed on nasal isolectin B4 positive epithelial cells, i.e. most 
probably M-cells.  
 
Intracellular targeting, induction of cytotoxic T cells 
After antigen uptake through the nasal epithelium, their uptake and processing by DC are 
the next critical steps that determine the immune response. Antigen delivery systems that are 
capable of disrupting the DC’s endosomal membrane and thereby promote endosomal escape 
can in principle be used to induce CTL responses. It has been shown that antigens 
incorporated in particulate antigen delivery systems are more effectively cross-presented than 
soluble antigens [114-116]. The efficiency of cross-presentation can vary between different 
types of particulate antigen delivery systems. 
ISCOMs and ISCOMATRIX adjuvant are 40-nm cage-like structures composed of Quillaja 
saponins, cholesterol, and lipids that can incorporate or associate membrane antigens and 
DNA. ISCOMs are well-studied nasal and parenteral adjuvants that induce not only mucosal 
and systemic humoral responses, but also CTL responses [117-121]. It is thought that ISCOMs 
can deliver antigens to the APC’s cytosol due to their membrane-disrupting properties [120], 
triggering endosomal escape. Additionally, it has been shown that CTL induction is markedly 
stronger when the antigen is physically attached to the ISCOMATRIX rather than administered 
unbound [118]. 
Virosomes can also induce strong CTL responses in addition to humoral and Th cell 
responses [86, 122] Influenza virosomes have been most extensively investigated. These 
virosomes contain influenza hemagglutinin, which binds to sialic acid residues on the cell 
surface and initiates receptor mediated endocytosis. Conformational changes in the influenza 
hemagglutinin due to acidification of the endosomes triggers the fusion of the endosomal 
membrane and the virosomal membrane, which enables release of the virosomal contents 
from the endosome into the cytosol. Subsequently the released antigens are degraded by the 
proteasome and presented through MHC I molecules [123]. Influenza virosomes have shown 
increased CTL responses against virosomal influenza [124-127], hepatitis C [128] and cancer 
antigens [129]. Virosomal influenza vaccines are the only virosomal vaccines that have been 
tested via the nasal route [130-133].  
 In addition to lipid based antigen delivery systems, polymeric biodegradable 
nanoparticles can enhance CTL induction in vitro [134] and in vivo after nasal vaccination 
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[135], as well as other routes [136-139]. Antigen loaded biodegradable PLGA nanoparticles are 
superior to nondegradable antigen adsorbed to latex nanoparticles [140], most likely due to 
hydrolysis of these polymeric nanoparticles in the acidic environment of endosomes. This 
facilitates endosomal escape [140-142] and antigen delivery into the cytosol, leading to 
enhanced MHC II presentation. The charge and structure of polymeric nanoparticles can also 
affect the uptake into DC. For instance, a positive charge has shown to increase phagocytic 
activity [141].  
To summarize, vaccine delivery systems and endosomal escape mediators can be used for 
MHC II antigen presentation and thereby could increase CTL responses to an antigen. 
 
Adjuvants 
TLR ligands. CpG motifs in bacterial dsDNA are recognized by TLR 9. CpG 
oligodeoxynucleotides (ODN) have been tested in mice as adjuvant for nasal vaccines against 
several pathogens. Table III gives an overview of the results from studies in which TLR ligands 
have been tested as adjuvants for nasal vaccines. In general, the addition of CpG ODN to a 
nasal vaccine results in increased serum and mucosal antibody levels as well as increased 
cellular responses [143-145]. Generally, the addition of CpG ODN shifts the immune response 
from Th2 biased to a balanced Th1/Th2 response, i.e. it increases the production of Th1 
cytokines and IgG2a. 
Double stranded RNA and poly (I:C) are ligands for TLR 3. Poly (I:C) has been tested in mice 
as an adjuvant in a nasal influenza vaccine, resulting in protective immunity against influenza 
[146]. Poly (I:C) also increased humoral immune responses to two antigen formulations of 
Bacillus anthracis, inducing maturation and migration of DC and directing the immune 
response from mainly Th2 to a more balanced Th1/Th2 response. Moreover, sIgA was 
detected in broncheo alveolar lavage fluid [147, 148]. 
TLR 3 and TLR 9 are located in endosomal membranes. Storni et al suggested therefore 
that TLR 3 and 9 ligands should be taken up by the same DC as the antigen to exert their 
adjuvant effect [149]. Following this hypothesis, Joseph et al encapsulated CpG motifs in 
liposomes with influenza antigen, which on nasal administration in mice led to an increased 
anti-influenza IgG2a response, cellular responses (splenocyte proliferation, CTL response and 
IFN-γ production), and protection against influenza virus challenge [150]. This is likely due to 
enhanced liposomal delivery of CpG motifs to the endosomal compartment. 
LPS, a major component of the outer membrane of Gram-negative bacteria, is a ligand for 
TLR 2 and TLR 4, and its adjuvant potential has been tested in various studies. Both Th1 [151, 
152] and Th2 responses [153-156] have been found after nasal administration of LPS-
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containing vaccines. These contrary results are not yet fully understood. Iwasaki and 
Metzhitov suggested that a lower dose of administered LPS corresponds to environmental 
antigens and induces Th2 responses and allergic inflammation, whereas a high dose 
corresponds to responses against infection and induces Th1 responses [37]. Monophosphoryl 
lipid A, a derivative of LPS and ligand for TLR 4, has similar adjuvant effects as LPS in nasal 
vaccines [151]. Increased mucosal sIgA and serum antibodies were found by using 
monophosphoryl lipid A as an adjuvant [151, 157] when compared to LPS [151]. 
Bacterial flagellins are ligands for TLR 5 and have been tested in nasal vaccines [158-160]. 
They induce mucosal and serum humoral responses. Vibrio vulnificus derived flagellin has thus 
far been the only flagellin tested as an adjuvant and induced mainly Th2 responses against 
model antigen tetanus toxoid [158]. Further research should clarify the potential of this group 
of TLR ligands as adjuvants for nasal vaccines.  
Other PRR include the intracellular NOD1 and NOD2 proteins, scavenger receptors, 
macrophage mannose receptors and other C-type lectin receptors as well as type 3 
complement receptors [37]. For instance, targeting of the C-type lectin, mannose receptor, on 
DC significantly increased antigen presentation on MHC II molecules [161]; [38].  
Altogether, it seems that many TLR ligands, and possibly other PRR ligands, can act as 
adjuvant for nasal vaccines. However, the shift towards Th1 immune responses as observed 
with parenteral vaccinations seems to be less evident with nasal vaccination where balanced 
Th1/Th2 immune responses are mostly observed with these adjuvants. Further research in the 
immunological mechanisms involved in eliciting mucosal immune responses is necessary to 
understand the role these adjuvants can play in future (nasal) vaccines.  
Toxin-based adjuvants. Enterotoxins like CT and LT are strong mucosal adjuvants that 
induce mucosal as well as serum antibody responses [41, 42]. In 1997 the first commercial 
nasal virosomal influenza vaccine adjuvanted with LT became available. Although the vaccine 
yielded a high percentage of protection, it was withdrawn from the market because its use 
was associated with an increased risk of developing Bell’s palsy [162]. The cause of the Bell’s 
palsy was linked to LT [163] and consequently LT and CT have no longer been used intensively 
in humans as an adjuvant for nasal vaccines. It has been reported that the coadministration of 
CT or LT redirects the antigen into the olfactory neuroepithelium, likely the cause of the 
neurological toxicity [164]. In an effort to make safe adjuvants based on CT and LT, several 
mutants of the toxins have been developed and tested [165]. Amino acid mutations in the 




Nasal application of vaccines adjuvanted with CT and its nontoxic mutants induces Th2 
type immune responses as well as mucosal sIgA production, whereas the differentiation of 
Th1 cells is suppressed [174-177]. On the other hand, LT and some mutants like LT(K63) [42, 
178] induce a more balanced Th1/Th2 response [179, 180]. Some mutants of LT, like LT(R72) 
induce a specific Th2 response [42, 178], while other LT mutants like induce a more Th1 
polarized response [181]. A clear correlation between mutation and type of induced immune 
response has not been established. A construct of CT with a synthetic dimer of the D-fragment 
of Staphylococcus aureus protein A, which targets to B-cell Ig receptors, resulted in a strong 
nontoxic adjuvant that induced a balanced Th1/Th2 response against several tested antigens 
[182]. 
Cytokines and costimulatory molecules. Cytokines like IL-1 [183, 184], IL-12 [185-187], and 
type 1 IFN [188, 189] have been used as adjuvants for nasal vaccines to induce stronger and 
regulated Th1/Th2 immune responses [165]. Especially IFN type 1 and IL-12 are promising 
nasal adjuvants promoting Th1 type immune responses. Costimulatory signals are non-antigen 
specific signals delivered by activated APC to T-cells or by Th cells to B-cells. Several pathways 
can be exploited as target for adjuvants. CD28, CD40, CD134 and CD137 have been 
investigated as adjuvant targets [190]. Monoclonal antibodies that mimic the agonistic binding 
of costimulatory molecules have been tested as ligands for these CD molecules. Anti-CD40 
monoclonal antibodies were coadministered as an adjuvant with a liposomal formulation of 
an influenza CTL epitope in subcutaneous and i.n. vaccination in mice. A decrease of lung viral 
titers after non-lethal challenge was observed after i.n. but not after subcutaneous 
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Although research and development of nasal vaccines has gained momentum over the last 
years, only one nasal vaccine is currently approved for human use, indicating that advances 
towards new effective vaccines have been slow, in particular for inactivated/subunit vaccines. 
However, the various attempts that have failed can teach us not to bet on one single horse. 
The opportunities in nasal vaccination are not in a single research field, but require the 
integration of immunology, biotechnology, microbiology and pharmaceutical sciences. 
Mechanistic insight into the hurdles that limit the efficacy of nasal vaccination will create 
opportunities for rationally designed nasal vaccines that can overcome these barriers. A 
concerted approach, combining various targeting techniques discussed in this paper, includes 
the use of particulate antigen carriers, which can be furnished with distinct functionalities 
such as mucoadhesive polymers, M-cell or DC targeting ligands, adjuvants and endosomal 
escape promoters. This could lead to “tailor made” vaccines that provide similar or even 
superior protection to diseases as provided by classical parental vaccines. The biggest 
challenge will be to combine these techniques in such a way that they do not interfere with 
one another, but synergistically enhance vaccine efficacy. 
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For oral vaccination, incorporation of antigens into nanoparticles has been shown to 
protect the antigen from degradation, but may also increase its uptake through the intestinal 
epithelium via M-cells. The aim of this study was to understand the mechanisms by which oral 
administration of antigen-loaded nanoparticles induces an immune response and to analyze 
the effect of the nanoparticle composition on these mechanisms. Nanoparticles made from 
chitosan (CS) and its N-trimethylated derivate, TMC, loaded with a model antigen ovalbumin 
(OVA) were prepared by ionic gelation with tripolyphosphate. Intraduodenal vaccination with 
OVA-loaded nanoparticles led to significantly higher antibodies responses than immunization 
with OVA alone. TMC nanoparticles induced anti-OVA antibodies after only a priming dose. To 
explain these results, the interaction of nanoparticles with the intestinal epithelium was 
explored, in vitro, using a follicle associated epithelium model and visualized, ex vivo, using 
confocal laser scanning microscopy. The transport of OVA-FITC-loaded TMC nanoparticles by 
Caco-2 cells or FAE model was higher than OVA-FITC-loaded chitosan or PLGA nanoparticles. 
The association of nanoparticles with human monocyte derived dendritic cells and their effect 
on their maturation were determined with flow cytometry. TMC nanoparticles but not 
chitosan or PLGA nanoparticles had intrinsic adjuvant effect on DCs. In conclusion, depending 
on their composition, nanoparticles can increase the M-cell dependent uptake and enhance 
the association of the antigen with DC. In this respect, TMC nanoparticles are a promising 



















Whereas most pathogens gain access to their hosts via mucosal surfaces, most human 
vaccines currently available are licensed for non-mucosal administration e.g. via subcutaneous 
or intramuscular injections. However, mucosal vaccines have several attractive features 
compared with parenteral vaccines. Mucosal immune responses are most efficiently induced 
by administration of vaccines onto mucosal surfaces[1]. Moreover, mucosal immunization is 
needle-free, patient-friendly and reduces the risk of infection. Nonetheless, if mucosal 
vaccination is to become a feasible alternative for parenteral immunization, there are still 
hurdles to overcome before such an approach can be used widely. Oral vaccine delivery raises 
particular challenges: the bioavailability of orally delivered antigen is limited by possible 
degradation in the gastrointestinal environment. Moreover, most antigens are bulky 
substances and therefore not easily absorbed into the intestinal epithelium. Finally, the 
intestine is a fairly immuno-tolerant site, and the default response to an antigen will often be 
tolerance instead of immunity[2,3]. 
To facilitate effective mucosal immunization, the antigen must be protected from 
degradation, its uptake/absorption enhanced and immune cells activated. Therefore, oral 
vaccines should ideally be multimeric/particulate, adherent to the intestinal surface, 
effectively target M-cells and efficiently stimulate innate and adaptive immune responses [1]. 
Polymeric nanoparticles in which the antigen is encapsulated have been designed for oral 
immunization [4-6]. Various studies have shown increased antibody responses when antigens 
are orally administered in poly-(lactic-co-glycolic acid) (PLGA) particles [7-10]. Particles 
composed of bioadhesive material like chitosan (CS) and its soluble derivate N-trimethyl 
chitosan (TMC) characterised by its permanent positive charges irrespective of pH, can 
prolong the residence time of the antigen in the intestine, increase its permeation and 
enhance its immunogenicity [11,12,13,14,15]. Although most of the polymers used allow 
protection of the antigen from degradation, their effects on interaction with intestinal surface 
and on antigen uptake is less well recorded and depends on the type of polymer used [4].  
What happens to an encapsulated antigen once it has reached the intestine is also not 
straightforward. M-cells in the follicle-associated epithelium (FAE) of intestinal Peyer’s patches 
and isolated lymphoid follicles are gatekeepers of the mucosal immune system. They sample 
the gut lumen and transport antigens in the underlying mucosal lymphoid tissue for 
processing and initiation of an immune response [16]. Given their unique features to 
transcytose particles, M-cells are an interesting target in oral vaccine delivery. It has been 
shown that nanoparticles are actively taken up by the FAE through M-cells [5,12,16,17]. 
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Moreover, M-cells have been suggested to transport antigen to underlying dendritic cells 
(DCs), without any degradation of the antigen, even without a protective carrier [18]. In vitro 
models of human FAE that have been recently developed are useful to study the contribution 
of M-cells to the transport of nanoparticles [5,17] 
Interestingly, nanoparticles are also reported to increase the antigen uptake by DCs and to 
induce the maturation of DCs [19,20]. The use of a nanoparticulate delivery system might 
therefore work as a double edged sword as it increases the uptake into epithelium and 
subsequently the uptake into antigen presenting cells (APCs). 
The aim of this study was to understand the mechanisms by which nanoparticles can 
enhance immune responses after oral administration apart from protection from degradation. 
Ovalbumin (OVA) was used as a model antigen and encapsulated with CS and TMC polymers 
to form nanoparticles. CS particles have been described as potential oral vaccine carrier [12] 
and transport of these particles by M-cells has been observed [21]. A drawback of CS is its 
water solubility. With CS’ pKa of 6.2, at physiological pH primary amines groups are protonated 
and consequently OVA/CS nanoparticles will loose their repulsive surface charge and show 
colloidal instability. The slightly acid environment of the jejunum will promote the stability of 
CS nanoparticles, but as soon as these particles are transported to the subepithelial space to 
interact with immune cells, the physiological pH will be deleterious for its stability. As TMC 
carries a permanent positive charge, OVA/TMC nanoparticles will not be affected by small pH 
shifts and may be a more suitable carrier for mucosal vaccination.    
An intraduodenal immunization study with OVA/CS particles, OVA/TMC and 
unencapsulated OVA nanoparticles was performed to analyse the extent and the type of 
immune response elicited [22]. To explore whether transport into the FAE and interaction 
with DCs are indeed factors that contribute to the increased immune response caused by CS 
and TMC nanoparticles, first the interaction of these vaccine carriers with the enterocytes and 
FAE was investigated in vivo and in vitro [5,8], allowing a direct comparison and quantification 
of the transepithelial transport of CS and TMC nanoparticles. Secondly, the effect of 
nanoparticle uptake by DCs and on the maturation of DCs was assessed. Negatively charged 
PLGA nanoparticles of comparable size as OVA/CS and TMC/OVA were included to investigate 
the effect of nanoparticle composition on M-cell transport and DC interaction. 
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Materials and Methods 
 
Materials 
N-trimethyl chitosan with a degree of quaternisation of 15% was obtained from 92% 
deacetylated (MW 120 kDa) chitosan (Primex, Avaldsnes, N), by NaOH induced methylation as 
described by Sieval [6]. Poly(lactic-co-glycolic acid) 50:50 (PLGA) (L:G 50:50 average Mw 5,000-
15,000) pentasodium tripolyphosphate (TPP), 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic 
acid (HEPES), dichloromethane, dimethyl sulfoxide (DMSO), 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), ovalbumin (OVA) grade V and sodium cholate were 
obtained from Sigma-Aldrich (Steinheim, DE). FITC-ovalbumin (FITC-OVA) was purchased from 
Molecular Probes (Invitrogen Breda, NL). All culture media, including penicillin/streptomycin 




CS and TMC nanoparticles were prepared by ionic complexation with pentasodium 
tripolyphosphate (TPP) [23]. CS and OVA were dissolved in a 0.1 M acetate buffer (pH 5) to a 
final concentration of respectively 1 mg/ml and 0.1 mg/ml. A TPP solution (1 mg/ml) was 
added under continuous stirring to weight ratio CS:TPP:OVA of 10:1.2:1. TMC and OVA were 
dissolved in a 5 mM Hepes buffer (pH 7.4) to a final concentration of 1 mg/ml and 0.1 mg/ml, 
respectively. TPP was added under continuous stirring to a weight ratio TMC:TPP:OVA of 
10:1.8:1. Nanoparticles were collected by centrifugation (30 min 15000 g) on a glycerol bed, to 
avoid aggregation. 
PLGA particles were prepared by a “water-in-oil-in-water” solvent evaporation method 
described by Garinot [8]. Briefly, 50 µL of 10 mg/mL OVA or FITC-OVA in 10mM phosphate 
buffer saline pH7.4 (PBS) was emulsified with 1 mL of dichloromethane containing 50 mg of 
PLGA with an ultrasonic processor for 15 s at 70 W (Branson Instruments, CT, USA). The 
secondary emulsion was prepared with 2 mL of 1% (w/v) sodium cholate in water. The double 
emulsion was then poured into 100 mL of a 0.3% sodium cholate aqueous solution, and stirred 
at 37°C for 45 min. The nanoparticle suspension was then washed twice in PBS by 
centrifugation at 22 000 g for 1 h. 
 
Nanoparticle characterisation 
Particle size distribution was determined by means of dynamic light scattering (DLS) using 
a NanoSizer ZS (Malvern Instruments, Malvern UK). The zeta potential of the particles was 
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measured with the NanoSizer ZS by laser Doppler velocimetry. Before the measurement, 
samples were diluted in 5 mM Hepes pH 7.4 or 50 mM acetate buffer pH 5.9 until a slight 
opalescent dispersion was obtained.  
The OVA content of the particles was determined with a BCA protein assay (Pierce, 
Rockford, IL, USA) according to the manufacturer’s instructions.The encapsulation efficiency 
was expressed in percentage as the amount of OVA encapsulated compared to the amount of 
OVA used to form the nanoparticles. The process yield was expressed in percentage as the 
weight of nanoparticles compared to the amount of polymers used for the formulation. 
 
Immunization with ovalbumin-loaded nanoparticles 
Female Balb/c mice 6 weeks old at the beginning of the experiment were purchased from 
JANVIER (Le Genest-Saint-Isle, FR). The mice were kept in hanging wire cages and allowed 
access to food and drink ad libitum. Mice were fasted the day before their immunization. All 
experiments were approved by the ethical committee for animal care of the faculty of 
medicine of the Université Catholique de Louvain. 
Mice received intramuscular injection of OVA (50 μg OVA/50 μL) as a positive control, or 
intraduodenal injections of OVA, OVA-loaded CS nanoparticles (OVA/CS) or TMC nanoparticles 
(OVA/TMC) (100 μl containing 50 μg of OVA). A boost was applied in similar fashion, 14 days 
after the priming. Blood samples were collected by retro-orbital punctures 14, 28, 42 days 
after priming. Sera isolated by centrifugation were stored at -20°C before analysis. OVA-
specific IgG, IgG1 and IGg2a levels were determined by enzyme-linked immunosorbent assay 
(ELISA) [8]. Serum dilutions were made in OVA-coated plates (Nunc-Immnuno Plate F96 
MAXISORP) and detection of anti-OVA antibodies was carried out using peroxidase-labelled 
rat anti-mouse immunoglobulin G, G1 and G2a (LO-IMEX, Brussels, BE). IgG titres were defined 
as the logarithm of the inverse of the sera dilution corresponding to an absorbance equal to 
0.2. 
   
Visualisation of OVA transport in vivo 
Female Balb/c mice were administered 50 µg FITC-OVA encapsulated in TMC or CS 
nanoparticles by intraduodenal injection. After 1h mice were sacrificed, pieces of jejunum and 
Peyer’s patches were harvested and washed with PBS. Tissues were formaldehyde fixed and 
incubated with PBS 0.2% Tween 100 and 2% Rhodamine-phalloïdin to stain membrane cells. 
Scanning laser confocal microscopy was used to visualise the luminal side. 
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Cell lines  
Human colon carcinoma Caco-2 line (clone 1) was obtained from Dr. Maria Rescigno, 
University of Milano-Bicocca, Milan, IT [24] and maintained in supplemented Dulbecco’s 
Modified Eagles Medium (DMEM) high glucose and L-glutamine, with 10% v/v foetal bovine 
serum (FBS) and 1% v/v non essential amino acids at 370C under a 5% CO2 water saturated 
atmosphere. Human Burkitt’s lymphoma Raji B-cell line (American Type Culture Collection, 
Manassas, VA, USA), was maintained in RPMI 1640, supplemented with 10% v/v FBS, 1% v/v L-
glutamine and 1% v/v non essential amino acids. 
  
Effect of polymers on cell viability 
Toxicity of the formulations on Caco-2 cells was assessed using the MTT method. Caco-2 
cells (10000/well) were seeded in a 96-well plate (Nunc, Roskilde, DK) and maintained for 2 
days at 37°C and 5% CO2. After 1 h exposure to 1 mg/ml of the various delivery systems, the 
cells were washed 3x with Hank’s Balanced Salt Solution (HBSS) and incubated for 3 h with 0.5 
mg/ml MTT in DMEM. Medium was removed and the purple formazan crystal was dissolved in 
100 μl DMSO. Absorbance at 570 nm was measured using a μQuant ELISA plate reader (Biotek, 
Winooski, VT, USA).  
 
In vitro human FAE culture 
FAE cultures were performed according to the protocol improved by des Rieux [5]. Briefly, 
5x105 Caco-2 cells were seeded on Matrigel (Becton Dickinson, Franklin Lakes, NJ, USA) coated 
12-well Transwell inserts (Corning, Schiphol-Rijk, NL) and cultivated for 3 days in 
supplemented DMEM + 1% PEST. Inserts were inverted, a piece of silicon rubber (Labo-
modern, Queveaucamps, BE) was placed around the basolateral side and transferred into a 
pre-filled Petri dish (VWR, Amsterdam, NL) with supplemented DMEM + 1% PEST. Inverted 
inserts were maintained for 10 days and the basolateral medium was refreshed every other 
day. 5x105 Raji-B cells, resuspended in supplemented DMEM+ 1% PEST, were added to the 
basolateral compartment of the inserts. The co-cultures were maintained for 5 days. Mono-
cultures were prepared in the same way, except that the Raji-B cells were left out. 
 
Nanoparticle transport in vitro 
For transport experiments mono- and co-culture inserts were reversed to their original 
orientation in 12-well plates (Corning) and washed with HBSS. After 20 minutes of 
equilibration at 37°C the trans-epithelial electrical resistance (TEER) was measured using a 
home made chop stick electrode couple to a MilliCellers® multimeter (Millipore, NL). 
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Nanoparticle formulations containing FITC-OVA were diluted to a final concentration of 1 
mg/ml in HBSS (corresponding to approximately 0.9x108 CS, 1.0x108 TMC and 1.0x108 PLGA 
nanoparticles per ml, as determined by flow cytometry) and 400 μl were applied to the apical 
compartment of the insert. At the basolateral side 1.2 ml HBSS was used as acceptor 
compartment. After incubation for 60 minutes at 37°C the amount of particles in the acceptor 
compartment was determined using flow cytometry (FACScalibur, Becton Dickinson) [5,8,17]. 
The transport of free FITC-OVA was evaluated by fluorimetry with an FS920 fluorimeter 
(Edinburgh Instruments, Campus Livingston, UK). 
The Papp (cm/s) was calculated as follows: 
 
Papp = dQ / dtAC0  
 
Where dQ/dt is the transport rate number of nanoparticles per ml or amount of FITC-OVA 
(mg) present in the basal compartment as function of time (s), A the area of Transwell (cm2) 
and C0 the initial concentration of nanoparticles (number/ml) or OVA (mg/ml) in the apical 
compartment. 
 
The apical compartment was harvested and centrifuged (14000 g, 30 min). The 
supernatant was used to quantify the release of lactate dehydrogenase (LDH) according to the 
manufacturer’s instructions (cytotoxicity detection kit, Roche, Woerden, NL).  
 
Human monocytes derived dendritic cells culture 
Monocytes were freshly isolated from human donor blood before each experiment by 
means of density gradients (Ficoll and Percoll) and depletion of platelets was performed by 
adherence of the monocytes in 24-well plate (Corning, Schiphol, NL) followed by washing. 
Monocytes (5x105 cells/well) were maintained for 6 days in RPMI 1640, supplemented with 
10% v/v FBS, 1% glutamine, 1% v/v PEST, GM-CSF 250 U/ml (Biosource-Invitrogen, Breda, NL) 
and IL-4 100 U/ml (Biosource) at 37°C and 5% CO2 to differentiate into immature DCs. Medium 
was refreshed after 3 days [25]. 
 
Interaction of nanoparticles with dendritic cells (DCs) 
DCs were incubated for 4 h at 37°C in RPMI 1640 and 500 U/ml GMCSF with 2 μg/ml FITC-
OVA either free or encapsulated in TMC, CS or PLGA nanoparticles (polymer concentration 20, 
20 and 100 µg/ml respectively). Cells were washed 3 times with PBS containing 1% w/v bovine 
serum albumin and 2% v/v FBS before FITC-OVA association with DCs was quantified using 
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flow cytometry (FACScalibur, Becton Dickinson). Live cells were gated based on forward and 
side scatter. FITC-OVA association was expressed as the mean fluorescence intensity (MFI) in 
the FL-1 channel. Histogram overlay were created with WinMDI vs 2.9. 
 
Effect of nanoparticles on DC maturation 
DCs were incubated for 48 h at 37°C in RPMI 1640 and 500 U/ml GMCSF with 2 μg/ml OVA, 
either free or encapsulated in TMC, CS or PLGA nanoparticles and LPS (100 ng/ml) as a positive 
control. Cells were washed 3 times with PBS containing 1% w/v bovine serum albumin and 2% 
v/v FBS and incubated for 30 min with mixture of 50x diluted anti-HLADR-FITC and anti-CD86-
APC (Becton Dickinson) on ice, to measure expression of MHCII and CD86 molecules on the 
DCs’ cell surface, respectively. Cells were washed and expression of MHCII and CD86, both 
markers for mature DCs [26], was quantified using flow cytometry (FACScalibur). Live cells 
were gated based on forward and side scatter. The amount of MHCII and CD86 double positive 
cells was expressed as a percentage of the live cell population. 
 
Statistics 
Immunoglobulin levels were compared by Kruskal-Wallis non parametric tests (significance 
p<0.05). Two-way ANOVA with Bonferroni post-tests were used for the transport study. One-
way ANOVA with Bonferroni post-tests was used for all the other in vitro studies. 
 
 
Results and discussion 
 
Nanoparticle formulations 
All OVA-loaded nanoparticles showed a mean size distribution between 200 and 300 nm 
with comparable size distributions and a good process yield (Table I). With an ionic 
complexation method using TPP, adapted from Calvo [23], OVA was efficiently encapsulated 
into fairly monodisperse (PDI<0.25) CS and TMC nanoparticles with a mean hydrodynamic 
diameter of approximately 300 nm. For comparison, monodisperse (PDI< 0.15) PLGA 
nanoparticles with an average size of 240 nm were prepared by emulsification/solvent 
extraction [8]. 
TMC nanoparticles carried a positive surface charge at physiological pH. CS nanoparticles 
however lost their positive zeta potential at pH 7.4 due to deprotonation of the primary amine 
groups and showed major colloidal instability. Therefore, the characterisation and in vitro 
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experiments with CS nanoparticles were conducted at pH 5.9. PLGA nanoparticles carried a 
negative surface charged due to deprotonated carboxyl groups. 
OVA was more efficiently encapsulated into CS or TMC nanoparticles (loading efficiency 
65% and 67 % respectively) than into PLGA nanopartlices (42%). This may be due to the 
different preparation protocol as well as the hydrophobicity and negative charge of PLGA, 
disfavouring the encapsulation of the hydrophilic, negatively charged OVA (pI=4.8). 
 
Table I: Characteristics of TMC, CS and PLGA nanoparticles  
91 ± 2.342 ± 0.9-36.3 ±2.20.118 ± 0.014240 ± 9.0PLGA/OVA**
89 ± 1.566 ± 2.727.8 ±1.50.202 ± 0.045291 ± 12TMC/TPP/OVA**














Data represent the mean of 4 independently prepared batches ± standard deviation.  
* Measurements performed in 50 mM acetate buffer pH 5.9 ** Measurements performed in 5 mM 
Hepes pH 7.4 
 
Mucosal immunization with OVA-loaded TMC and CS nanoparticles 
A mucosal immunization study was performed to compare the ability of OVA-loaded TMC 
and CS nanoparticles to elicit an immune response. Therefore, 50 μg of free OVA and 50 μg of 
encapsulated OVA in TMC and CS nanoparticles were administered by intraduodenal injection 
to mice.  
Two weeks after priming, TMC nanoparticles showed an immune response in 5 out of 8 
mice, whereas free OVA, OVA encapsulated in CS nanoparticles or intramuscular injection of 
OVA induced a low IgG response in 2 out of 8 mice (Fig. 1a). On day 42 (4 weeks after 
boosting), all mice vaccinated with OVA loaded nanoparticles showed a strong and significant 
enhancement (over 1000 fold) in IgG production compared to intraduodenal immunization 
with free OVA (Fig. 1b). No significant difference in IgG titres was observed between the 2 
groups vaccinated with nanoparticles. Interestingly, OVA administered by intramuscular 
injection, while yielding a 100 fold higher IgG titre than free OVA given intraduodenally, 
resulted in a lower immune response than the intraduodenal delivery of OVA in 
nanoparticulate formulations. This could indicate that the increased immune response caused 
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by encapsulation of the antigen is not solely due to a more efficient delivery of the antigen to 
the target cells but also to an intrinsic immunopotentating capacity of the nanoparticles 
[19,20]. 
Compared to intraduodenal immunization with free OVA, TMC and CS encapsulated OVA 
induced higher IgG1 and IgG2a titres (p<0.05) (Fig. 2a). Mice vaccinated with free OVA by 
intramuscular injection and intraduodenal delivery showed a mean IgG2a/ IgG1 ratio of 0.5 
and 0.1, respectively. Mice vaccinated with CS and TMC nanoparticles had a more balanced 
ratio of 1 and 0.8, respectively (Fig. 2b). It has been reported that soluble antigens usually 
elicit high levels of IgG1 antibodies, but very low levels of IgG2a [27]. Both polymers (TMC and 
CS) have been described in the literature as being mucosal adjuvants and their influence on 
the Th1/Th2 balance seems to be very dependent on the antigen and route of administration 
[28-30]. The shift in profile of the immune response towards a Th1 response by the 
nanoparticulate formulations could be due to proton scavenger properties of CS and TMC, 
which may facilitate endosomal escape of the antigen and thereby promote antigen 





















Figure 1. OVA-specific IgG titres in serum 
of Balb/c mice intraduodenally fed with 
OVA solution, OVA-loaded TMC 
nanoparticles or CS nanoparticles, as 
compared to intramuscular injection 
with OVA solution. a) Total IgG titres 14 
days after priming. b) Total IgG titres 42 
days after priming (28 days after 
boosting). **OVA-loaded TMC and CS 
nanoparticles induced higher IgG titres 













































































































This study as well as other reports [12,32] clearly demonstrates that TMC and CS 
nanoparticles are potential candidates for oral delivery. It is generally accepted that 
nanoencapsulation can protect the antigen from degradation in the gastrointestinal tract; this 
however does not explain why encapsulation of OVA leads to a higher immune response than 
intramuscular injection or why a shift to Th1 response has been observed. Hence, the 
mechanisms by which TMC or CS nanoparticles could act as adjuvant, either as delivery 
systems and/or as immunomodulator were investigated. We hypothesized that the particulate 
form and the positive charge (unencapsulated OVA is negatively charged) account for the 
immuno-stimulatory effect. Therefore OVA-loaded PLGA nanoparticles with a similar size 
distribution as OVA/CS and OVA/TMC were included to serve as a negatively charged 
counterpart to the CS and TMC based particles. The effect of nanoparticle composition on 
their uptake by M-cells, was studied in vivo and in vitro. Moreover, their effect on DC uptake 




Figure 2. OVA-specific IgG1 and IgG2a titres in serum of Balb/c mice intraduodenally fed 
with OVA solution, OVA-loaded TMC and CS nanoparticles. Intramuscular injection was 
used as a positive control. a) IgG1 and IgG2a 28 days after boost. *IgG1 and **IgG2a 
induced by TMC/TPP/OVA and CS/TPP/OVA were significantly higher than those induced by 
free OVA (pb0.05). b) Ratio of IgG2a on IgG1 titres 28 days after boost. **Ratio induced by 
OVA-loaded CS nanoparticles immunization was significantly different from those induced 
by OVA solution (p<0.01). 
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Localization of antigen in Peyer’s patches 
A confocal microscopy of the gut of mice after intraduodenal delivery of free or 
encapsulated FITC-labelled OVA was performed to check if the TMC and CS particleswere 
specifically taken up by M-cells in Peyer's patch. Free FITC-OVAwas detected in neither regular 
(Fig. 3a) nor Peyer's patch epithelium (Fig. 3b), which could account for the poor 
immunogenicity of OVA observed after intraduodenal administration. Consistent with 
previous studies conducted by van der Lubben [12,21], who found M-cell specific uptake of CS 
microparticles, uptake of FITC-OVA encapsulated in CS (Fig. 3d) or TMC (Fig. 3f) nanoparticles 
was detected mainly in the Peyer's patches. In general, regular intestinal epithelium exhibited 
less intense OVA related fluorescence than the M-cell rich Peyer's patch area (Fig. 3c and e). 
x–z analysis clearly shows that CS and TMC nanoparticles were taken up by cells in the 
jejunum and Peyer's patches. This indicates that 1 h after of intraduodenal administration a 
significant part of the antigen has accumulated in the Peyer's patch, which is most probably 
due to M-cell specific uptake. The ability of M-cells to transport particulate structures is well 
established [33] and increasing the M-cell uptake has become an attractive strategy to 
improve current mucosal vaccines [34–36]. The particulate nature of the encapsulated FITC-
OVA therefore seems to be one of the major reasons for the active uptake by the FAE. To 
support these findings and to assess whether encapsulation in CS or TMC nanoparticles is 
beneficial for M-cell mediated transport, FITC-OVA transport studies over an in vitro FAE was 
performed. 
 
In vitro studies with FAE  
Cell viability and monolayer integrity 
As cell viability and monolayer integrity are vital for the interpretation of the transport 
experiments, the toxicity of the nanoparticles on Caco-2 cells was assessed with an MTT assay 
and a LDH release test, and monolayer integrity was evaluated by monitoring the TEER (Table 
2). At 1.0 mg/ml, the same concentration as used in the transport experiments, no significant 
cytotoxicity of CS and PLGA nanoparticles on Caco-2 cells was observed by the MTT assay. 
However, TMC nanoparticles caused a 20% reduction of cell survival (pb0.05). No LDH release 
(b1%) was detected. MTT as well as LDH assay performed at pH 5.9 showed similar results 
(data not shown). The toxicity of TMC could be due to its higher positive charge density 
leading to a higher interaction with cell membrane and higher uptake [32]. CS and TMC have 
been reported as enhancers of oral absorption, due to the opening of tight junctions between 
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the epithelial cells [11-15,32]. The relatively small but significant decrease of electrical 
resistance across the monolayer of both Caco-2 monocultures and co-cultures induced by CS 
and TMC particles (pb0.05) indicates that nanoparticles composed of these cationic 
biopolymers modified the tight junctions. In contrast, no changes in TEER were observed after 
exposure to PLGA nanoparticles. Although tight junction opening has been described as 
mechanism promoting antigen uptake, it is unlikely that an antigen encapsulated in a 300 nm 
sphere, will diffuse through these tight junction openings as FITCdextran (4 kDa and 12 kDa) 
were not significantly transported by co-cultures [5]. Therefore the immune- enhancing effect 
of CS and TMC nanoparticles should not be attributed to their ability to modify tight junctions. 
 
Nanoparticle transport across human FAE culture 
M-cells present in the FAE are known for their transcytotic transport capacity and may be 
critical for effective antigen transport to subepithelial immune cells [1,16]. Therefore, 
nanoparticle transport across the intestinal epithelium was investigated in vitro by measuring 
the amount of FITC-OVA-loaded particles in the basolateral compartment of Caco-2 mono-
cultures as well as Caco-2/Raji-B co-cultures. The Raji-B cells induce the generation of M-cells 
within the epithelial cell layer, permitting us to discriminate between M-cell dependent and 
M-cell independent transport (Fig. 4). All types of nanoparticles were more transported in the 
presence of M-cells, although only CS and TMC particle transport increased significantly 
(p<0.01). 
 
Table II: Effect of nanoparticles on Caco-2 cell survival and monolayer integrity after 1 h of exposure 
to 1 mg/ml free or nanoparticulate OVA 




Final TEER (% of initial 
value) b 
  Mono-culture Co-culture Mono-culture Co-culture 
OVA (aq)° 97.7 ± 10.5 240 ± 24 111 ± 11 99.4 ± 0.7 92.7 ± 2.7 
CS/TPP/OVA*  93.3 ± 23.1 219 ± 15 101 ± 12 70.5 ± 5.0# 60.5 ± 3.1# 
TMC/TPP/OVA° 78.3 ± 3.4# 222 ± 12 100 ± 7 74.8 ± 1.8# 70.7 ± 2.0# 
PLGA/OVA° 103.0 ± 12.8 205 ± 12 117 ± 14 103.0 ± 1.6 96.3 ± 1.0 
 
a
 Cell viability was assessed by an MTT test. Results are expressed as percentage (mean ± SEM; n=14) of 
the medium control (100%) 
b Monolayer integrity was investigated by measuring the TEER before and after the experiment. Values 
represent mean ± SEM (n=14)  
# p<0.05, compared to OVA solution ° HBSS pH 7.4 * HBSS pH 5.9 
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The increase in CS and TMC particle transport in the co-culture is consistent with the 
preferential localisation in Peyer's patches in vivo (Fig. 3). TMC particle transport by the mono-
culture and co-culture was higher than CS and PLGA particle transport, independent of the 
presence of M-cells (pb0.01). Transport by co-cultures was equivalent for PLGA and CS 
particles. It could be related to the higher positive charge density which is a critical factor for 
bioadhesion and penetration enhancement towards intestinal epithelium. It could also be 
related to the increase of quaternization degree favouring the mucoadhesion or to the small 
toxic effect of TMC (Table 2), which may have negatively affected the integrity of the 
monolayer. For the lower transport of CS particles in comparison with TMC particles, a key 
element could be the instability of the CS particles. The colloidal stability of OVA/CS is fragile 
and very sensitive to pH shifts, ionic strength and medium composition [37,38]. Thus, it is well 
possible that many particles exposed to pHN6.5 had aggregated before they reached the 
basolateral compartment [39,37] or that CS could be less condensed because the amine 
groups will not be charged and so, be less transported [40,15].  
In conclusion, nanoparticles seem to direct the antigen towards the Peyer's patches as 
their particulate nature favours M-cell specific uptake, compared to unencapsulated antigen. 
Hence, M-cell uptake seems to be the most likely route of CS or TMC nanoparticles, although 
active transport by epithelial cells [41] or uptake by extruding DCs [24] cannot be ruled out. 
 
In vitro studies with DCs 
Effect of nanoparticles on FITC-OVA association with DC 
Immature human DCs were stimulated for 4 h with either FITCOVA alone or nanoparticles 
containing FITC-OVA to investigate if encapsulation of OVA increased its association with DCs. 
Treatment with 2 μg/ml FITC-OVA led to an increase in mean fluorescence intensity compared 
to unstimulated DCs, indicating association of the antigen with the DCs. The positively charged 
formulations (OVA/CS and OVA/TMC) showed significantly increased association with DCs (Fig. 
5a). Interestingly, OVA incorporated in PLGA nanoparticles was not taken up by DCs more 
efficiently than free 
OVA, probably because the DC-PLGA interaction was less pronounced due to the 
unfavourable electrostatic interactions between the negative surfaces of PLGA nanoparticles 








Figure 3. Representative confocal microscopy images of murine jejunum (a, c, e) 
and a Peyer's patch (b, d, f) from murine jejunum, isolated 1 h after intraduodenal 
injection with 50 μg of FITC-OVA alone (a, b), incorporated in CS nanoparticles (c, d) 
or in TMC nanoparticles (e, f). Tissues were formaldehyde fixed for 90 min and 
incubated with PBS containing 0.2% Triton X-100 and Rhodamine-phalloïdin (1/50 
v/v) to stain cell membranes. Scanning laser confocal microscopy was used to 
visualize the luminal side and to perform x–z analysis. 






















































Effect of nanoparticles on DC maturation 
Uptake of antigen by DC does not necessarily mean that a successful immune response will 
be started. DCs sample their environment continuously, but only become activated if the 
antigen is recognized as dangerous. To measure whether nanoparticles supply a ‘danger 
signal’ next to increasing the delivery of the antigen, the maturation of human monocyte DC 
was studied. After 48 h of exposure to the different OVA formulations, clear differences in the 
maturation status of the DCs could be observed (Fig. 5b). The positive control, LPS-stimulated 
DCs expressed maturation markers to a very high extent, as 90% of the total DCs population 
was positive forMHCII as well as CD86. DCs treated with OVA showed no maturation, but 
OVA/TMC nanoparticles increased the number of MHCII/CD86 double positive DCs (pb0.01).  
The type of biopolymer seems to be an important parameter determining DCs maturation, 
as for PLGA and CS nanoparticles no significant increase of mature DCs was observed. 
Figure 4: FITC-OVA-loaded nanoparticle transport over Caco-2 monolayers (white 
bars) and Caco-2/Raji-B co-cultures (grey bars) quantified by FACS analysis. 
Transport is expressed as apparent permeability (Papp). Error bars represent 
standard error of the mean (SEM). M-cell, only present in co-culture significantly 
enhance the transport of OVA inside CS and TMC particles, but not unformulated 
OVA (n=18). Level of significant differences in Papp values are indicated by * 




Induction of DC maturation by CS and PLGA particles has been investigated by other groups 
with inconclusive results. Increased DC maturation by PLGA and CS biofilms in vitro [42] and 
by CS solutions in vivo [30] has been shown, but also studies claiming no stimulatory effect of 
these biopolymers exist [43,44]. Fisher et al. have recently addressed this discrepancy [45] and 
explained it by slight differences in preparation of the formulations and possible endotoxin 
contamination. To rule out LPS contamination in our experiments, TLR-4 transfected HEK cells 
were exposed to the formulations and we found the LPS content to be below the detection 
limit (<0.1 ng/ml, data not shown).  
As only the (positively charged) TMC nanoparticles induced DC maturation, but no DC 
maturationwas found after exposure to soluble antigen, (negatively charged) PLGA particles 
and (positively charged) CS particles, the nanoparticles material rather than the zeta potential, 
is an important factor in the process of DCs maturation. Effect of TMC 
on cell viability could also trigger DC maturation. As CS particles were incapable of 
activating DCs, but were effective in inducing an immune response, CS apparently acts as an 
adjuvant via a different mechanism. Possibly a depot is formed by OVA/CS particles that 
aggregate as soon as they are secreted into the subepithelial space and come into contact 
within a higher pH and medium constituents [39]. Why TMC has immunopotentiating capacity 
is unclear. To our best knowledge, this is the first time that the direct effect of TMC 
nanoparticles on DCs was assessed and TMC is a not a known ligand for pathogen recognition 





This study shows that if the right nanoparticle material is selected, the transport of the 
antigen into the FAE, association with APC, maturation of DCs and modulation of the immune 
response can be accomplished. The particulate nature of the delivery system increases the M-
cell specific transport into the FAE and a positive surface charge seems to cause an enhanced 
association of antigen with DCs, increasing the probability of successful antigen uptake. 
Moreover, TMC nanoparticles exerted intrinsic adjuvant properties, as it induces maturation 
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Figure 5. Interaction of OVA with human monocyte derived DCs. DCs were exposed to 2 μg/ml soluble 
or encapsulated FITC-OVA for 4 h. a) OVA-FITC association with DCs measured by flow cytometry. 
Bars represent mean values of 5 experiments from 5 different donors. Insert: Representative overlay 
histogram of a single DC-association experiment: control DCs (filled), DCs pulsed with 2 μg/ml FITC-
OVA (black line) or FITC-OVA loaded TMC nanoparticles (dashes line) analyzed after 4 h of incubation. 
b) Maturation of DCs exposed to 2 μg/ml soluble or encapsulated OVA, or 10 ng LPS, for 48 h. Cells 
were stained with anti-HLADR-FITC and anti-CD86-APC. Expression of surface molecules MHCII and 
CD86 was determined by flow cytometry. Double positive cells for MHCII and CD86 were considered 
matured (see insert). Bars represent mean values of 5 experiments from 5 different donors. Error bars 
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Nasal vaccination is a promising, needle-free alternative to classical vaccination. 
Nanoparticulate delivery systems have been reported to overcome the poor immunogenicity 
of nasally administered soluble antigens, but the characteristics of the ideal particle are 
unknown. This study correlates differences in physicochemical characteristics of nanoparticles 
to their adjuvant effect, using ovalbumin (OVA)-loaded poly(lactic-co-glycolic acid) 
nanoparticles (PLGA NP), N-trimethyl chitosan (TMC) based NP (TMC NP) and TMC-coated 
PLGA NP (PLGA/TMC NP).  
PLGA NP and PLGA/TMC NP were prepared by emulsification/solvent extraction and TMC 
NP by ionic complexation. The NP were characterized physicochemically. Their toxicity and 
interaction with and stimulation of monocyte derived dendritic cells (DC) were tested in vitro. 
Furthermore, the residence time and the immunogenicity (serum IgG titers and secretory IgA 
levels in nasal washes) of the nasally applied OVA formulations were assessed in Balb/c mice.  
All NP were similar in size, whereas only PLGA NP carried a negative zeta potential. The NP 
were non toxic to isolated nasal epithelium. Only TMC NP increased the nasal residence time 
of OVA compared to OVA administered in PBS and induced DC maturation. After i.m. 
administration all NP systems induced higher IgG titers than OVA alone, PLGA NP and TMC NP 
being superior to PLGA/TMC NP. Nasal immunization with the slow antigen-releasing particles, 
PLGA NP and PLGA/TMC NP, did not induce detectable antibody titers. In contrast, nasal 
immunization with the positively charged, fast antigen-releasing TMC NP led to high serum 
antibody titers and sIgA levels.  
In conclusion, particle charge and antigen-release pattern of OVA-loaded NP has to be 
adapted to the intended route of administration. For nasal vaccination, TMC NP, releasing 
their content within several hours, being mucoadhesive and stimulating the maturation of DC, 















The nasal cavity is one of the most promising administration sites for vaccines. The nose is 
easily accessible, low on proteolytic enzymes compared to the oral route and has interesting 
immunological characteristics. As the nasal cavity is a major route of entry for pathogens, the 
nasal epithelium is equipped with a large amount of immune cells to fight off infection and is 
capable of producing secretory IgA. Several studies have shown systemic as well as local 
antibody responses after nasal administration of an antigen [1-7]. Administration of subunit 
vaccines alone, however, seldom leads to a protective antibody response. The residence time 
of a soluble antigen in the nose is limited, which results in a very small dose reaching antigen-
presenting cells (e.g. dendritic cells) in the sub epithelial region. Moreover, subunit vaccines 
are often poorly immunogenic as they lack the necessary danger signals to activate dendritic 
cells (DC) and subsequently, T-cells.  
To overcome these obstacles, encapsulating antigen into particulate systems is a popular 
method [8]. Particles prepared with mucoadhesive substances can increase the antigens’ 
residence time in the nasal cavity [9], increasing the chance of uptake by the epithelium. 
Obviously, a size reduction of the particle from micro to nano scale could be beneficial as 
nanoparticles (NP) penetrate the nasal epithelium more easily [10, 11]. Once particles have 
crossed the epithelium they can facilitate the uptake of the antigen by DC. Furthermore, the 
multimerization of epitopes on the particle surface and the possibility of co-encapsulation 
with adjuvants can increase the immune recognition by B-cells and other antigen-presenting 
cells [10, 11]. 
Evidently, a NP that has all of the above mentioned characteristics is preferred. How such a 
particle looks like in terms of its physical and chemical properties like material, size, surface 
charge, physical stability, antigen stability and antigen release profile is currently unknown 
[12]. In the literature a wide variety of particles, including liposomes, virosomes, oil-in-water 
emulsions, nanocomplexes and polymer based carriers are mentioned [13], all with a different 
immunological outcome. For instance, a particle capable of provoking a strong antibody 
response may fail to trigger the cellular arm of the immune system, or may not induce the 
production of mucosal, sIgA mediated immunity. This enigma stresses the importance of 
combining thorough characterization of the delivery system together with in vitro analysis of 
its interaction with immune cells and extensive evaluation of immunological effects in vivo. 
Two of the most studied polymers for vaccine delivery are undoubtedly poly(lactic-co-
glycolic acid) (PLGA) and chitosan (derivatives). Both polymers share the properties to be safe, 
biodegradable and suitable to prepare (nano)particles. PLGA has been used for controlled 
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drug release purposes for decades and is therefore an obvious choice for encapsulation of 
antigen. Because of PLGA’s hydrophobic character, PLGA particles are generally prepared by 
oil-in-water emulsification or solvent evaporation techniques, generally resulting in negatively 
charged, smooth surfaced and spherical particles. These particles are relatively resistant to 
salt and pH induced instability, and slowly release their content, based on the hydrolysis rate 
of the polymer [14]. Promising results for nasal vaccination studies using PLGA particles have 
been reported [10, 15], but also unsuccessful results have been observed [16], which the 
authors attributed to the lack of mucoadhesiveness and immune-stimulating factors. 
Chitosan (CS) is a (under acidic conditions) water soluble, positively charged polymer and 
therefore has completely different properties than PLGA. CS particles are often prepared by 
ionic complexation or spray drying techniques, resulting in positively charged, rather irregular 
shaped complexes [17, 18]. In contrast to PLGA, CS particles have been described as 
mucoadhesive and their ability to cross epithelial barriers has been widely accepted. However, 
they are susceptible to dissociation by exposure to salts and are very unstable at physiological 
pH [19]. An improvement over CS particles are particles prepared from N-trimethyl chitosan 
(TMC), a derivate of CS that carries a positive charge independent of the pH. Consequently, 
TMC particles are much more stable at neutral pH than CS particles. Nasal administration of 
tetanus toxoid or hemagglutinin loaded TMC nanoparticles (TMC NP) resulted in strong 
antibody- and hemagglutinin inhibition titers, respectively [20, 21]. Interestingly, recently TMC 
coated PLGA particles (PLGA/TMC) loaded with Hepatitis B surface antigen have been 
developed; nasal vaccination of mice with these particles resulted in a marked increase of 
antigen specific antibodies compared to nasal immunization with HBsAg loaded PLGA particles 
[22].  
This study aims to characterize and compare the physical properties of PLGA NP, TMC NP 
and TMC-coated PLGA NP (PLGA/TMC NP) loaded with ovalbumin (OVA), a model antigen that 
elicits little response by itself. The impact of these characteristics on important aspects of 
nasal vaccination like local toxicity, DC uptake and DC maturation were investigated in vitro 
using a model for ciliary beat frequency (CBF) and human monocyte derived dendritic cells. In 
vivo, nasal residence was investigated using a live fluorescence imaging technique; 
immunogenicity in terms of systemic and secretory antibody (sub)class titers was investigated 
after nasal as well as i.m. administration to Balb/c mice. In parallel to these experiments 
extensive investigation into the T-cell responses resulting from nasal immunization with NP 
has been performed, the results of which will be presented elsewhere.   
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Materials and Methods 
 
Materials 
Ovalbumin (OVA) was purchased from Calbiochem (Merckbioscience, Beeston,UK). N-
trimethyl chitosan with a degree of quaternization of 15% was obtained from 92% 
deacetylated (MW 120 kDa) chitosan (Primex, Alversham, Norway), by NaOH induced 
methylation as described by Bal [23]. KCl, NaCl, HNa2PO4 and KH2PO4 were purchased from 
Merck (VWR, Amsterdam, The Netherlands). Poly(lactic-co-glycolic acid) (PLGA) 50:50 Mw 
5000-15000 Da, pentasodium tripolyphosphate (TPP), 4-(2-hydroxyethyl)-1-piperazine-
ethanesulfonic acid (HEPES), Tween 20, dichloromethane (DCM), dimethyl sulfoxide (DMSO), 
2-mercapto ethanol and Protease Type XIV were obtained from Sigma-Aldrich (Steinheim, 
Germany). 10% polyacrylamide SDS-PAGE gels were acquired from Biorad (Veenendaal, The 
Netherlands). Poly-(ethylenimine) (PEI) was a generous gift from Wim Hennink (Utrecht 
Institute of Pharmaceutical Sciences, Utrecht, The Netherlands). Goat anti mouse IgG, IgG1, 
IgG2a or IgA conjugated with horseradish peroxidase was purchased at Southern Biotech 
(Birmingham, AL). DMEM-Ham’s F12 (1:1) medium, Ultroser G and NU-serum were obtained 
from Life Technologies Ltd. (Paisley, UK). RPMI 1640, Foetal Bovine Serum (FBS), penicillin-
streptomycin (P/S) solution, fluorescein isothiocyanate and Alexa fluor 647 conjugated 
ovalbumin (OVA-FITC and OVAAlexa Fluor 647) and Lysotracker were acquired from Invitrogen 
(Breda, The Netherlands).  
 
 
Nanoparticle preparation and characterization 
 
Nanoparticle preparation  
TMC NP were prepared by ionic complexation of TMC with TPP. To 5 ml of a 2 mg/ml TMC 
solution, 1 ml of 0.1 % w/v OVA solution was added under continuous stirring. Subsequently 
0.3 ml water, 2 ml 25 mM Hepes pH 7.4 and 1.7 ml 0.1% w/v TPP solution were added. After 
15 min of stirring, particles were collected by centrifugation (10000 g, 15 min) on a glycerol 
bed, washed once with water and finally resuspended in water and stored at 4°C. 
PLGA NP were obtained with a double emulsion method. 50 µl of a 1% w/v OVA solution 
was dispersed in 1 ml 2.5% w/v PLGA in DCM by tip sonication (15 s 20 W). The obtained 
water-in-oil (w/o) emulsion was dispersed in 2 ml of 1% v/v Tween 20 by sonication (15 s, 20 
W). This w/o/w emulsion was added drop wise to a 50 ml warm (40°C) 0.02% v/v Tween 20 
aqueous solution (extraction medium) under continuous stirring to extract and evaporate the 
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DCM. After 1 hour, particles were collected by centrifugation (8000 g, 10 min), washed twice 
with water to remove free OVA and stored at 4°C until further analysis. 
PLGA/TMC NP were prepared as described for the PLGA NP, with the difference that TMC 
was added to the extraction medium to a final concentration of 80 µg/ml. Using FITC-labelled 
TMC we estimated that ca. 90% of the added TMC was associated with the PLGA NP. 
Supernatants were stored at 4°C for determination of the loading efficiency.  
NP containing OVA-FITC or OVAAlexa Fluor 647 were prepared in exactly the same manner by 
replacing OVA with its fluorescent counterpart. 
 
Physical characterization of nanoparticles 
Size and morphology of the NP were visualized with scanning electron microscopy (SEM). 
50 µl of 0.1% w/v particle suspension was air dried overnight on a metal stub. Particles were 
gold/palladium sputtered using a sputter coater device K650X (Emitech, Hailsham, UK) and 
analyzed with a JEOL JSM-6700F scanning electron microscope (Jeol, Tokyo, Japan). 
Mean size distribution was determined with dynamic light scattering (DLS) using a 
NanoSizer ZS (Malvern Instruments, Malvern UK). The zeta potential of the particles was 
measured by laser Doppler velocimetry using the same apparatus. Before the measurement, 
samples were diluted in 5 mM Hepes pH 7.4 until a slightly opalescent dispersion was 
obtained. 
Loading efficiency (LE) was calculated from the amount of OVA detected in the 
supernatant and expressed as percentage of the total amount of OVA added (LE= 100-
(OVAsup/OVAtot*100)). OVA concentrations were determined with a BCA protein assay (Pierce, 
Rockford, IL, USA) according to the manufacturer’s instructions. 
 
Assessment of antigen release and stability 
To determine the release characteristics, NP containing OVA-FITC were diluted to a 
concentration of 1 mg/ml NP in 5 ml PBS containing 0.01% Tween 20. Dispersions were 
incubated at 37°C for 25 days under continuous stirring (200 rpm). At different time points, an 
aliquot (0.30 ml) was taken (and not replaced with fresh PBS). Aliquots were centrifuged for 
20 min at 13000 g and supernatants were stored at 4°C until fluorescence intensity was 
assessed using an FS920 fluorimeter (Edinburgh Instruments, Campus Livingston, UK). 
To determine the stability of the antigen, supernatants from OVA loaded particles were 
collected after 11 days. Residual OVA was extracted from the pellet according to a protocol by 
Ghassemi et al [24]. Briefly, the pellet was freeze dried overnight, and the lyophilized product 
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was reconstituted in 200 µl DMSO. Subsequently, 800 µl of 0.5 % w/v SDS and 0.05 M NaOH 
were added and the mixture was left at room temperature for 2 h.  
OVA content was determined with BCA protein assay and a total of 0.6 µg OVA was loaded 
on a 10% poly(acrylamide) gel under reducing conditions. Protein bands were visualized with 
silver staining (Silver Stain Plus, Biorad) according to the manufacturer’s instructions. Western 
blot analysis was performed as previously reported [25]. 
 
 
Ciliary beat frequency measurements 
 
Cell isolation and culture 
Human nasal epithelial cells were isolated from nasal biopsies according to a previously 
described method [26]. The cells were plated in 12-well plates pre-coated with 0.2% rat tail 
collagen at a density of 5*105 cells/well in a final volume of 2 ml medium and incubated at 
37°C and 5% CO2. The medium was refreshed 24 h after plating and subsequently every other 
day. Ciliary beat frequency (CBF) measurements were performed on day eight to ten after 
plating. All experiments were performed in an air-conditioned room at a constant 
temperature of 22°C. Cell culture plates were removed from the incubator one hour prior to 
the experiment, in order to allow the medium to adapt to the environmental temperature. 
Cells were exposed for 45 minutes to 2.5 ml DMEM-Ham’s F12 (1:1) medium (negative 
control), 0.5 mg/ml or 5 mg/ml of nanoparticle dispersion or 0.5 mg PEI (positive control), 
after which cells were washed twice with DMEM-Ham’s F12 (1:1) medium. Cells were allowed 
to recover for 90 minutes after which CBF was assessed again.  
 
Data acquisition 
An inverted microscope (Olympus IX70) was used at a magnification of 600 times. A 
MotionScope high-speed digital camera and PCI application software, running in a Windows 
2000 environment (Redlake MASD Inc., San Diego, CA), were used for image acquisition. The 
images were captured at a frame rate of 500 frames per second with a sampling interval of 2 
ms, before, after and during exposure to the nanoparticles. A sequence of 1024 images was 
recorded for each area. Each sequence of frame-by-frame images was stored in a file folder 






Dendritic cells studies 
 
Human monocyte derived dendritic cell culture 
Monocytes were freshly isolated from human donor blood before each experiment by 
means of density gradients (Ficoll and Percoll) and depletion of platelets was performed by 
adherence of the monocytes in 24-well plate (Corning, Schiphol, The Netherlands) followed by 
washing. Monocytes (5*105 cells/well) were maintained for 6 days in RPMI 1640, 
supplemented with 10% v/v FBS, 1% v/v glutamine, 1% v/v P/S, GM-CSF 250 U/ml (Biosource-
Invitrogen, Breda, The Netherlands,) and IL-4 100 U/ml (Biosource) at 37°C and 5% CO2 to 
differentiate into immature DC (imDC). Medium was refreshed after 3 days. 
  
Interaction of nanoparticles with dendritic cells 
ImDC were incubated for 4 h at 37°C in RPMI 1640 and 500 U/ml GMCSF with 2 μg/ml 
OVA-FITC either free or encapsulated in TMC, PLGA or PLGA/TMC NP. Cells were washed 3 
times with PBS containing 1% w/v bovine serum albumin and 2% v/v FBS before OVA-FITC 
association with DC was quantified using flow cytometry (FACSCantoII, Becton Dickinson). Live 
cells were gated based on forward and side scatter. OVA-FITC association was expressed as 
the mean fluorescence intensity (MFI) in the FL-1 channel.  
For confocal microscopy, 50,000 imDC were plated on a poly-lysine coated Petri dish 
(Corning) and incubated for 30 minutes at 37°C. Cells were washed with PBS, and exposed for 
1 h to OVAAlexa Fluor 647 containing formulations. Cells were washed 3 times with PBS and 
exposed to 1 µM Lysotracker® for 15 minutes. Cells were washed 2 more times before 
visualization. 
 
Effect of nanoparticles on DC maturation 
DC were incubated for 48 h at 37°C in RPMI 1640 and 500 U/ml GMCSF with 2 μg/ml OVA, 
either free or encapsulated in PLGA, PLGA/TMC or TMC NP and LPS (100 ng/ml) as a positive 
control. Cells were washed 3 times with PBS containing 1% w/v bovine serum albumin and 2% 
v/v FBS and incubated for 30 min with a mixture of 50x diluted anti-HLA-DR-FITC, anti-CD83-
phycoerythrin(PE) and anti-CD86-allophycocyanin(APC) (Becton Dickinson) on ice, to measure 
expression of MHCII, CD83 and CD86 molecules on the DC’ cell surface, respectively. Cells 
were washed and expression of MHCII, CD83 and CD86 was quantified using flow cytometry 
(FACSCantoII, Becton Dickinson), assuming 100% maturation for LPS treated DC. Live cells 
were gated based on forward and side scatter.  
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In vivo studies 
 
Determination of nasal residence time 
Nasal residence time measurements were performed in accordance to the protocol 
described by Hagenaars et al. [29]. In short, female Balb/c (nu/nu) mice (Charles River, 
L’Árbresle, France) mice were lightly anesthetized using isofluorane prior to the administration 
of 5 µg OVA conjugated to a near infrared dye (IRdye™ 800CW, LI-Cor, USA). Nose was cleaned 
with a paper towel and immediately fluorescence intensity in the nasal cavity was determined 
using an IVIS Spectrum® (CaliperLS, USA). Every 10 minutes, fluorescence intensity was 
determined. Between measurements, mice were conscious.   
 
Administration of antigens, immunization and sampling schedules 
Female Balb/c mice received 20 µg OVA per nasal or i.m. administration. One priming dose 
was followed by 2 nasal or i.m booster doses 3 and 6 weeks after priming. For nasal 
administration, formulations were applied in a volume of 10 µl PBS, 5 µl per nostril. For i.m. 
administration, 25 µl of formulation in PBS was injected in the thigh muscle. Blood samples 
were taken from the tail vein before every immunization and 2 weeks after the final booster 
dose.  
 
Determination of serum IgG, IgG1, IgG2a and secretory IgA 
Microtiter plates were coated with 100 ng OVA in carbonate buffer pH 9.4 for 24 hours at 
4°C. To reduce non specific binding, wells were blocked with 1% BSA in PBS for 1 hour at 37°C. 
Serial dilutions of serum ranging from 20 to 2*106, were applied for 1.5 hours at 37°C, nasal 
washes were added undiluted. OVA specific antibodies were detected using horseradish 
peroxidase (HRP) conjugated goat anti mouse IgG, IgG1, IgG2a or IgA (1 hour 37°C) and by 
incubating with tetramethylbenzidine (TMB)/H2O2 in acetate buffer pH 5.5 for 15 min at room 
temperature. Reaction was stopped with 2 M H2SO4 and absorbance was determined at 450 
nm with an EL808 microplatereader (Bio-Tek Instruments, Bad Friedrichshall, Germany) 
 
Statistics 
All the data of the in vitro studies were analyzed with a one-way ANOVA with 
Bonneferoni’s post-test, with the exception of size and zeta potential measurements, which 
were analyzed with a Students T-test. Antibody titers were analyzed with a Kruskal-Wallis test 






Physical characterization of nanoparticles 
The NP characteristics are summarized in Table 1. Dynamic light scattering showed fairly 
monodisperse (PDI<0.25) NP with an average size of about 300 nm (PLGA and TMC NP) or 450 
nm (PLGA/TMC NP). PLGA NP carried a negative charge at pH 7.4, whereas TMC NP and 
PLGA/TMC NP were slightly positively charged. Encapsulation efficiency of OVA (pI 4.8) was 
much higher in the positively charged particles (71.6% and 60.2%) compared to PLGA NP 
(34.2% p<0.05).  
 
Table 1: Physical properties of OVA-loaded nanoparticles. Values represent mean +/- standard 
deviation of 5 independently prepared batches. 






320 +/- 17.9 0.151 +/- 0.033 - 48.2 +/- 0.59 34.2 +/- 3.3 
PLGA/TMC/OVA 
 
448 +/- 55.9 0.234 +/- 0.031   24.5 +/- 0.90 71.6 +/- 6.2 
TMC15/TPP/OVA 
 
258 +/- 28.8 0.200 +/- 0.020   10.4 +/- 0.20 60.2 +/- 4.1 
 
SEM reveals the size and the shape of the particles after air drying. The mean size of the 
PLGA and PLGA/TMC NP corresponded well to the size found with DLS. TMC NP appeared to 
be smaller than measured with the DLS, probably due to dehydration of the sample. PLGA and 
PLGA/TMC NP had a spherical appearance and a smooth surface (Figure 1). In contrast, TMC 











Figure 1: Scanning electron microscopy images of OVA-loaded nanoparticles: a) PLGA NP, b) 
PLGA/TMC NP and c) TMC NP. 
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To simulate the stability of the NP after nasal administration, the size of the NP was 
assessed in vitro by incubation in PBS at 37°C (Figure 2). PLGA/TMC and TMC NP showed a 
small (<30%), but not significant (p>0.05) size increase, within 8 hours. TMC NP showed signs 
of aggregation, as the PDI increased (p<0.05). No changes in size and PDI values for the PLGA 




















Antigen release and stability 
Release of OVA-FITC from the nanoparticles was monitored over 25 days in PBS pH7.4 at 
37°C. PLGA NP showed no significant burst release (figure 3b) and up to 80% of their original 
content in 25 days (figure 3a). In contrast, TMC NP showed 20-30% release within the first 24 
h, followed by no release over the remainder of 25 days. However, the release of OVA by 
these particles was enhanced by further dilution in PBS (figure 3b), showing that the 
disintegration of TMC NP is dependent on the concentration and thus is likely to occur very 
rapidly in vivo. This concentration dependent initial release was not observed for PLGA NP. 
PLGA/TMC NP showed release characteristics of TMC as well as PLGA NP, as a moderate 
concentration dependent OVA release over the first 24 h was observed (20% at 1 mg/ml, 
figure 3b), followed by progressive release up to 100% after 12 days (figure 3a).  
Figure 2: Short term (8 h) stability of OVA-loaded NP in PBS at 37°: a) PLGA NP, b) 
PLGA/TMC NP and c) TMC NP. Results are the average +/- SD of 3 independently 




As PLGA particles have been described as deleterious for the stability of incorporated 
biopharmaceuticals [30], the integrity of encapsulated (Figure 4a) OVA was investigated with 
SDS-PAGE and Western blotting. Sonication and contact with DCM did lead to some 
degradation and aggregation, however the majority of the OVA appeared to be intact with 
respect to preservation of size and epitopes (Figure 4a lane 2,4,5). Moreover, encapsulation in 
PLGA and TMC NP did not seem to adversely affect the integrity of OVA (figure 4a lane 4-6). 
However, OVA extracted from PLGA and PLGA/TMC was not recognized by anti-OVA IgG 
antibodies to a similar extent as native OVA or OVA extracted from TMC NP (figure 4b), 
indicating that some of the B-cell epitopes of OVA may have been damaged during the 
encapsulation process. 
                                                                                                                                                     















To explore the safety characteristics of the particles for nasal vaccination, the CBF was 
measured after 45 min exposure to the particle dispersions in PBS (Figure 5). Poly-
(ethylenimine) (PEI) was used as positive (toxic) control. Application of a 0.5 mg/ml PEI 
solution resulted in the complete disappearance of the CBF, within 45 minutes. After removal 
of the polymer, no recovery of the CBF was recorded. All nanoparticulate formulations were 
less toxic than PEI solution and did not significantly decrease the CBF. Only at high 
concentrations (5 mg/ml) TMC/TPP slightly decreased the CBF by about 20% (data not shown).  
 
 
Figure 3: OVA release from PLGA NP (circles), PLGA/TMC NP (squares) and TMC NP (triangles).  
a) OVA release from 1 mg/ml particle dispersions was monitored over 25 days at 37°C in PBS. 
b) Burst release of OVA from these particles as function of NP concentration, assessed after 1 h 
incubation in PBS (pH7.4). Results are the average +/- SD of 3 independently prepared batches. 






































Figure 4: Stability of OVA after encapsulation into nanoparticles. a) Silver stained SDS-PAGE 
gel; b) Anti-OVA Western blot of a second gel run in parallel. 1 = OVA stock solution, 2 = OVA 
2x15 s sonicated, 3 = OVA 2x15 s sonicated + DCM extracted, 4 = OVA extracted from PLGA 
NP, 5 = OVA extracted from PLGA/TMC NP and 6 = OVA extracted from TMC NP. Gel and blot 
are representative examples of 3 experiments. 
 
Figure 5: Ciliary beat frequency 
after exposure to 0.5 mg/ml 
OVA-loaded nanoparticles as a 
measure for nasal cilia toxicity. 
Nasal epithelium was exposed 
for 45 min to formulations, after 
which the epithelium was 
washed (arrow) and the CBF 
allowed to recover for 90 min. 
Closed diamond = non-exposed, 
closed circle= PEI solution (0.5 
mg/ml), open square= PLGA, 
open triangle= PLGA/TMC and 
closed square= TMC/TPP. Data 





Nasal residence time 
Prolonging the residence time of an antigen may be crucial for nasal delivery, as it 
increases the chance of absorption into the nasal epithelium. Using a fluorescent label we 
were able to study the clearance of OVA from the nasal cavity. An exponential decay in 
fluorescence intensity was observed for all formulations (Figure 6). The data could be 
reasonably fitted by an exponential decay function, from which apparent first-order clearance 
rate constants were determined (Figure 6 insert). Compared to an OVA solution, only TMC NP 
significantly decreased the clearance rate (p<0.01). The particulate structure of PLGA NP did 



























Figure 6: Nasal residence time of OVA determined using fluorescence detection of OVA-IRdye CW 
800. a) Emission (λ=800 nm) 0, 20, 40 and 100 min after nasal administration of OVA-IRdye CW 
800. b) Intensity of fluorescence signal from the nasal cavity normalized for time point 0. 
Individual time points were fitted using a model for exponential decay. b-insert) apparent first-
order clearance rate constants of OVA from the nasal cavity were derived from exponential fits. 
Data represent mean +/- SD of n=3. * p<0.01 
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Dendritic cells studies 
Interaction and uptake of the nanoparticles by monocyte derived DC was studied using 
flow cytometry (Figure 7a) and confocal microscopy (Figure 7b,c). The positively charged 
particles (PLGA/TMC NP and TMC NP) interacted strongly with DC compared to PLGA NP and 
OVA alone (p<0.05). However, in the same experiment conducted at 4°C similar fluorescence 
levels for PLGA/TMC NP and TMC NP treated cells were observed, indicating that the 
fluorescence was mainly caused by association to the cell membrane rather than uptake by 
the DC. Indeed, confocal microscopy showed little evidence for TMC NP uptake (nor 
PLGA/TMC uptake, data not shown) by DC as the particles were almost exclusively detected 
on the outside of the cell membrane (Figure 7c). This is in contrast to a solution of OVA which 
accumulated in lysosomal compartments (Figure 7b).  
 
                   
                 


















Despite being poorly taken up by DC, TMC NP were able to induce DC maturation (figure 
8). Although the expression of all measured maturation markers was not as extensive as after 
LPS exposure, it was significantly increased (p<0.05) compared to OVA or PLGA NP, both of 
Figure 7: Interaction of 
OVA-loaded nanoparticles 
with DC. a) Association of 
particles with human DC 
quantified using flow 
cytometric analysis. Bars 
represent mean +/- SD of 6 
different monocytes 
donors. *p<0.05 compared 
to OVA 37°C. Merged 
confocal microscopy 
image of DC exposed to b)  
OVAalexafluor647 (Red) and 
Lysotracker® (Green) or c) 
TMC/TPP/OVAalexafluor647 
and Lysotracker. Orange 





which did not result in increased DC maturation. Again TMC coated PLGA NP appeared to be 
the middle ground between PLGA and TMC NP, as all maturation markers seemed to be a bit 





























Nasal vaccination revealed considerable differences between the NP. Negligible IgG titers 
were detected after nasal vaccination with PLGA NP and PLGA/TMC NP, whereas only a 
priming dose of TMC NP was necessary (p<0.001 compared to OVA) to induce detectable OVA 
specific IgG antibodies (figure 9). After the 3 nasal challenges, TMC NP immunized mice even 
Figure 8: DC maturation after 48h stimulation with OVA-containing nanoparticles. 
Levels of a) MHCII, b) CD83 and c) CD86 were expressed as a percentage of LPS 
stimulated DC. Histogram represents the mean of 6 independent experiments. Error 
bars are SEM. * p<0.05 **p<0.01 vs. OVA-treated DC. 
a b
c
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showed similar IgG titers as their i.m. vaccinated counterparts. Furthermore, only nasal 
washes from TMC NP nasally immunized mice contained OVA specific sIgA (figure 10b). All 
mice responded to i.m. immunization, irrespective of the formulation administered (figure 9). 
However, the NP formulations were more immunogenic than an OVA solution. Both PLGA NP 
and TMC NP elicited high IgG titers after a priming dose, whereas the titers induced by 
PLGA/TMC NP were only slightly higher than the OVA induced titers (p<0.01). Vaccination with 
PLGA NP caused a significant shift in the IgG1/IgG2a ratio towards IgG2a compared to i.m. 




























Figure 9: OVA specific IgG titers in serum of Balb/c mice 3 weeks after a priming, booster 
and 2nd booster dose of 20 µg OVA administered i.m. or nasally. Data represent mean +/- 























Although nanoparticles have been described as very promising nasal vaccine carriers [8, 
13], surprisingly little is known about the physicochemical properties of nanoparticles in 
relation to the immune response they elicit. The particle size is probably one of the 
parameters which is most adequately described, as several studies using micro- and 
nanoparticles point to smaller particles being more immunogenic [8, 10, 11, 31-33]. Studies by 
Jung et al. and Gutierro et al. seem to indicate, however, that intranasally applied antigen-
loaded particles of about 200 nm and 500 nm do not differ in immunogenicity [10, 32]. As the 
nanoparticles in our present study were all smaller than 500 nm and showed only minor 
differences in size compared to the above range, size variation between the particles is most 
probably not the factor that caused the differences in immunogenicity. To a somewhat lesser 
extent, the zeta potential of particles has been investigated, leading to the conclusion that a 
positive surface charge may be favourable in nasal vaccination [9, 21, 34, 35]. The result of our 
present study supports that conclusion, as the positively charged TMC NP outperformed the 
negatively charged PLGA NP after nasal administration. However, it is also clear that the zeta 
potential is not the sole determinant of the resulting antibody responses. TMC and PLGA/TMC 
Figure 10: a) IgG1/IgG2a balance after i.m. vaccination, and for TMC NP also after nasal 
vaccination. ‡ p<0.05 compared to OVA. Bar represents mean. b) OVA specific sIgA in 
nasal washes of mice after i.m. (grey bars) or nasal (white bars) administration. Bars 
represent mean (i.m. n=5, nasal n=8) +/- SEM .*** p<0.001 compared to naïve mice. 
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NP are both positively charged, but TMC NP induced superior IgG titers compared to 
PLGA/TMC NP.  
Although measuring immune responses after nasal administration of antigen loaded 
nanoparticles is very useful, it restricts us to a mere trial-and-error based approach of nasal 
vaccine design. For instance, it does not answer the question why PLGA/TMC NP elicit a 
different immune response than TMC NP. Both particles are in the same size range and do not 
contain any known immunomodulatory substances other than TMC [20, 36, 37]. Focusing on 
the various aspects of nasal vaccination; like the clearance from the nasal cavity, the uptake by 
DC and the maturation of antigen-presenting cells as function of particle characteristics may 
answer this question and would allow us to improve nanoparticulate vaccine carriers in a 
rational way. Using this approach, we were able to explain differences in immunogenicity 
between PLGA, PLGA/TMC and TMC NP. Both PLGA and PLGA/TMC NP failed to elicit an 
antibody response after nasal vaccination. Nonetheless, after i.m. administration both 
particles induced higher IgG titers than OVA, implying that these particles can augment the 
immune response, but are not suitable for nasal administration. In contrast, TMC NP elicited 
strong antibody responses via both vaccination routes, indicating that TMC NP have certain 
characteristics which are profitable for nasal vaccination.  
Like PLGA and PLGA/TMC NP, TMC NP were found not to be toxic to the cilia (figure 5) or 
mucosal epithelial cells [38-40] and are therefore likely do not damage the nasal epithelium. 
TMC NP do not promote the uptake by DC (figure 7), but do prolong the residence time of 
OVA in the nasal cavity (figure 6), compared to PLGA and PLGA/TMC NP. The nasal residence 
time of OVA encapsulated in the particles correlates with the IgG titers of mice nasally 
challenged with these particles, suggesting that the difference in immunogenicity between the 
particles is related to the delivery of antigen into the nasal epithelium.  
PLGA’s immunopotentiating effect after parenteral administration has been attributed to 
its slow release characteristics, leading to a depot formation and subsequently causing 
enhanced B-cell and T-cell proliferation [41-43]. Indeed, PLGA and PLGA/TMC NP released 
their content over a prolonged period of time (figure 3) and showed an increased antibody 
response when administered by i.m. injection. PLGA/TMC NP released OVA faster than PLGA 
in vitro, which may contribute to the slightly lower IgG titers in mice immunized i.m. with 
PLGA/TMC NP, as compared to the PLGA NP group. Although depot formation can be a 
mechanism to potentiate the immune response after parenteral injections, it is very unlikely 
that it is a driving force behind nasal vaccination, as the nasal residence time is limited. 
Moreover, in contrast to uptake by DC, antigen uptake by B-cells is a highly specific process 
mediated by the contact of the antigen with the B-cell receptor [44]. Therefore, uptake of OVA 
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by B-cells will be dependent on either surface coated or released OVA and encapsulated 
antigen is not easily taken up by B-cells [45]. As a consequence, for nasal vaccination a slow 
release rate may be detrimental as only little time for B-cell uptake is available. Keijzer et al. 
indeed showed that nasal immunization of mice with TMC NP and to a lesser extent 
PLGA/TMC, but not PLGA NP, results in OVA specific B-cells in the nasal associated lymphoid 
tissue and in cervical lymph nodes (manuscript in preparation). In the same study nasal 
immunization with PLGA NP or PLGA/TMC NP of mice which received an adoptive transfer of 
OVA specific CD4+ T-cells showed effective T-cell activation and proliferation in the nasal 
associated lymphoid tissue and cervical lymph nodes. This indicates that PLGA and PLGA/TMC 
NP do cross the nasal epithelium and are taken up by DC (which in turn are capable of 
activating T-cells), but do not deliver their antigen to B-cells as effectively as TMC NP. 
Finally, the nasal epithelium is renowned for being a tolerogenic site, making maturation of 
imDC into mature DC essential for an effective nasal vaccine. TMC NP were shown to stimulate 
the maturation of imDC, which may contribute to TMC NP’s effectiveness as a nasal adjuvant. 
OVA-loaded PLGA particles have been reported before not to increase DC maturation [39, 46] 
and although TMC has been reported as an adjuvant [23], the addition of TMC to the PLGA 
particles only caused a small increase in expression of maturation markers (Figure 8). This 
could be explained by the substantially higher ratio TMC:OVA in the TMC NP compared to the 
PLGA/TMC particles (10:1 vs. 2:1), or to the different architecture of TMC NP versus 
PLGA/TMC particles. 
The data presented in this study indicate that contributing factors to TMC NP being a good 
nasal vaccine carrier system may be that they (i) prolong the nasal residence time of its 
incorporated antigen, (ii) quickly release the antigen to promote the formation of OVA specific 
B-cells and (iii) effectively induce DC maturation breaking the nasal tolerance. However, TMC 
NP vaccinated mice showed little evidence of activation of the cellular arm of the immune 
system; the IgG1 titers far exceeded the IgG2a titers (figure 10a). This is in line with previous 
studies demonstrating that the use of TMC as an adjuvant induces Th2 type responses [20, 23, 
47]. The addition of a Th1 skewing adjuvant (like CpG) to the TMC NP could make these 












The composition and characteristics of nanoparticles greatly influence the extent and the 
type of immune response elicited after nasal vaccination. TMC NP were shown to be superior 
over PLGA NP and PLGA/TMC NP in the elicitation of antibody responses after nasal 
administration. This may be due to their mucoadhesiveness, the rapid release of the contained 
antigen, and immune stimulatory capacity, in order to respectively prolong the nasal residence 
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In recent years, biocompatible and biodegradable polymeric nanoparticles have gained 
interest as antigen delivery systems. We investigated whether antigen-encapsulated PLGA 
(poly-Lactic-co-Glycolic Acid), PLGA-TMC (N-Trimethyl Chitosan) and TMC-TPP (Tri-Poly-
Phosphate) nanoparticles can be used to modulate the immunological outcome towards 
active immunity or mucosal tolerance after nasal application.  
The model protein ovalbumin (OVA) was encapsulated into PLGA, PLGA-TMC or TMC-TPP 
nanoparticles to explore induction of the antigen-specific B cell mediated humoral response 
and CD4+ T cell mediated responses after nasal application in a BALB/c mouse model.  
We have demonstrated that nanoparticles enhanced the antigen presentation capacity of 
dendritic cells as shown by increased in vitro CD4+ T cell proliferation. We showed that nasal 
vaccination with low-dose OVA-encapsulated nanoparticles enhanced CD4+ T cell proliferation 
in contrast to low-dose sOVA treatment and that this coincided with enhanced FoxP3 
expression in the NALT and CLN only when PLGA encapsulated OVA was applied. In nasal 
prime boost vaccination studies we showed that only with TMC-TPP treatment a humoral 
immune response was induced, which coincided with the enhanced generation of OVA-
specific B cells in the CLN. Finally, in an OVA-specific DTH-model, nasal vaccination with PLGA 
nanoparticles induced mucosal tolerance as revealed by decreased levels in ear swelling at 24 
h post challenge.  
We have uncovered a role for nanoparticles to differentially direct the nasal mucosal 
immune response, towards B cell mediated protective immunity or towards CD4+ T cell 
mediated mucosal tolerance. The exploitation of this differential regulation capacity of 
nanoparticles to guide the immune response towards active or tolerogenic responses can lead 
to innovative vaccine development for prophylactic vaccination required in infectious diseases 















Nasal vaccination is mainly described for the prevention of infectious diseases such as 
hepatitis B [1, 2] or influenza [3, 4]. However, in recent years, nasal application of antigen has 
become of interest in therapeutic interventions in the field of autoimmunity [5-8] and allergies 
[9]. Similar to other forms of mucosal immunization, such as oral immunization, nasal antigen 
application can stimulate antigen-specific responses locally and in the peripheral mucosal 
tissues [10-15]. Vaccination via the nasal mucosa might be preferred over oral vaccination due 
to the lower proteolytic activity at the nasal mucosa; this route of immunization requires a 
lower dose of antigen than for example oral immunization. Simultaneously, low antigen 
exposure might also reduce the chance of developing side-effects [16]. In general, mucosal 
antigen application can elicit protective immunity and/or a state of immunologic 
unresponsiveness, also termed antigen-specific mucosal tolerance [17-19]. Therefore, also 
nasal vaccination may divert immune responses to either activation of a protective antibody 
and/or T cell response desired during conventional vaccination or it may induce 
immunological tolerance desired as therapeutic treatment of autoimmune diseases. 
The effectiveness of a nasal vaccine depends largely on the uptake of antigen by the 
nasopharynx-associated lymphoid tissue (NALT) [10, 11, 14, 15]. Since antigens are known to 
be more immunogenic in particulate form than in soluble form, advanced vaccine delivery 
systems are being developed, that specifically target NALT epithelium to enhance mucosal 
immunity [3, 13, 16, 20]. Nanoparticles are an example of such delivery systems and seem to 
be promising candidates for nasal vaccination due to their non-toxic characteristics [20-22].  
In recent years, several in vivo studies have been conducted to investigate the additive role 
of nanoparticle mediated enhanced delivery of antigen at mucosal sites. The readout to 
evaluate the effectiveness of the applied vaccine relied mostly on induction of humoral 
responses as indicated by increased antigen-specific antibody titers [3, 23, 24]. However, it 
does not give insight in the underlying immunological mechanism that drives the response 
towards active immunity or tolerance induction. In addition, little is known about the role of 
CD4+ T cells in nasal vaccination and how nanoparticle treatment might influence the 
activation of these cells, locally and in the peripheral tissues. Therefore, we set out to 
understand how we can direct the induced response towards active immunity or tolerance 
through nasal nanoparticle delivery. In general, it is accepted that the induced response 
following mucosal antigen application depends on many factors such as the nature of the 
antigen (soluble versus particulate), antigen dose, size and delivery to the mucosal tissues as 
shown by previously conducted studies. For example, nasal application of TMC-TPP particles is 
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known to elicit a more active immune response as described by Amidi et al [3] . In this study, 
mice received three successive intranasal treatments with 3 weeks interval of TMC-TPP 
containing monovalent H3N2 influenza antigen particles with an average size of 800 nm. 
Treated mice showed a significant increase in antigen-specific immune responses as shown by 
an increase in antigen-specific IgG1/IgG2a serum titers and increased IgA titers in nasal 
washes  [3].  
In contrast to induction of active immunity, a study conducted by Kim Wan-Uk et al [23] 
showed that mice fed with a single dose of 40 µg of type II collagen (CII)-containing PLGA 
particles, with an average size of 300 nm, had reduced severity of arthritis and reduced anti-
CII-specific IgG antibody titers and CII-specific T cell responses. 
As mentioned before, the nasal route of antigen delivery has some advantages compared 
to oral application. Since this route of immunization requires a lower dose of antigen due to 
the low proteolytic activity locally, it might also reduce the chance of developing side-effects 
[16]. This could be of great benefit in the treatment of ongoing chronic inflammatory diseases, 
such as rheumatoid arthritis.  
To study the mechanisms behind active immunity or tolerance after nasal vaccination in more 
detail, we chose three polymeric nanoparticles that have previously shown to provoke active 
immunity or tolerance after nasal administration; PLGA (poly-lactic-co-glycolic acid) [25, 26], 
PLGA-TMC (N-trimethyl chitosan) [27] and TMC-TPP (tri-polyphosphate) [28, 29] nanoparticles 
that all contained the model antigen ovalbumin (OVA). These particles have a similar average 
diameter, but differ in their surface charge and antigen release kinetics [24]. We investigated 
whether these nanoparticles can shift the immunological outcome towards active immunity or 
tolerance after nasal antigen application.  More specifically, we have explored the effect of 
nasal application of OVA-encapsulated nanoparticles compared to soluble OVA delivery. More 
insight in the mechanism by which nanoparticles drive the immune response towards 
tolerogenic or protective responses will assist future rational vaccine design not only to 
prevent infectious diseases but also for therapeutic vaccination in autoimmune diseases.  
 
 
Materials and Methods  
 
Mice 
Male BALB/c mice (8-12 weeks) were purchased from Charles River Laboratories 
(Maastricht, The Netherlands). OVA-specific TCR transgenic (Tg) mice on BALB/c background 
(DO11.10 mice) [30], were bred at the Central Animal Laboratory (GDL), Utrecht University, 
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the Netherlands. All mice were kept in our animal facility under routine laboratory conditions. 
Experiments were approved by the Animal Experiment Committee of the Utrecht University 
(Utrecht, The Netherlands). 
   
Antibodies, antigens and OVA encapsulated nanoparticles  
In all in vitro and in vivo experiments, intact 98% pure OVA (either from Sigma Aldrich 
(Zwijndrecht, The Netherlands) or from Calbiochem (San Diego, CA) was used. OVA-
encapsulated PLGA, PLGA-TMC and TMC-TPP nanoparticles were generated as described 
previously [24]. The anti-clonotypic mAb for the DO11.10 Tg TCR (KJ1.26) was purified from 
culture supernatant and biotinylated, according to the manufacturer’s protocol (Molecular 
Probes, Leiden, The Netherlands). 7-Amino-actinomycin-D (7-AAD)-unconjugated, Anti-CD11c 
(HL3), anti-CD4 (RM4-5), anti-CD40 (3/23), anti-CD86 (GL1), anti-MHC class II (M5/114), anti-
CD25 (PC61) and anti-CD69 (H1.2F3) antibodies were purchased from BD Pharmingen 
(Woerden, The Netherlands). Anti-FoxP3-PE (FJK-16s) and an appropriate isotype control were 
purchased from eBioscience (Breda, The Netherlands).  
 
DC isolation and culture 
Bone marrow-derived dendritic cells (BMDC) were cultured from BALB/c donor mice as 
previously described by (Lutz 1999) with minor modifications. Briefly, on day 0, femurs and 
tibia of adult BALB/c mice were flushed with Iscove’s Modified Dulbecco’s Medium (IMDM; 
Gibco, Invitrogen) that contained heat-inactivated 10% FCS (Bodinco). Single cell suspensions 
were seeded at 3 x 106 per petri dish in complete medium with 20 ng/ml murine rGM-CSF 
(Cytogen). On day 2 and 4, 10 ng/ml murine rGM-CSF was added. On day 7, the BMDCs were 
harvested and used for further experiments. 
 
CD4+ T cell enrichment and CFSE labeling 
Spleens were isolated from DO11.10 donor mice and were prepared into single cell 
suspensions. Erythrocytes were lysed and CD4+ T cells were obtained by negative selection 
with sheep-anti-rat IgG Dynabeads (Dynal, Invitrogen, Breda, the Netherlands) using an excess 
amount of anti-B220 (RA3-6B2), anti-CD11b (M1/70), anti-MHC class II (M5/114), anti-CD8 
(YTS169) mAbs. Enriched CD4+ T cells were routinely pure between 85 and 90%. Labeling of 
cells with carboxy-fluorescein diacetate succinimidyl ester (CFSE; Molecular Probes, Leiden, 





In vitro effect of nanoparticles on BMDC maturation, antigen uptake and T cell activation 
To address direct maturation of BMDC by nanoparticles, BMDC were cultured in the 
presence of OVA containing PLGA, PLGA-TMC or TMC-TPP nanoparticles (25 ng/ml to 1 µg/ml), 
or 10 ng/ml LPS (Sigma) as a maturation control. After 24 h, DC maturation was determined by 
flow cytometry (FACS-Calibur; BD Pharmingen) and FlowJo Software V8.8.6. 
BMDCs were incubated for 1.5 hours at either 4°C or 37°C with FITC-labeled OVA protein 
purchased from Molecular probes (Invitrogen, Breda, the Netherlands) solved in saline or 
incorporated into PLGA, PLGA-TMC or TMC-TPP. To quench external FITC, trypan blue stain 
(Gibco, Invitrogen) was added to each sample 5 minutes before FACS analysis at a final 
concentration of 0.02%. OVA-FITC uptake by BMDCs was analyzed by flow cytometry. BMDCs 
were pre-incubated at 37°C for 2 h in the presence of OVA protein solved in saline or OVA-
nanoparticles; PLGA, PLGA-TMC or TMC-TPP at concentrations of 25 ng/ml, 0.5 µg/ml or 1 
µg/ml.  OVA-specific CD4+ T cells were added at a 1:10 ratio and T cell proliferation was 
assessed at 72 h post culture by CFSE dilution. 
 
T cell activation in the local lymph nodes after nanoparticle vaccination 
BALB/c acceptor mice were adoptively transferred with 1.107 CFSE-labeled CD4+KJ1.26+ 
cells in 100 µl saline, intravenously (i.v.) injected via the lateral tail vain. The next day mice 
received either a single application of 30 µg of OVA i.n. solved in 10 µl of saline or 
encapsulated into PLGA, PLGA-TMC or TMC-TPP nanoparticles, or  a single immunization of 30 
µg of OVA intramuscularly (i.m.) in the hind limbs solved in 50 µl of saline or encapsulated in 
nanoparticles. At 72 h post i.n. or i.m. OVA administration, the spleen, the nose-draining NALT 
[11, 32] and cervical lymph nodes (CLN) as well as the thigh-draining inguinal lymph nodes 
(ILN) were removed and single cell suspensions were analyzed to evaluate in vivo T cell 
division by flow cytometry as described earlier.      
    
Nasal prime-boost vaccination 
BALB/c mice received three nasal applications of 20 µg of OVA i.n. dissolved in 10 µl of 
saline or encapsulated into PLGA, PLGA-TMC or TMC-TPP nanoparticles, with a 3 week 
interval. Three weeks after third OVA vaccination, the spleen, NALT and CLN were removed 
and single cell suspensions were analyzed to evaluate OVA-specific T and B cell responses. 
Single cell suspensions were restimulated with  OVA protein at final concentrations of 100 
µg/ml for a 72 h period and 0.4 µCi 3H-thymidine (Amersham Health, Little Chalfont, 
Buckinghamshire,UK) was added for an additional 18 h to address proliferation. Supernatants 
were analyzed for cytokine production. 
Nanoparticles modulate balance between immunity and tolerance 
 
 97 
The in vivo B cell response was assessed by detection of OVA-specific antibody titers in 
serum of immunized mice as described elsewere [24] by ELISPOT. Single cell suspensions from 
the NALT, CLN and spleen were cultured with OVA (1 µg/well) or control high protein binding 
filter plates (MultiScreen-IP, Millipore) for 48 hours. After incubation, SFC were detected with 
goat- anti mouse IgG-biotin (Sigma), Avidin-AP (Sigma). Plates were developed with NBT-BCIP 
(Roche) and analyzed by using the Aelvis spotreader and software. Data are shown as the net 
OVA-specific B cell count per 1*106 cells calculated as background (spots medium coated 
plates) substracted from OVA-specific spots. 
 
Mucosal tolerance induction and delayed-type hypersensitivity (DTH) reaction Balb/c mice 
received 20 µg of OVA i.n. three times at 24 h intervals either dissolved in saline or 
encapsulated in PLGA, PLGA-TMC or TMC-TPP nanoparticles. Control groups received saline 
alone or OVA at a final concentration of 300 µg in saline. Mice were sensitized for a DTH the 
next day with 100 µg of OVA in 25 µl of saline, mixed with 25 µl of IFA (Difco, BD. Alphen a/d 
Rijn, The Netherlands) subcutaneously (s.c.) administered in the tail base. Five days later, 
directly before challenge, the initial thickness of both ears was measured with an engineer’s 
micrometer (Mitutoyo, Tokio, Japan). Subsequently, mice were challenged with 10 µg of OVA 
in 10 µl of saline given in the auricle of each ear and 24 h post-challenge, increase in ear 




The amount of cytokine secreted during a 72 h re-stimulation period was assessed by 
analyzing the culture supernatants. Briefly, fluoresceinated microbeads coated with capture 
antibodies for simultaneous detection of IFN-γ (AN18), IL-2 (JES6-1A12), IL-4 (BVD4-1D11), IL-5 
(TRFK5), IL-6 (MP5-20F3), IL-10 (JES5-2A5), IL12p70 (9A5), IL-17A (TC11-18H10) and TNF-α 
(G281-2626)(BD Biosciences Pharmingen) were added to 50 µl of culture supernatant. 
Cytokines were detected by biotinylated antibodies IFN-γ (XMG1.2), IL-2 (JES6-5H4), IL-4 
(BVD6-24G2), IL-5(TRFK5), IL-6 (MP5-32C11), IL-10 (SXC-1), IL12p70 (C17.8), IL-17(DuoSet 
ELISA kit, R&D systems Europe Ltd, Oxon, the U.K.) and TNF-α (MP6-XT3)(BD Biosciences 
Pharmingen) and PE-labeled streptavidin. Flurescence was measured using a Luminex model 







Total mRNA was purified from single cell suspensions from NALT, CLN, ILN or spleen using 
the RNeasy kit (Qiagen Benelux B.V.) according to the manufacturer’s protocol. RNA was 
reverse transcribed into cDNA using the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, 
B.V) according to the manufacturer’s protocol. Real-time quantitative PCR was performed 
using a MyiQ Single-Color Real-Time PCR detection system (Bio-Rad Laboratories B.V.) based 
on specific primers and general fluorescence detection with SYBR Green (iQ SYBR Green 
Supermix, Bio-Rad laboratories, Hercules, CA). Conditions for the Real-time quantitative 
reaction were (95°C for 3 min and 40 cycles of 95°C for 10 s and 59.5°C for 45 s). Expression 
was normalized to the detected Ct values of hypoxanthine-guanine phosphoribosyltransferase 
(HPRT) for each sample. The expression levels relative to HPRT were calculated according to 
the Real-Time PCR Bio-Rad manual by following the equation: relative expression level = 2-ΔΔCt 
(Livak Method).  
Specific primers were designed across different constant region exons resulting in the 
following primers: 
 
HPRT sense 5’-CTGGTGAAAAGGACCTCTCG-3’, antisense 5’- TGAAGTACTCATTATAGTC 
AAGGGCA-3’. IL-10 sense 5’- GGTTGCCAAGCCTTATCGGA-3’, antisense 5’- ACCTGCTCC 
ACTGCCTTGCT-3’. FoxP3 sense 5’- CCCAGGAAAGACAGCAACCTT-3’, antisense 5’-TTCT 
CACAACCAGGCCACTTG-3’. IL-4 sense 5’- GGTCTCAACCCCCAGCTAGT-3’, antisense 5’- 
GCCGATGATCTCTCTCAAGTGAT-3’. IL-17 sense 5’- GCTCCAGAAGGCCCTCAGA-3’, anti sense 5’- 
AGCTTTCCCTCCGCATTGA-3’. IFN-γ sense 5’- TCAAGTGGCATAGATGTGGAAG AA-3’, antisense 
5’- TGGCTCTGCAGGATTTTCATG-3’. T-BET sense 5’- CAACAACCCCTTT GCCAAAG-3’, antisense 




Statistical analysis was performed with Prism software (Graphpad Software Inc., San Diego, 
version 4.00) using an unpaired two-tailed Student’s t test, a one-way ANOVA followed by 
Tukey’s multiple comparison test or by Dunn’s multiple comparison test or Bonferroni’s 
multiple comparison test. Error bars represent the SEM as indicated. Statistical differences for 
the mean values are indicated as follows: *, P< 0.05; **, P< 0.01; ***, P<0.001. 





Differential uptake of OVA labeled FITC by BMDCs after in vitro nanoparticle treatment 
From previous studies we know that nanoparticles show differences in localization after DC 
encounter as visualized by tracing uptake of OVA [20]. Based on these results we hypothesized 
that these differences in localization might modulate the subsequent antigen presentation 
capacity of DCs. 
To investigate this hypothesis, we treated DCs in vitro with OVA encapsulated PLGA, PLGA-
TMC or TMC-TPP nanoparticles or soluble OVA (sOVA) as a control and studied phenotypic and 
functional differences. First we studied whether nanoparticle treatment has an effect on DC 
maturation, viability and differentiation. The cells were stained for CD11c+, MHC-class-II+, and 
7-AAD- and analyzed for their expression of CD40 and CD86. We did not observe differences in 
DC viability or maturation after nanoparticle treatment at OVA concentrations varying from 1 
ng/ml to 1 µg/ml. Furthermore, we could not detect significant differences in culture 
supernatants that were analyzed for cytokine secretion of TNF-α, IL-12p70, IL-4, IL-5 (data not 
shown).  
Next, we studied the uptake of the PLGA, PLGA-TMC and TMC-TPP nanoparticles with OVA 
labeled FITC. Then the cells were stained for CD11c and MHC-class-II and uptake of OVA-FITC 
was assessed by flow cytometric analysis after silencing extracellular FITC signaling with trypan 
blue. OVA-FITC association with DCs is shown as the FITC ΔMFI expression (figure 1A) or 
percentage of OVA-FITC positive cells (figure 1B).  
OVA-FITC uptake by DCs treated with TMC-TPP was lower compared to soluble OVA 
(sOVA)-FITC treatment as shown by a low FITC ΔMFI expression and decreased percentage of 
OVA-FITC positive cells (figure 1A-B). Furthermore, compared to sOVA, PLGA-TMC treatment 
enhanced the antigen uptake by DCs even at low (25 ng/ml) OVA concentrations. Both PLGA 
and PLGA-TMC treatment enhanced antigen uptake was observed with OVA at 0.25 µg/ml. We 
could not detect differences in antigen uptake at 1.00 µg/ml sOVA, PLGA or PLGA-TMC 
treatment suggesting a maximum antigen uptake after 1.5 h of incubation (figure 1B).   
In summary, nanoparticle characteristics affected the antigen uptake by DCs in vitro as 
shown by a lower number of OVA-FITC positive cells when DCs encounter TMC-TPP particles 







OVA-encapsulated nanoparticles enhance OVA-specific CD4
+
 T cell proliferation in vitro 
To investigate whether enhanced antigen uptake by DCs also affects the antigen 
presentation capacity of DCs, nanoparticle treated cells were studied in vitro by co-culture 
assay. DCs treated with OVA encapsulated PLGA, PLGA-TMC or TMC-TPP particles were 
cultured in the presence of OVA-specific CFSE-labeled CD4+ T cells isolated from spleen of 
DO11.10 mice. T cell proliferation as measured by CFSE dilution served as readout for antigen 
presentation efficiency of DCs.  
Antigen presentation capacity of DCs was significantly enhanced after nanoparticle 
treatment in contrast to sOVA since T cells stimulated by particle treated DCs showed 
enhanced T cell proliferation compared to T cells cultured in the presence of sOVA treated 
DCs. Especially, PLGA and PLGA-TMC particles potently enhanced CD4+ T cell proliferation 
even at a low OVA concentration of 25 ng/ml (figure 1C). Additionally, in the culture 
supernatants of T cells stimulated in the presence of 1.0 µg/ml OVA containing PLGA or PLGA-
TMC particles more IL-2, IFN-γ and IL-10 was detected compared to cultures with TMC-TPP 
particles or sOVA (figure 1D). 
In conclusion, all three OVA loaded nanoparticles enhanced the antigen presentation by 
DCs, as shown by increased CD4+ T cell proliferation profiles as compared to sOVA.   
 
 






































Figure 1:  Nanoparticle mediated enhanced antigen presentation capacity of BMDCs in vitro. BMDC were 
incubated in the presence of sOVA-FITC or OVA-FITC encapsulated into PLGA, PLGA-TMC or TMC-TPP 
nanoparticles at different concentrations. External FITC signaling was silenced by trypan blue. The ΔMFI of 
OVA-FITC was assessed by subtraction of FITC signaling at 4°C from 37°C (1A). OVA-FITC uptake by BMDC 
shown as the percentage of OVA-FITC positive cells 1.5 h post-culture were calculated as the percentage at 
4°C subtracted from the percentages at 37°C (1B). Data are representative for 3 independent experiments. 
mean ± standard error of the mean (s.e.m.).BMDCs were cultured in the presence of sOVA or OVA 
encapsulated into PLGA, PLGA-TMC or TMC-TPP nanoparticles at different concentrations and OVA-specific 
CFSE-labeled CD4
+
 T cells Gray filled histograms; unstimulated CD4
+
 T cells, Black overlays; CD4
+
 T cell 
division patterns at different OVA concentrations after 72 hours (1C). Data are are representative for at 
least 3 independent experiments. Cytokine concentrations of IL-2, IFN-γ and IL-10 (ng/ml) were determined 
in culture supernatants, after 72 h of culture (1D). Data are representative for 3 independent experiments. 






 T cell proliferation at mucosal (nasal) and non-mucosal 
(intramuscular) sites and enhanced local mRNA expression of FoxP3 after nanoparticle 
vaccination 
Next, we questioned whether nanoparticle treatment also affects T cell response in vivo. 
We know from former studies that especially TMC-TPP nanoparticles induced increased 
generation of antigen-specific IgG1 and IgG2a antibody titers after both i.n. and i.m. 
vaccination, whereas PLGA and PLGA-TMC only resulted in higher IgG titers after i.m 
vaccination and had little effect on the humoral immune response after i.n. treatment [24]. 
Here, we explored whether nanoparticle treatment affects the CD4+ T cell response and how 
this depends on nanoparticle type. First we studied the short-term CD4+ T cell response in 
mice that were either treated i.n. or i.m. with 30 µg of sOVA or OVA encapsulated particles. 
Proliferation of OVA-specific CFSE-labeled CD4+ T cells was addressed locally in the draining 
lymph nodes as well as systemic in the spleen at 72 h post treatment (figure 2A). 
Nasal vaccination enhanced local CD4+ T cell proliferation in the NALT and CLN compared 
to sOVA treatment, irrespective of the type of nanoparticles. However, none of the 
formulations induced measurable CD4+ T cell activation in the spleen at 72 hours after 
vaccination upon i.n. immunization (figure 2A; left). In contrast, non-mucosal vaccination 
resulted in proliferation both in the draining ILN and spleen at this time point (figure 2A; 
right). 
We could not detect significant differences in cytokine profiles in culture supernatants of 
the isolated draining CLN and ILN organs after particle vaccination (data not shown). 
However, we observed a significant increase in the relative FoxP3 mRNA expression in the CLN 
and a slightly increased expression in the NALT of mice that had received a single i.n. PLGA 
vaccination (figure 2B). Mice that were vaccinated i.m. with TMC-TPP particles showed less 
expression of FoxP3 mRNA compared to PLGA and PLGA-TMC treated mice. 
These data show that i.n. vaccination with low-dose OVA encapsulated nanoparticles 
enhanced CD4+ T cell proliferation in contrast to low-dose sOVA treatment (2A) and coincided 
with enhanced FoxP3 in the NALT and CLN only when PLGA encapsulated OVA was applied. 
This effect was lacking in the i.m. treated mice in all treatment groups (figure 2B) showing that 
both particle and route of application determine the outcome of the CD4+T cell response. 
Although induced CD4+ T cell proliferation mediated by TMC-TPP was less efficient compared 
to PLGA and PLGA-TMC treatment in vitro (figure 1C), we were not able to detect such 
significant differences in CD4+ T cell proliferation profiles in vivo (figure 2A).  
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Figure 2: Enhanced OVA-specific CD4
+
 T cell proliferation at mucosal and non-mucosal sites, after 
nanoparticle treatment. OVA-specific CFSE labeled CD4+ T cells were transferred to BALB/c acceptor mice one 
day prior to vaccination. Mice received a single i.n. application of 30 µg of sOVA or OVA encapsulated into 
PLGA, PLGA-TMC or TMC-TPP nanoparticles. For induction of a non-mucosal response, mice received a single 
i.m. immunization in the hind limbs. At 72 h post  i.n. or i.m. OVA administration, in vivo T cell division was 
addressed in  spleen, nose-draining NALT and CLN as well as the thigh-draining ILN (2A). Data are 
representative for at least 3 (intranasal) and 2 (intramuscular) independent transfer studies. 
Total mRNA was purified from single cell suspensions from *NALT, CLN, and ILN. Relative mRNA expression to 
HPRT of FoxP3 was determined 72 h post i.n. or i.m. OVA application (2B).  
NALT: intranasal treatment (cells isolated from NALT were pooled per group). CLN: PLGA (n=5); PLGA-TMC 





T cell and B cell response after nasal prime-boost vaccination 
In the previous study we explored the differences in the induction of an OVA-specific CD4+ 
T cell response in a T cell transfer study. The effect of differences in antigen delivery (soluble 
versus particulate), antigen dose (low or high) and route of administration (i.n. or i.m.) was 
assessed by comparing the induced CD4+ T cell response 72 h post nasal vaccination. We were 
able to detect a significant difference in the enhanced CD4+ T cell proliferation profile 72 h 
post nasal vaccination of mice that received a single low-dose of OVA encapsulated PLGA, 
PLGA-TMC or TMC-TPP nanoparticles in contrast to sOVA treatment (figure 2A). In addition, 
the local CD4+ T cell response seemed to be specifically shifted to a regulatory response upon 
i.n. PLGA treatment as shown by enhanced expression of the relative mRNA FoxP3 expression 
in these mice (figure 2B). As mentioned before, in a previous study we described that 
especially i.n. TMC-TPP vaccination induced enhanced generation of antigen-specific IgG1 and 
IgG2a antibody titers while PLGA and PLGA-TMC had hardly any effect on the induced humoral 
immune response [24].  
We performed an additional vaccination study to further assess the effect of i.n. 
nanoparticle treatment on the induction of an OVA-specific T cell or B cell response. Briefly, 
mice received 20 µg of OVA i.n. three times at three week intervals. Three weeks after the 
final OVA application single cell suspensions from the spleen, NALT and CLN were analyzed to 
evaluate OVA-specific T and B cell responses by 3H-thymidine incorporation or ELISPOT, 
respectively. We could not detect significant differences in the T cell proliferation profiles of 
CLN and spleen after i.n. treatment. However, a slightly enhanced T cell proliferation profile 
was observed after PLGA vaccination in contrast to PLGA-TMC and TMC-TPP as indicated by 
the SI and cpm (figure 3A-B).  
Beside the T cell response we investigated if nanoparticle treatment had a differential 
effect on B cell stimulation. Here, results showed that after i.n. vaccination, both sOVA and 
TMC-TPP treatment slightly enhanced the generation of OVA specific B cells locally in the 
draining CLN as shown in figure (figure 3C). Moreover, increased numbers of OVA-specific B 
cells were detected in the spleens of mice after TMC-TPP and PLGA-TMC vaccination (data not 
shown). These results correlate with the findings of increased generation of antigen-specific 
antibodies after nasal TMC-TPP vaccination as described by Slütter et al [24]. 
In summary, we were able to detect significant differences in the induced type of immune 
response after nanoparticle treatment. Nasal treatment with low-dose OVA encapsulated 
PLGA nanoparticles enhanced the CD4+ T cell response and relative FoxP3 mRNA expression 
locally in the NALT and CLN. Although TMC-TPP nanoparticles showed to be superior in the 
activation of the humoral arm of the nasal mucosal immune system as shown by increased 
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generation of OVA-specific B cells and OVA-specific antibody titers in serum and nasal washes, 
this effect was not observed for PLGA treated mice. From these data we hypothesized that 
nasal application of slow release PLGA nanoparticles induced T cell mediated mucosal 
tolerance whereas TMC-TPP showed to induce protective immunity upon i.n. vaccination. To 
further study if these differences are of functional importance, the nanoparticles we tested in 






























Figure 3: OVA-specific CD4
 + 
T cell and B cell response after nasal prime-boost vaccination. Effect of 
nanoparticles after nasal vaccination on OVA-specific T cells (A-B). Mice received three times 20 µg of OVA 
solved in PBS or encapsulated into PLGA, PLGA-TMC or TMC-TPP nanoparticles. Three weeks post the final 
OVA administration, the OVA-specific T cell proliferation was assessed ex vivo. Single cell suspensions were re-
stimulated for 72 h in the presence of OVA prior to 
3
H-thymidine incorporation. Data are shown as the 
stimulation index (SI) of cells isolated from the CLN (3A) or spleen (3B). Effect of nanoparticles after nasal 
vaccination on OVA-specific B cells (C). Mice were treated as described above. Three weeks post the final OVA 
administration, the OVA-specific B cell response was assessed ex vivo 48 h post re-stimulation of single cell 
suspensions by ELISPOT. Data are shown as cells isolated from CLN (3C). Data are shown as the Δ OVA-specific 
B cell count per 1*10
6
 cells calculated as background (spots counted on medium coated plates) subtract from 
OVA-specific spots. n=5 mice per group; mean ± standard error of the mean (s.e.m.). 
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Nasal application of slow-release PLGA particles suppressed a Th-1-mediated 
hypersensitivity reaction, while TMC-TPP enhanced humoral immunity, in an OVA-specific 
delayed-type hypersensitivity (DTH)-model  
In general we showed that after nasal vaccination PLGA treatment induced a more T cell 
mediated immune response, whereas TMC-TPP particle treatment resulted in increased 
numbers of OVA-specific B cells. To see if these differences are of functional importance, the 
nanoparticles were tested in a DTH-model. After 24 h, changes in ear swelling were 
determined and compared with values prior to challenge. Clearly, PLGA nanoparticle 
treatment suppressed the OVA specific DTH response, whereas PLGA-TMC and TMC-TPP 
nanoparticle treated mice failed to suppress the DTH response 24 h post challenge (figure 4A). 
In contrast to PLGA and PLGA-TMC, nasal application of TMC-TPP significantly increased the 
generation of OVA-specific B cells locally in the draining CLN (figure 4B) and to a lower extent 
in the spleen (figure 4C). This suggests a main role for TMC-TPP in the activation of the 
humoral immune response and agrees with earlier findings [24]. In addition, a significant 
increase in the relative IL-10 mRNA expression was detected in the CLN (figure 4D), but not in 
the spleen (data not shown) of mice that were tolerized by PLGA vaccination. Although we 
could detect increased expression of relative FoxP3 mRNA in the T cell transfer study (figure 
2B) we were not able to detect such significant differences in the DTH model, probably due to 
experimental differences in timing and presence of OVA-specific T cells in draining lymph 
nodes (data not shown). 
To summarize, nasal treatment with PLGA nanoparticles induced mucosal tolerance but 
did not induce protective immunity as shown by the absence of antigen-specific responses 
(figure 4A-C). In contrast to PLGA and PLGA-TMC immunization, only TMC-TPP treatment led 
to activation of the humoral immune response as shown by local increased generation of 
antigen-specific B cells (figure 3C, 4B-C) and increased levels of antigen-specific antibody titers 
systemically. We were not able to detect a clear T or B cell induced response upon nasal PLGA-
TMC treatment (figure 3 and 4). However, we can conclude that PLGA-TMC immune 
regulation was somewhere intermediate, since PLGA-TMC treatment only partially suppressed 
the DTH response (figure 4A).  
 
 






































Figure 4: Low Nasal application of slow-release PLGA particles suppressed a Th-1-mediated 
hypersensitivity reaction, while TMC-TPP enhanced humoral immunity, in an OVA-specific DTH model. Effect 
of nanoparticles on nasally induced suppression of a DTH response in BALB/c mice (4A). Mice received 20 µg 
of OVA i.n. either solved in PBS (black circles) or encapsulated in TMC-TPP (white circles), PLGA (black 
triangles) or PLGA-TMC (white triangles) nanoparticles for three successive days. Control mice were treated 
with PBS only (black squares) or with OVA at a concentration of 100 µg (white squares). Mice were sensitized 
subcutaneously at the tail base with 100 µg of OVA in IFA 1 day post the final nasal OVA administration. Five 
days after sensitization, mice were challenged with 10 µg of OVA in 10 µl of PBS in the auricle of both ears. 
After 24 h, changes in ear thickness were determined and compared with values before challenge. Enhanced 
OVA-specific B cell response induced after nasal nanoparticle treatment (4B-C). OVA-specific B cell response 
was assessed ex vivo 48 h post re-stimulation of single cell suspensions by ELISPOT. Data are shown as cells 
isolated from CLN (4B) and spleen (4C)  Data are shown as the Δ OVA-specific B cell count per 1*10
6
 cells 
calculated as background (spots counted on medium coated plates) subtract from OVA-specific spots. OVA-
encapsulated PLGA nanoparticles enhance local mRNA expression of IL-10 after nasal vaccination (4D). Total 
mRNA was purified from single cell suspensions from the CLN and subsequently reverse transcribed into 
cDNA. Relative mRNA expression to HPRT of and IL-10 was determined 48 h post OVA challenge in the CLN 
(4D) of mice. n=5 mice per group; mean ± standard error of the mean (s.e.m.). One representative experiment 





The nasal route is an attractive alternative for classical vaccination based on several 
specific characteristics of the mucosal tissue [16, 33]. Former studies already showed that 
upon nasal nanoparticle treatment the humoral immune response can be enhanced and that 
autoimmunity could be suppressed by mucosal tolerance induction [3, 23, 24]. Since there is 
not much known about the role of CD4+ T cells upon nasal nanoparticle treatment, we 
explored how nanoparticle treatment affected CD4+ T cell activation both in vitro and in vivo. 
In this study we investigated whether OVA-encapsulated nanoparticles can modulate the 
immunological outcome towards active immunity or tolerance after nasal antigen application.  
We showed in vitro that particle characteristics influenced OVA-specific CD4+ T cell 
proliferation as shown in figure 1C by the absence of activated T cell after sOVA treatment. 
While PLGA and PLGA-TMC nanoparticles enhanced CD4+ T cell proliferation to a degree that 
all T cells had divided at least one time, we observed a relative high peak of undivided T cells 
when DCs were pulsed with TMC-TPP nanoparticles at similar concentrations, at 72 h post 
culture. The amount of antigen uptake does not necessarily correlate with the percentage of 
cell division since we observed a relative lower uptake of OVA-FITC in TMC-TPP pulsed DCs, 
whereas T cell proliferation was enhanced. One possible explanation can be that the 
differential CD4+ T cell proliferation profiles are caused by the diversity in how the 
nanoparticles encounter DCs. Previous studies have described significant differences in how 
nanoparticles interact with DCs in vitro [20]. TMC-TPP particles release the antigen by a 
mechanism of rapid content release. Since these particles easily associate with the outer cell 
wall [24, 34], antigen may be efficiently taken up by DCs in contrast to sOVA that is scattered 
throughout the entire culture supernatant. Although these particles are less efficiently taken 
up compared to PLGA and PLGA-TMC they may in time increase the antigen uptake by DCs as 
shown by enhanced CD4+ T cell proliferation in vitro in comparison with sOVA at 72 h post 
culture. We were not able to detect differences in DC maturation or phenotype suggesting 
that particle treatment mainly affects the antigen presentation capacity of DCs. Since direct 
evidence is lacking, the functional interaction of nanoparticles with DCs may receive further 
attention. 
We showed that low-dose OVA encapsulated nanoparticles enhanced OVA-specific CD4+ T 
cell proliferation locally in the NALT and CLN after a single nasal application, which was not 
seen with low-dose sOVA. This showed the superiority of nanoparticle mediated OVA delivery 
versus sOVA delivery. Interestingly, due to the absence of activated OVA-specific T cells in the 
spleen following nasal treatment we can conclude that more time is required to elicit systemic 
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responses in comparison to non-mucosal antigen immunization (figure 2A). Our data also 
confirm that the route of antigen delivery, mucosal versus non-mucosal, differentially 
activated the immune system as previously described by Unger et al [19]. 
It was already described that both protective immunity and mucosal tolerance induction 
could be enhanced after nasal nanoparticle treatment 10. The differential role of nasal 
nanoparticle application in the activation of fundamental T and B cells function however had 
not been investigated. In a prime-boost vaccination study, we showed that nasal vaccination 
with low-dose OVA-encapsulated PLGA nanoparticles enhanced primarily T cell activation both 
in the local CLN and systemically in the spleen. Such enhanced T cell proliferation was not 
detected after TMC-TPP or PLGA-TMC application. In contrast to PLGA and PLGA-TMC, 
treatment with TMC-TPP led to increased generation of OVA-specific B cells locally in the CLN 
and this correlates with increased levels of antigen-specific antibody titers. Altogether, these 
data clearly show that nanoparticles differentially modulate the activation of T and B cells 
after nasal delivery. 
From the literature it is known that CD4+CD25+FoxP3+ regulatory T cells play an important 
role in the induction of mucosal tolerance [35, 36]. Therefore, we decided to explore the 
expression of FoxP3 by T cells after nasal nanoparticle treatment. We were capable of 
detecting a significant difference in the mRNA FoxP3 expression levels between the 
nanoparticle treatment groups locally in the CLN. Interestingly, we observed an increased 
FoxP3 expression only for PLGA treatment (figure 2B).  
Finally, we studied the functional significance of these basic findings by testing the 
nanoparticles in a DTH-model. We found that when mice were tolerized for OVA by nasal 
treatment with low-dose OVA-encapsulated PLGA nanoparticles, a T cell mediated tolerogenic 
response was induced. This type of tolerance induction was lacking in TMC-TPP treated mice 
that again showed a significant increased generation of OVA-specific B cells in the CLN in 
contrast to the other treatment groups. Although we observed a significant increased 
expression of FoxP3 mRNA in mice treated with PLGA nanoparticles in the OVA-specific CD4+ T 
cell transfer studies, we were not able to detect such differences in FoxP3 expression levels in 
this experiment. However, in the T cell transfer studies, the number of OVA-specific T cells 
was enhanced as compared to the DTH model, making it less likely to detect these cells. In 
addition, transferred T cells in the transfer model were analyzed 72 h post transfer when OVA-
specific T cells were still present locally in the draining lymph nodes as shown earlier in figure 
2A. Compared to the transfer model, in the DTH experiment, T cells were analyzed 9 days 
after the last nasal immunization giving T cells enough time to enter the circulation and 
making it difficult to detect them locally. Although the subtype of T cell that mediated 
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tolerance remains unclear, we were able to observe a significant increased expression of IL-10 
mRNA after PLGA treatment locally in the CLN (figure 4D). Therefore we suggest that 
tolerance after nasal PLGA treatment may be IL-10 mediated.    
In conclusion, our results indicate that nasal PLGA or TMC-TPP nanoparticles can shift the 
antigen-specific immune response to tolerance or active immunity, respectively. These 
findings may increase the possibility to use nanoparticles to drive the immune response 
towards tolerance or protective immunity and enable future rational vaccine design not only 
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In this study we explored the immunization route-dependent adjuvanticity of cationic 
liposomes loaded with an antigen (ovalbumin; OVA) and an immune potentiator (CpG). Mice 
were immunized intranodally, intradermally, transcutaneously (with microneedle pre-
treatment) and nasally with liposomal OVA/CpG or OVA/CpG solution. 
In vitro, OVA/CpG liposomes showed enhanced uptake by DCs of both OVA and CpG 
compared to OVA+CpG solution. A similar enhanced uptake by DCs was observed in vivo when 
fluorescent OVA/CpG liposomes were administered intranodally. However, after 
transcutaneous and nasal application a lower uptake of OVA/CpG liposomes compared to an 
OVA+CpG solution was observed. Moreover, the IgG titers after nasal and transcutaneous 
administration of OVA/CpG liposomes were reduced compared to administration of an 
OVA+CpG solution. Although serum IgG titers may suggest limited added value of liposomes to 
the immunogenicity, for all routes, OVA/CpG liposomes resulted in elevated IgG2a levels, 
whereas administration of OVA+CpG solutions did not.  
These data show that encapsulation of antigen and adjuvant into a cationic liposome has a 
beneficial effect on the quality of the antibody response in mice after intranodal or 
intradermal immunization, but impairs proper delivery of antigen and adjuvant to the lymph 




















Vaccine development has shifted focus from the classical live-attenuated and inactivated 
vaccines to the development of subunit vaccines. Subunit vaccines, consisting of purified 
proteins, are safer than live-attenuated and inactivated vaccines, but lack strong 
immunogenicity. A common strategy to improve their immunogenicity is encapsulation of the 
antigen into nanoparticles. Antigen encapsulation offers the advantages of i) protection from 
enzymatic breakdown, ii) sustained antigen release over time [1, 2], iii) enhanced uptake by 
professional antigen presenting cells such as DCs [3] and iv) possibility of co-encapsulation of 
adjuvants [4, 5]. Liposomes are a type of nanoparticles that have been widely studied as 
antigen carriers and their usage in vaccination studies dates back to 1974 [6]. Although 
liposomes themselves are not very immunogenic, they have been described to enhance the 
immune response because of the above mentioned advantages [6-11]. Cationic liposomes are 
considered the most effective vaccine delivery systems for administration via injection [12-
14]. To improve the immunogenicity of liposomes, adjuvants can be co-encapsulated together 
with the antigen [15, 16]. Recently we showed that intradermal vaccination in mice with 250-
nm sized cationic liposomes containing ovalbumin (OVA) and CpG, a Toll-like receptor 9 (TLR9) 
ligand, induced strongly elevated IgG2a titers and IFN-γ production by restimulated 
splenocytes [17].  
Besides the attention given to vaccine formulation, interest is aroused for vaccine delivery 
via non-invasive routes, such as the nose and the skin [18, 19]. Both the nose and the skin are 
in direct contact with the environment and therefore densely populated with immune cells to 
protect the body against pathogens. The nasal epithelium is equipped with the nasal 
associated lymphoid tissue (NALT) and the skin is densely populated with epidermal 
Langerhans cells (LCs) and dermal dendritic cells (DCs). The presence of high numbers of DCs 
at these delivery sites could facilitate the liposome’s full potential to enhance antigen uptake 
by DCs and induce a potent, protective immune response. Moreover, liposomes can protect 
the antigen from enzymatic activity, which is especially an issue for nasal vaccination. 
Nonetheless, the beneficial effect of liposomes and nanoparticles in general for these delivery 
routes is under debate [20-23]. For instance, (nano)particulate matter could have more 
difficulties crossing the skin barrier [23, 24] and to a lesser extent (because of possible M-cell 
transport [3, 4]) the nasal epithelium [25] (figure 1).  
The aim of the present study was to investigate the impact of encapsulating the antigen 
and the adjuvant in cationic liposomes on the (antibody mediated) immune response after 




antigen and adjuvant co-encapsulation on both the transport through the epithelium and 
transport of the vaccine to the lymph nodes, by quantifying the amount of OVA and CpG 
positive DCs (CpG+ or OVA+) in the draining lymph nodes after intranodal, intradermal, 
transcutaneous (in combination with microneedle pre-treatment) and nasal administration. 
The added value of OVA- and CpG-containing cationic liposomes on immunogenicity was 
evaluated, by determining the total serum IgG levels and secretory IgA levels in nasal washes. 




Material and Methods 
 
Materials 
Soybean phosphatidylcholine (PC), 1,2-dioleoyl-3-trimethylammonium-propane chloride 
salt (DOTAP) and 1,2-dioleoyl-sn-glycero-3-ghosphoethanolamine (DOPE) were kindly 
provided by Lipoid GmbH (Ludwigshafen, Germany). Endotoxin free OVA was purchased at 
Merck (Darmstadt, Germany). Anti CD11c-PE/Cy7, CD86-FITC was acquired from Becton 
Dickinson (Franklin Lakes, NJ USA). Invitrogen (Breda, The Netherlands) supplied fluorescein 
isothiocyanate AlexaFluor647 labeled OVA (OVAAF647), bovine serum albumin (BSA), 
chromogen 3, 3', 5, 5'-tetramethylbenzidine (TMB) and the substrate buffer. Polyclonal rabbit 
anti-OVA IgG and goat anti-rabbit IgG-HRP conjugate were acquired from Southern Biotech 
(Birmingham, AL, USA). CpG-ODN 2006 and its fluorescein isothiocyanate labelled equivalent 
(CpGFITC) were purchased at Invivogen (Toulouse, France). Nimatek
® (100 mg/ml Ketamine, 
Eurovet Animal Health B.V., Bladel, The Netherlands), Oculentum Simplex (Farmachemie, 
Haarlem, The Netherlands), Rompun® (20 mg/ml Xylazine, Bayer B.V., Mijdrecht, The 
Netherlands) and phosphate buffered saline (PBS 0.9% NaCl) were obtained from a local 
pharmacy. All other chemicals were purchased at Sigma-Aldrich (Zwijndrecht, The 














































Figure 1: Schematic illustration (relative size of organs and cells not on scale) of antigen transport 
mechanisms after immunization via different administration routes. A) After intranodal injection (1) the 
antigen will directly be taken up by lymphnode resident DCs (2). B) After intradermal injection (1) the antigen 
can be taken up by an immature DC (2) which matures (3) or drains directly to the lymph node (4). This will 
result in both peripheral as well as lymph node resident DCs that are antigen positive (5). C) Transcutaneous 
immunization: microneedle application creates small conduits through which the antigen can diffuse (1). 
Immature DCs are abundantly present in the epidermis and dermis and will take up the antigen (2,) and will 
subsequently cross the basal membrane (3), mature (4) and reach the lymph node (5). Because the long route 
the antigen has to take, direct drainage of the antigen to the lymph node (6) may be limited. D) After nasal 
administration (1) the antigen can pass the epithelium either by paracellular diffusion between the epithelial 
cells(2) or through active transport by M-cells(3) and be taken up by immature mucosal DCs (4) which mature 




Preparation and characterization of liposomes 
Cationic liposomes were prepared using the film rehydration method [26], followed by 
extrusion as described previously [17]. Briefly, a thin lipid film was made of PC, DOTAP and 
DOPE (9:1:1 molar ratio) by evaporating the chloroform using a rotary evaporator followed by 
flushing with nitrogen. To prepare empty liposomes, the film was rehydrated in a 10 mM 
phosphate buffer pH 5 (0.1 mM Na2HPO4 and 9.9 mM NaH2PO4), whereas OVA loaded 
liposome were prepared by rehydration in a 10 mM phosphate buffer 
pH 7.4 (7.7 mM Na2HPO4 and 2.3 mM NaH2PO4), containing 1.5 mg/ml OVA. The final 
concentration of lipids was 5% (w/v).  
To obtain liposomes of an equal size the solution was extruded (LIPEXTM extruder, 
Northern Lipids Inc., Canada) 4 times through a carbonate filter with a pore size of 400 nm and 
4 times through a filter with a pore size of 200 nm (Nucleopore Millipore, Amsterdam, The 
Netherlands). For adjuvanted liposomes, after rehydration CpG (final concentration of 1.5 
mg/ml) was added and the dispersions were freeze-dried followed by rehydration and 
extrusion as described above.  
After monodisperse, unilamellar liposomes were obtained, unencapsulated antigen and 
adjuvant were separated from the liposomes by a Vivaspin 2 centrifugal concentrator (PES 
membrane, MWCO 300 kDa, Sartorius Stedim, Nieuwegein, The Netherlands) and (by using 
their fluorescently labelled analogues) quantified with a FS920 fluorimeter (Edinburgh 
Instruments, Campus Livingston, UK). The same technique was applied to investigate the 
association of OVA with empty liposomes. The size of the liposomes was determined by 
dynamic light scattering (DLS) and the zeta potential was measured by laser Doppler 
velocimetry using a Zetasizer® Nano ZS (Malvern Instruments,UK).  
 
Vaccination 
8 week old female Balb/c mice (Charles River, Maastricht, The Netherlands) received OVA 
or OVA- and CpG-containing formulations via transcutaneous, nasal, intradermal or intranodal 
administration. Based on literature and earlier studies from our group [27-29] the antigen 
dose and volume was adjusted to the administration route. The dose was chosen is such a way 
that the IgG response after immunization with a solution of OVA would be minimal and allow 
optimal discrimination between administration of OVA alone and liposomal OVA formulations.  
For transcutaneous vaccination mice were shaved before pre-treatment with microneedles 
as described by Ding et al. [30]. Assembled metal microneedle arrays (4x4) with a length of 
300 µm were used and applied with an electrical applicator as described before [24]. The 
formulations were applied occlusively on the skin (~2 cm2 area restricted by a metal ring). 
Route specific adjuvant effect of cationic liposomes 
 
 119 
After 2 h the abdominal skin of the mice was washed extensively with lukewarm water. 
Intranodal injections in the inguinal lymph nodes were performed as described by Johansen et 
al [31]. Intradermal and nasal immunizations were carried out as described previously [27, 28]. 
After 3 weeks, blood samples were drawn from the tail vein and mice received a booster dose. 
After 6 weeks blood samples were drawn from the femur artery and mice were sacrificed. 
 
Determination of serum IgG, IgG1, IgG2a and secretory IgA 
Microtiter plates (Nunc, Roskilde, Denmark) were coated overnight at 4°C with 100 ng OVA 
per well in a 100 mM carbonate buffer pH 9.4. Wells were blocked with 1% BSA in PBS for 1 
hour at 37°C. Serial dilutions were applied for 1.5 hours after which OVA-specific antibodies 
were detected using HRP conjugated goat anti-mouse IgG, IgG1, IgG2a or IgA. Enzyme activity 
was determined by incubating with TMB/H2O2 in 100 mM acetate buffer pH 5.5 for 15 min at 
room temperature. Reaction was stopped with 2 M H2SO4 and absorbance was determined at 
450 nm with an EL808 microplatereader (Bio-Tek Instruments, Bad Friedrichshall, Germany). 
 
In vitro uptake by dendritic cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from fresh human blood using a 
Ficoll gradient as previously described [32]. Subsequently, monocytes were isolated from the 
PBMCs using a Percoll gradient as previously described [33]. After isolation, monocytes were 
adhered on 24-well plates by incubation for 1 hr at 37°C and 5% CO2, and depleted of platelets 
by washing. Monocytes were differentiated into immature DCs by incubation for 6 days with 
RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 1 mM 
sodium pyruvate, 500 U/L penicillin/streptomycin, 250 U/ml GM-CSF and 100 U/ml IL-4.  
Immature DCs were exposed for 4 h at 37°C to 0.5 µg/ml CpGFITC and/or 0.5 µg/ml OVAAF647 
in free or encapsulated form. Cells were washed three times with FACS buffer (1% w/v BSA in 
PBS with 2% v/v fetal bovine serum), and the number of FITC or AF647 positive DCs (CpG+ or 
OVA+) was quantified with a flow cytometer (FACSCanto II, Becton Dickinson) using quadrant 
analysis.  
 
Determination of antigen specific DCs in lymph node 
Mice were vaccinated with the same formulations as described in Table I, but OVA was 
substituted with OVAAF647 and CpG with CpGFITC. After 4 or 24 h mice were sacrificed, the 
draining lymph nodes (for transcutaneous, intradermal and intranodal administration the 
inguinal and for nasal the cervical lymph nodes) were removed and single cell suspensions 




detection of DCs. Using flow cytometry (FACSCantoII, Becton Dickinson) the amount of 
OVAAF647
+ and CpGFITC
+ DCs was determined. 
 
Statistics 
All the data were analyzed with a one-way ANOVA with Bonferroni’s post-test, with the 
exception of the antibody titers, which were processed with a Kruskal-Wallis test with Dunn’s 





Cationic liposomes improve uptake of OVA and CpG by DCs in vitro 
To assess whether our cationic liposomes increase the uptake of OVA and CpG, the uptake 
by human monocyte derived DCs was measured in vitro. Consistent with our previous study 
[17], OVA-containing liposomes with an average size of 130 nm bearing a positive zeta 
potential (23 mV) and OVA/CpG liposomes with a size of 263 nm and a zeta potential of 18 mV 
were obtained. The cationic liposomes significantly enhanced the uptake of their encapsulated 
cargo by DCs (figure 1). Plain OVA was readily taken up by DCs, as approximately 20% of the 
DCs was OVA+ after 4 h of incubation with OVA (figure 2A), but when encapsulated into 
liposomes, the number of OVA+ DC was significantly increased (p<0.001), reaching a value of 
approximately 50% OVA+ DCs. In contrast to OVA, non encapsulated CpG was hardly taken up 
by DCs in its plain form as only 6% CpG+ DCs were observed (figure 2B). Encapsulation of CpG 
in cationic liposomes however increased the number of CpG+ DCs with an order of magnitude. 
Co-encapsulation of OVA and CpG+ in cationic liposomes caused a major improvement in the 
number of OVA/CpG+/+ DCs (figure 2C), compared to addition of a solution of OVA and CpG. In 
conclusion, co-encapsulation of OVA and CpG in cationic liposomes enhanced their 



























Liposomes enhance the uptake of OVA and CpG by lymph node resident DCs. 
Because of the large numbers of T cells present in the lymph nodes, activated DCs that 
have taken up an antigen have a good chance of finding antigen specific T cells there. 
Therefore the draining lymph node is the most prominent site of activation for T cells after 
immunization and can be considered the actual target of vaccines. As a consequence, direct 
injection of a vaccine into the lymph nodes could be a very efficient method of administration, 
requiring only very low amounts of antigen to result in an effective immune response, as 
processes like peripheral uptake of the antigen by DCs and drainage to the lymphnodes are 
circumvented (figure 1A). Indeed after intranodal injection a rapid uptake of fluorescently 
labeled OVA and CpG by DCs was observed as can be inferred from the high percentage of 
OVA+ and CpG+ DCs already after 4 h (figure 3). Liposomal encapsulation of OVA and CpG led 
to significantly elevated numbers of OVA+, CpG+ and OVA/CpG+/+ DCs compared to the 
administration of a soluble mixture of OVA and CpG. The percentage of DCs that had taken up 
both OVA and CpG increased by 4-fold compared to injection of a physical mixture of CpG and 
OVA. After 24 h the levels had decreased drastically, suggesting that OVA and CpG had been 
processed. Alas, next to in vitro, also in vivo cationic liposomes have the potential to increase 
the delivery of the antigen and the adjuvant. 
 
Figure 2: Uptake of a) OVA and b) CpG by human monocyte derived DCs determined by FACS 
analysis. c) number of OVA and CpG double positive DCs after 4 h exposure. n=3 Average + SEM. 






High IgG2a titers after intranodal injection of OVA/CpG liposomes 
In spite of the favorable effect of liposomal co-encapsulation of OVA and CpG on DC 
uptake, intranodal vaccination showed similar total serum IgG titers for all formulations 
(figure 4A). Both after the prime and booster immunization no effect of either liposome 
encapsulation or CpG was observed, indicating that an antigen injected directly into the lymph 
node does not need a delivery vehicle or an adjuvant to induce a humoral immune response. 
However, whereas IgG titers provide information about the extent of the antibody response, 
subtyping of the IgG response can give insight into the type of immune response elicited. 
Therefore, IgG1 levels, indicative of a Th2 type (humoral) response and IgG2a titers, indicative 
of a Th1 type (cellular) response [34, 35], were quantified to investigate the quality of the 
immune response after the boost immunization (figure 4B). IgG1 titers appeared to be 
virtually in synchronicity with the IgG titers, again indicating that all formulations triggered the 
humoral immune response. However, co-encapsulation of CpG and OVA in liposomes 
drastically increased IgG2a levels compared to OVA (p<0.001) as well as non encapsulated 
OVA + CpG (p<0.001). As such OVA/CpG liposomes caused a significant decrease in IgG1/IgG2a 
ratio, compared to all other formulations (p<0.05, figure 3C). This shows that intrinsically, 
OVA/CpG liposomes are a very immunogenic and effectively delivery system that can induce a 







Figure 3: Quantification of 
OVA+ (white bars), CpG+ ( 
grey bars) and OVA/CpG
+/+
 
(black bars) DCs in the 
draining lymph nodes 4 
and 24 h after intranodal 
vaccination, Bars 
represent the mean n=3 + 
SEM. *p<0.05, **p<0.01. 
 





























Intradermal vaccination  
 
Cationic liposomes reduce direct drainage to the lymph node 
In contrast to intranodal injection, antigen that is administered intradermally can reach the 
lymph nodes in two ways, it can either directly drain in a quick manner to nearest lymph node 
via the interstitial fluid and lymphoid vessels or it can be taken up by local DCs and 
transported to the draining lymph nodes in a process that takes longer (figure 1). Intradermal 
injection of fluorescent OVA and CpG showed the presence of both these routes; already 4 h 
after administration, OVA+ DCs could be detected in the lymph nodes, but these cells had not 
Figure 4: OVA-specific serum IgG, IgG1 and IgG2a titers after intranodal 
vaccination. A: IgG titers after prime and boost. B: IgG1 and IgG2a titers after 
booster immunization. Bars represent SEM of n=5 (A and B). C: Corresponding 
IgG1/IgG2a ratio for each individual mouse. Mice non-respondent for either 






taken up CpG (figure 5). Liposomal delivery to the lymph nodes after intradermal 
administration was a slower process, as not 4 h but only 24 h after injection OVA+ and CpG+ 
DCs were found in the draining lymph nodes. These suggest both OVA and CpG were retained 
at the injection side. Indeed the formation of an antigen depot that was visible by eye at the 
injection site, even 24h after injection. Liposomal encapsulation did not further increase the 
number of OVA+ and CpG+ DCs after 24 h compared to intradermal administration of non 













Cationic liposomes have an adjuvant effect and increase IgG2a levels significantly 
Vaccination via the intradermal route showed that cationic liposomes can have an 
adjuvant effect when mixed with OVA (p<0.01), whereas encapsulated liposomal OVA did not 
lead to a significant increase in IgG levels (figure 6A). Addition of CpG clearly increased the 
antibody levels compared to OVA after the first (p<0.001), as well as the second immunization 
(p<0.001) and also compared to OVA + liposomes after the first vaccination (p<0.05). 
Intradermal application of OVA/CpG liposomes increased the IgG levels to a similar extent as a 
solution of OVA and CpG.  
After intradermal administration IgG1 titers mimicked the IgG titers and IgG2a levels were 
very low with the exception those of the mice immunized with OVA/CpG liposomes (figure 
6B). Just like after intranodal vaccination, these mice had significantly higher IgG2a titers 
compared to those receiving plain OVA (p<0.001), resulting in a significant shift in the 




Figure 5: Quantification of 
OVA
+
 (white bars), CpG
+
 ( 
grey bars) and OVA/CpG+/+ 
(black bars) DCs in the 
draining lymph nodes 4 
and 24 h after intradermal 
vaccination, Bars 
represent the mean n=3 + 
SEM. *p<0.05 
 






































Figure 6: OVA-specific serum IgG, IgG1 and IgG2a titers after intradermal 
vaccination. A: IgG titers after prime and boost. B: IgG1 and IgG2a titers after 
booster immunization. Bars represent SEM of  n=5 (A and B). C: Corresponding 
IgG1/IgG2a ratio for each individual mouse. Mice non-respondent for either 
IgG1 or IgG2a were removed from the data set. Bar represents geomean * 
p<0.05, ** p<0.01.  
 
Figure 7: Quantification of 
OVA+ (white bars), CpG+ ( 
grey bars) and OVA/CpG
+/+
 
(black bars) DCs in the 
draining lymph nodes 4 and 
24 h after transcutaneous 
vaccination with microneedle 
pretreatment, Bars represent 







Liposomes reduce transport of OVA and CpG through the skin 
Transcutaneous administration involves an extra transport step across the epidermis 
compared to intranodal and intradermal injection (figure 1). Consequently, there was no 
trafficking to the lymph node resident DCs after 4 h. Only after 24 h measurable OVA and CpG 
levels were observed (figure 7). A clear detrimental effect of liposomal encapsulation on the 
amount of OVA and CpG reaching the lymph nodes is shown, as application of non 
encapsulated OVA and CpG resulted in significantly higher numbers of OVA+ and CpG+ DCs 


























Figure 8: OVA-specific serum IgG, IgG1 and IgG2a titers after transcutaneous 
vaccination. A: IgG titers after prime and boost. B: IgG1 and IgG2a titers after 
booster immunization. Bars represent SEM of n=8 (A and B). C: Corresponding 
IgG1/IgG2a ratio for each individual mouse. Mice non-respondent for either IgG1 
or IgG2a were removed from the data set. Bar represents geomean * p<0.05, ** 
p<0.01.  
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Liposomal co-encapsulation of OVA and CpG reduce IgG titers, but enhance IgG2a levels 
The immune enhancing effect of cationic liposome, as observed after intradermal 
administration was not apparent after transcutaneous administration. Regardless whether 
OVA was encapsulated or not encapsulated in liposomes no increased IgG titers compared to 
plain OVA after transcutaneous immunization on microneedle pre-treated skin were observed 
(figure 8A). Contrarily, administration of a OVA + CpG solution resulted in strongly enhanced 
IgG titers both after the prime and subsequent booster vaccination compared to an OVA 
solution (p<0.05). This effect was abolished by encapsulation of antigen and adjuvant into 
liposomes (p<0.01). As far as the subtiters are concerned, unlike after intranodal and 
intradermal vaccination, transcutaneous immunization with encapsulated and non-
encapsulated CpG did not significantly elevate OVA-specific IgG2a titers (figure 8B), but 
encapsulated CpG reduced the IgG1 levels, thereby causing a significant decrease in the 
IgG1/IgG2a ratio (p<0.05). 
 
 
Nasal vaccination  
 
Liposomes reduce transport of OVA and CpG through the nasal epithelium 
Comparable to transcutaneous vaccination, nasal administration involves an extra 
transport step across the epithelium (figure 1). Ergo, 4 h after nasal application of fluorescent 
OVA and CpG no OVA+ and CpG+ DCs were detected in the cervical lymph nodes (figure 9). 
After 24 h DCs had taken up OVA and CpG, but similarly as after transcutaneous 
administration; the numbers of OVA and CpG positive DCs in the draining (cervical) lymph 












Figure 9: Quantification of OVA
+
 
(white bars), CpG+ (grey bars) and 
OVA/CpG
+/+
 (black bars) DCs in the 
draining lymph nodes 4 and 24 h 
after transcutaneous vaccination 
with microneedle pretreatment, Bars 




Liposomal co-encapsulation of OVA and CpG not necessary to induce IgG2a titers  
Mice receiving the formulations nasally showed a similar IgG pattern compared to 
transcutaneous vaccination (figure 10A): liposomes did not stimulate the anti-OVA IgG 
response and soluble OVA adjuvanted with CpG induced the strongest response already after 
a priming dose (p<0.001 compared to OVA). When CpG was co-encapsulated with OVA in 
liposomes the effect of CpG was reduced, altough the serum antibody levels were higher as 
compared to OVA alone. This was not observed in contrast to transcutaneous vaccination. 
Nasal co-administration of OVA + CpG, did significantly increase the IgG2a levels compared to 
OVA (figure 10B, p<0.001). Co-encapsulation of CpG and OVA in liposomes also increased the 
IgG2a titers compared to encapsulation of OVA alone (p<0.01), but did not result in a 
significant shift in the IgG1/IgG2a ratio compared to a solution of OVA and CpG (figure 9C), as 
observed for intradermally and intranodally vaccinated mice.  
Finally, only nasal administration resulted in detectable levels of secretory IgA (sIgA) in the 
nasal washes of the mice. Nasal immunization with a both encapsulated as well free OVA and 






















specific serum IgG, 
IgG1 and IgG2a 
titers after nasal 
vaccination. A: IgG 
titers after prime 
and boost. B: IgG1 
and IgG2a titers 
after booster 
immunization. Bars 
represent SEM of  
n=8 (A and B). C: 
Corresponding 




either IgG1 or IgG2a 
were removed from 
the data set. Bar 
represents geomean 
* p<0.05, *** 
p<0.001.  
 






















Nasal and microneedle-based transcutaneous vaccination potentially provides a safe and 
patient friendly alternative to classical vaccine administration via the needle. However, 
vaccination via non-invasive routes is challenging as the antigen will first have to pass a barrier 
(nasal epithelium or the skin), which limits the amount of antigen that reaches the DCs. To 
provoke a strong immune response with a limited amount of antigen, high immunogenicity of 
vaccine is very important. The immunogenicity of subunit vaccines can be enhanced if the 
antigen is properly formulated. Therefore the use of cationic liposomes as a carrier system 
makes sense; they provide efficient antigen encapsulation and their particulate nature makes 
them a natural target for DCs, which can enhance the uptake of their cargo by DCs. Co-
encapsulation of an adjuvant will result in the concomitant delivery of antigen and adjuvant to 
DCs, which has been described as crucial for a potent immune response [36, 37]. However, 
compared to solutions of antigens and adjuvants, liposomes might have difficulties passing the 
epithelial barriers.  
Co-encapsulation of antigen and adjuvant into liposomes had a positive effect when the 
formulations were injected: intranodal or intradermal injection of OVA/CpG liposomes 
strongly boosted IgG2a titers (indicative for a Th1 response), whereas administration of non-
Figure 11: OVA-specific secretory IgA in nasal 
washes after nasal vaccination. Bars represent 





encapsulated OVA + CpG did not. This effect may be related to the site of action of the 
adjuvant used. CpG is a ligand for TLR9, which is localized in the endosomal compartment of 
APCs. It is therefore imperative for CpG to be endocytosed by the APC, in order to be able to 
interact with TLR9. Here we show that in vitro, cationic liposomes can facilitate CpG uptake by 
DCs, adding to the increase in IgG2a titers after intradermal and intranodal injection. In vivo 
the DC uptake after intranodal injection corresponds well with the in vitro data, as in both 
cases a clear benefit of co-encapsulation on DC uptake was observed. 
Interestingly, after intranodal administration OVA/CpG liposomes was the only formulation 
to have a beneficial effect on the IgG2a titer, whereas all formulations induced similar IgG and 
IgG1 titers via this route. It is likely that the injection itself will already induce a danger signal 
to the residing DCs, thereby inducing DC activation and maturation [38], sufficient to induce a 
humeral (IgG1) response [29]. The additional benefit of adjuvanted liposomes on the total 
immune response via this route, using this amount of antigen, is therefore negligible, but the 
effect on the immune bias is substantial. Since high IgG2a levels were obtained with the 
OVA/CpG liposomes, this indicates that liposomal co-encapsulation of antigen and adjuvant is 
essential for induction of a Th1 type immune response. 
Intradermal administration of OVA with empty liposomes significantly increased antibody 
titers compared to administration of OVA alone. As empty liposomes do not activate 
immature DCs, the adjuvanticity of these vesicles can most probably be attributed to the 
antigen depot it forms upon injection, likely through interaction of liposomes and antigen with 
the extracellular matrix. According to Henriksen-Lacey et al. this depot could be detected up 
to 14 days post intramuscular or subcutaneous injection and promoted the immunogenicity of 
the antigen [10]. However, the current study also shows that depot formation prohibits rapid 
drainage of the antigen to the lymph node. Antigens in solution can directly drain to the lymph 
node and be taken up by a large population of immature lymph node resident DCs [39], as 
reflected in our study by the high number of OVA+ DCs found in the lymph nodes 4 h after 
injection of OVA. Liposomal administration and the resulting antigen depot reduced the 
amount of antigen that directly drains to the lymph nodes, but induced prolonged OVA 
delivery compared to a mixture of OVA and CpG. These two processes can induce two distinct 
waves of antigen reaching the lymph nodes, and may be imperative for provoking a good 
(memory) immune response [40]. This could explain why intradermal application of OVA with 
empty liposomes induced a better response than OVA loaded liposomes. The latter does not 
allow direct drainage of the antigen to the lymph nodes, but only a prolonged release, 
whereas the first approach might have resulted in both direct and prolonged release. 
Route specific adjuvant effect of cationic liposomes 
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Nasally and especially transcutaneously, liposomes were found to be a suboptimal vaccine 
delivery system. Although nasal administration of OVA/CpG loaded liposomes did show an 
increase in IgG titers compared to administration of OVA alone, this was due to the presence 
of CpG rather than its formulation into liposomes, as nasal administration of OVA + CpG as a 
solution induced superior antibody titers. After transcutaneous vaccination with 
microneedles, encapsulation of CpG into liposomes even completely inhibited the positive 
effect of the adjuvant. We showed that liposomes dramatically decreased the amount of 
antigen and adjuvant reaching the DCs. Significantly less OVA+ or CpG+ DCs were detected in 
the draining lymph nodes 24 h after nasal or transcutaneous administration of OVA/CpG 
liposomes compared to administration of OVA + CpG. Possibly the concomitant size increase 
caused by the encapsulation into the liposome and the positive charge of the delivery system 
obstructed the transport of the antigen and adjuvant to the lymph node.  
An interesting difference between the the nasal and the transcutaneous route was 
observed; whereas after transcutaneous immunization a solution of OVA or non-adjuvanted 
liposomes were capable of inducing seroconversion in all mice, nasal vaccination required the 
addition CpG to induce measurable antibody titers. This may be related to the nasal 
epithelium being a rather tolerogenic immunization site [41], making the activation of DCs 
with an adjuvant an important requirement for the induction of antibodies. The skin DCs, 
however, are known to not only playing a role in tissue homeostasis, but also having a strong 
pro-inflammatory function [42, 43]. This may have an evolutionary purpose as a micro-
organism that has breached the skin barrier is more dangerous that an organism that has 
ended up in the nasal epithelium. 
Although after nasal and transcutaneous vaccination the total humoral immune response 
did not benefit from co-encapsulation of OVA and CpG into liposomes, liposomal co-
encapsulation may have a pronounced effect on the induction of a cellular response. Nasal 
and transcutaneous administration of OVA/CpG liposomes induced relatively more IgG2a 
compared to IgG1 than the administration of a physical mixture of these 2 components. Co-
localization of antigen and adjuvant therefore still remains an important mechanism to 
enhance the immunogenicity of a non-injectable subunit vaccine, but should not be 
established by using a particulate delivery system. Antigen-adjuvant conjugates or Fc-receptor 
immune complexes have been reported to very efficiently target DCs [44, 45] and due to their 









Despite the advantages of using cationic liposomes as a vaccine adjuvant, careful 
consideration should be given when such systems are designed for transcutaneous and nasal 
vaccination. These data show that, intrinsically, liposomes containing both the antigen as well 
as the adjuvant enhance the immunogenicity of the antigen and promote the induction of 
both IgG1 and IgG2a type antibodies. However, likely due to poor penetration of the 
microneedle pre-treated skin and nasal mucosa, they are unsuitable for application via the 
transcutaneous or nasal route.  
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Subunit vaccines are generally safer, but often less effective than live attenuated vaccines 
as they lack the necessary co-stimulatory factors. The formulation of an adjuvant like N-
trimethyl chitosan (TMC) with an antigen can overcome its poor immunogenicity. Recent data 
suggest the importance of incorporating the antigen and the adjuvant into one entity for 
maximum immunostimulatory effect, e.g. by using (nano)particles. 
In the present paper we introduce the conjugation of an antigen, ovalbumin (OVA), to TMC 
as an alternative to nanoparticles for subunit vaccination. OVA was covalently linked to TMC 
using thiol chemistry (SPDP method). The uptake of the resulting TMC-OVA conjugate by 
dendritic cells (DC) and its effect on DC maturation was assessed in vitro and its 
immunogenicity was investigated in mice. We found that with the SPDP method a reducible 
covalent bond between TMC and OVA could be introduced, without disrupting the protein’s 
antigenicity and structure. Uptake of TMC-OVA conjugate by dendritic cells was similar to the 
uptake of TMC/OVA nanoparticles, over 5-fold increased compared to a solution of OVA and 
TMC. Mice immunized with TMC-OVA conjugate produced 1000-fold higher OVA specific IgG 
titers than mice immunized with either OVA or a physical mixture of TMC and OVA. Moreover, 
these antibody titers were slightly elevated compared to the titers obtained with TMC/OVA 
nanoparticles. Conjugation of the antigen to an adjuvant is therefore a viable strategy to 





















Vaccination has been one of the most effective ways of preventing disease. However, 
development of new vaccines is increasingly complicated, in part due to the complex nature of 
the targeted diseases [1], but also because of regulatory concerns [2]. Safety issues, like local 
as well as systemic adverse effects and possible recombination of a weakened pathogen into a 
virulent species [3], have sparked the interest in subunit vaccines. Subunit vaccines contain 
only part of the pathogen (often only one single protein) and are stripped of any virulence 
factors. This makes them generally safer and pharmaceutically better defined. The lack of 
virulence factors, however, causes a dramatic decrease in the effectiveness of these subunit 
vaccines. Antigen presenting cells (APCs), like dendritic cells (DCs) and macrophages play a key 
role in effectively inducing an immune response. They continuously sample their environment 
for antigens and are capable of presenting epitopes of these antigens on MHC class I and/or 
MHC class II molecules. However, these APCs have to be stimulated by a danger signal, for  
them to mature and properly activate T-cells [4-6]. 
Recently, we and other groups have shown that co-administration of a chitosan derivate, 
N-trimethyl chitosan (TMC), with the antigen leads to increased antibody production and 
protection when compared to administration of an antigen alone [7-9]. Moreover, TMC was 
shown to be well tolerized by mice, biodegradable and (especially those with a low degree of 
quarternization) much less toxic than other cationic polymers [10, 11].  In vitro experiments 
showed that treatment of immature DCs with TMC induces upregulation of several maturation 
markers on DCs [12], indicating that TMC’s immunopotentating effect is indeed mediated by 
DC activation. Simple co-administration of an antigen with an adjuvant may however not be 
the most effective way to administer a vaccine. For instance, particles have been associated 
with stronger immune responses compared to antigen solutions, as they allow multimeric 
antigen presentation and (depending on the type of delivery system) can create a depot effect 
[13]. Moreover, encouraging results using particles containing both the antigen and the 
adjuvant have been obtained [14]. Studies in which both components were combined in one 
delivery system have shown beneficial effects of the cointernalization of an antigen with a 
adjuvants like flagellin [15], CpG [16, 17] and LPS [18]. Similarly, TMC nanoparticles loaded 
with hemagluttin has been shown to be very immunogenic in mice [8]. It has been suggested 
that only an APC that has taken up the antigen and the adjuvant in significant amounts is able 
to activate T-cells, whereas an APC that has only taken up either of the two components does 
not stimulate T-cell proliferation [19, 20]. Therefore, combination of the antigen and the 
adjuvant in one entity may be a good strategy for future vaccine development. These studies 
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all used particulate systems to co-deliver antigen and adjuvant. We hypothesize that ‘simple’ 
covalent linkage of an antigen, ovalbumin (OVA), to an adjuvant, TMC, could insure that both 
reach the APC at the same time and therefore enhance the immune response as well (figure 
1). By introducing a disulfide bond as the linker between the 2 molecules, both adjuvant and 
antigen should be released once the conjugate has reached the reducing environment of an 


























Chitosan, as a polymer of interest in pharmaceutical applications, has been conjugated to 
various chemical entities, mainly through its abundant primary amine groups [23, 24]. Similar 
conjugation strategies may be used for TMC [25], especially TMC with a low degree of 
quaternization (20% in this study) which still carries residual primary amines. The aim of the 
Figure 1: Subunit antigens are taken up by DCs but lack the necessary danger signals to 
induce DC maturation. An antigen-adjuvant mixture stimulates the activation of immature 
DCs, but antigen and adjuvant should be taken up simultaneously by a DC to effectively 
induce T-cell activation and antibody production. An antigen-adjuvant conjugate increases 
the chance of simultaneous uptake of both adjuvant and antigen, resulting in many mature 
antigen-carrying DCs, strong T-cell proliferation and high antibody levels. 
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present paper was to conjugate OVA to TMC and evaluate the immunogenicity of these 
conjugate compared to TMC/OVA nanoparticles, a mixture of OVA and TMC, and plain OVA. 
Using a method earlier described by Dijk-Wolthuis et al [26], both the protein and the polymer 
were thiolated by treatment with N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP), 
followed by the formation of a disulfide bond. To assess its immunogenicity, uptake of the 
conjugate by DCs and subsequent DC activation was investigated in vitro and its ability to 
induce antibodies was determined in vivo. 
 
 
Materials and Methods 
 
Materials 
N-trimethyl chitosan (TMC) with a degree of quaternization of 20% was synthesized 
starting from 92% deacetylated (MW 120 kDa) chitosan (Primex, Siglufjordur, IC), by NaOH 
induced methylation as earlier described [27]. The average molecular weight of TMC was 90 
kDa (determined by gel permeation chromatography (GPC) with low angle light scattering 
detection [11]). The number of primary amines present on the synthesized TMC was 
determined with a ninhydrin assay [28], to be 55 NH2/mol TMC. Antibodies, polyclonal rabbit 
anti-OVA IgG and goat anti-rabbit IgG-HRP conjugate, were acquired from Millipore 
(Amsterdam, NL) and anti-CD86-APC from Becton Dickinson (Franklin Lakes, NJ USA). 
Invitrogen (Breda, NL) supplied fluorescein isothiocyanate (FITC) labeled OVA and all cell 
culture products.  Endotoxin free OVA was purchased at Calbiochem (Merck, Darmstad, DE). 
N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP), dithiothreitol (DTT), Carboxymethyl 
Sepharose gel, pentasodium tripolyphosphate (TPP) and all other salts/chemicals were 
acquired from Sigma-Aldrich (Zwijndrecht, NL), unless stated otherwise. 
 
TMC-OVA conjugate synthesis  
TMC was functionalized with pyridyldithiol using the heterobifunctional crosslinker N-
succinimidyl 3-(2-pyridyldithio) propionate (SPDP), to accommodate disulfide bond formation. 
TMC was dissolved in 10 mM phosphate buffered saline (0.9% w/v NaCl, pH 7.4) to a final 
concentration of 2.5 mg/ml. SPDP dissolved in acetonitrile (35 mg/ml) was added to the TMC 
solution, in a TMC:SPDP molar ratio ranging from 1:1 till 1:40. These ratios correspond to an 
NH2/SPDP ratio of 55:1 to 1.4:1. After 1 h of shaking at room temperature, the reaction was 
stopped by removing the unreacted crosslinker and reaction intermediates with a PD-10 
desalting column (GE Healthcare, Eindhoven, NL).  
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OVA was similarly functionalized with SPDP (figure 2a). OVA was dissolved in PBS pH 7.4 to 
a final concentration of 1 mg/ml. SPDP in acetonitrile (35 mg/ml) was added to the OVA 
solution, in molar ratio OVA:SPDP ranging from 1:1 till 1:15. After 1 h of shaking at room 
temperature, the reaction was stopped by removing unreacted SPDP and reaction 
intermediates with a PD-10 desalting column. 
Prior to the final conjugation step, functionalized TMC-PDP was reduced to remove the 
protective pyridine-2-thione group and obtain sulfhydryl activated polymer (figure 2b). This 
was done by adding a 1 mg excess of 1% w/v dithiothreitol (DTT) dissolved in water to the 
polymer solution. After 30 min of mild shaking, the excess DTT was removed with a PD-10 
desalting column. Subsequently, the activated TMC (TMC-SH) was mixed with the OVA-PDP 
and incubated for 16 h at 40°C in PBS (figure 2c). The average number of –SH moieties per 
TMC molecule was kept constant at 1 or 2 moles –SH per mol TMC, while the average number 
of PDP groups on OVA was varied from 1 to 7 moles PDP per mol OVA. Molar ratio TMC:OVA 






















Figure 2: Reaction scheme of TMC-OVA conjugation. (a) Primary amine groups on OVA are 
functionalized with SPDP. (b) Primary amine groups on TMC are similarly functionalized and 
subsequently reduced with DTT, yielding TMC containing thiol groups. (c) An activated thiol group 
on TMC reacts with a disulfide bond of functionalized OVA, creating a disulfide bond between the 
two molecules. Reaction was performed at 40°C and stopped after 16 h. 
 




Purification of TMC-OVA conjugates 
Free OVA was removed from the reaction mixture by solid phase extraction. 
Carboxymethyl Sepharose gel (Sigma-Aldrich), a cation exchange sorbent, was packed into an 
empty syringe with a final column volume of 4 ml. The column was equilibrated at room 
temperature with PBS pH 7.4, after which 5 ml reaction mixture was applied onto the column. 
Free OVA and other impurities were eluted with PBS, after which the TMC-OVA conjugate as 
well as free TMC was eluted using a 20 mM citrate buffer containing 1 M NaCl, pH 3.3.  
Fractions were collected and analyzed for protein content with a bicinchoninic acid (BCA) 
protein assay (Pierce, Etten Leur, NL) according to the micro plate procedure provided by the 
manufacturer. The conjugate-containing fractions were pooled and dialyzed against distilled 
water for 1 day, and subsequently freeze-dried for 48 h at -60°C and 0.8 mbar. Prior to use or 
analysis, the conjugate was reconstituted in PBS. 
 
GPC 
The formation of conjugates was determined by gel permeation chromatography (GPC) by 
adapting a method described by Verheul et al [29]. In short, a Shodex OHPak SB-806 column 
(15 cm) was used with 0.3 M sodium acetate, adjusted to pH 4.4 with acetic acid, as running 
buffer to minimize interaction between free OVA and TMC. An online 2475 Multi-Wavelength 
Fluorescence Detector (Waters, Milford MA, excitation 295 nm, emission 340 nm) was used to 
measure Trp fluorescence intensity. Fractions were collected for SDS-PAGE analysis. 
 
SDS-PAGE & Western blotting 
SDS-PAGE was performed to detect covalently bound OVA and to check for residual free 
OVA. Samples were run at 120 V under reducing and non-reducing conditions, in a 10% SDS-
polyacrylamide gel. Samples were prepared in electrophoresis loading buffer (60 mM Tris-HCl, 
pH 6.8, with 25% glycerol and 2% SDS, 0.1% bromophenol blue solution and 5% v/v β-
mercaptoethanol) and heated for 2 min at 90°C.  After electrophoresis, bands were stained 
using a Silver Stain Plus kit (Bio-Rad, Veenendaal, NL), according to the manufacturer’s 
instructions. To perform Western blot analysis bands were transferred to a nitrocellulose 
membrane (Whatman, Maidstone, UK) overnight at 30 V. Blot was blocked with 8% non fat 
milk (Campina, Amersfoort, The Netherlands) and incubated with polyclonal rabbit anti-OVA 
IgG  for 24 h. Subsequently, the blot was treated with goat anti-rabbit IgG-HRP conjugate, 






UV-VIS spectra were recorded using an Agilent 8354 spectrophotometer (Agilent 
Technologies, CA, USA). TMC, OVA and TMC-OVA conjugate were diluted to a final 
concentration equivalent to 0.5 mg/ml OVA and 1 mg/ml TMC in a 50 mM acetate buffer pH 
3.0 with 0.9% NaCl. Tertiary protein structure was investigated by taking the second derivative 
of the zero order spectra [30].  
 
Steady-state fluorescence 
To study protein conformation, the intrinsic fluorescence of OVA (diluted to 0.05 mg/ml) 
was measured. Steady-state fluorescence was performed with an FS920 fluorimeter 
(Edinburgh Instruments, UK) at 25°C using a quartz cuvette with a path length of 10 mm. 
OVA’s tryptophan residues were excited at λ=295 nm. Emission spectra were recorded 
between 305 and 400 nm, with steps of 1 nm and a cumulative addition of 2 scans per 




TMC/OVA nanoparticles were obtained by ionic complexation with TTP and OVA, as 
described before [12]. In short, OVA was added to a 0.2% w/v TMC solution in 5 mM Hepes 
(pH 7.4). Under continuous stirring (300 rpm) TPP was added to a weight ratio TMC:OVA:TPP 
of 10:1.0:1.7. Particles were washed and collected by centrifugation on a glycerol bed for 15 
min at 12000 g and resuspended in 5 mM Hepes (pH 7.4). The particle size of the obtained 
particles was measured by dynamic light scattering (ZetaSizer Nano, Malvern Instruments, UK) 
and the zeta potential was determined by laser Doppler electrophoresis using the same 
apparatus 
 
Dendritic cell studies 
Peripheral blood mononuclear cells (PBMCs) were isolated from fresh human blood using a 
Ficoll gradient as previously described [31]. Subsequently, monocytes were isolated from the 
PBMCs using a Percoll gradient as previously described [32]. After isolation, monocytes were 
adhered on 24-wells plates by incubation for 1 h at 37°C and 5% CO2, and depleted of platelets 
by washing. Monocytes were differentiated into immature DCs by incubation for 6 days with 
RPMI 1640 medium supplemented with 10% fetal bovine serum, 250 U/ml GM-CSF and 100 
U/ml IL-4.  
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For uptake of the TMC-OVA conjugate by DCs, FITC labeled OVA was covalently linked to 
TMC following the same method as described above. Immature DCs were exposed to TMC-
OVA-FITC conjugates for 4 h at either 37°C or 4°C. Cells were washed three times with FACS 
buffer (10 mg/ml bovine serum albumin in PBS with 2% v/v fetal calf serum), and the 
fluorescence of the OVA-FITC-containing DCs was quantified with a flow cytometer 
(FACSCanto II, Becton Dickinson).  
Dendritic cell maturation was determined by pulsing immature DCs with OVA, TMC and 
OVA, TMC-OVA conjugate, TMC/OVA nanoparticles or LPS for 4 h. Cells were washed with 
culture medium and plated in a 24-wells plate in the presence of GM-CSF. After 48 h, the DCs 
were washed twice with FACS buffer and stained with anti-CD86-APC for 30 min on ice. CD86 
expression was determined with flow cytometry.  
 
Immunogenicity 
Eight week old female BALB/c mice received one intramuscular dose of 20 µg OVA in either 
free (with or without TMC), conjugated (TMC-OVA conjugate) or particulate form (TMC-OVA 
nanoparticles). Blood samples were taken one day before and 3 weeks after immunization. 
IgG titers were determined using a similar ELISA procedure as for anti-diphtheria toxoid (DT) 
[33], replacing the DT coating with an OVA coating (100 ng/well).   
 
Statistics 
The immunization data were analyzed with a Kruskal-Wallis test. DC uptake studies were 
analyzed using a two-way ANOVA with Bonferroni’s posttest. All analyses were performed 





Synthesis of TMC-OVA conjugate 
To establish a disulfide bond between OVA and TMC both molecules were functionalized 
with protected thiol groups, by reaction with SPDP. Reduction with DTT (figure 2) enabled us 
to monitor with UV spectroscopy the number of protected thiol groups (PDP) introduced per 
protein/TMC molecule, as the resulting leaving group, pyridine-2-thione, has an extinction 
maximum at 343 nm. We found that the number of PDP groups introduced can be controlled 
by the feed of SPDP: a linear relationship between PDP incorporation and SPDP feed was 
observed, up to 3 moles PDP per mol OVA or TMC (figure 3a,b), after which the reaction 
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became unpredictable due to precipitation. This allows tailoring the average number of PDP 
groups on both OVA and TMC. For the conjugation step, the number of functional groups on 
OVA was varied, while the average number of functional groups on TMC was either 1 or 2 
moles per mol TMC, as a higher substitution degree induced precipitation of the polymer. An 
increasing number of PDP groups on OVA led to an increase in a higher conjugation efficiency, 
up to a maximum efficiency of ≈ 25% (figure 3c,d). Increasing the number of thiol groups on 
TMC from 1 to 2, decreased the number of required PDP groups on OVA from 4 to 2 to reach 
an efficiency of 25%, but did not lead a higher maximum efficiency. 
Based on the results described above, a TMC-OVA conjugate made from TMC-SH 
molecules containing 2 thiol groups on average and OVA-PDP containing an average of 2 PDP 
moieties per molecule was selected for further studies. Protein analysis showed 17% w/v OVA 
in the freeze dried product, corresponding to a molar ratio OVA:TMC of about 1:3 in the 























Figure 3: Functionalization and conjugation of TMC and OVA. Effect of SPDP 
feed on the amount of functionalized group on OVA (a) and TMC (b). PDP 
incorporation was monitored by UV-Vis detection at 343 nm. Efficiency of OVA 
conjugation to TMC-SH containing 1 mol SH/mol TMC (c) or 2 mol SH/mol TMC 
(d). 



















Characterization of TMC-OVA conjugate 
Formation of the conjugate was confirmed with GPC, using fluorescence detection (ex 295 
nm, em 340 nm). TMC is not detected with this method, making it specific for OVA. Conjugates 
contained larger species than native OVA as the main conjugate peak shifted from 30-31 min 
to 28-29 min (figure 4a), whereas a mixture of TMC and OVA did not cause such as shift (data 
not shown). Reduction of the conjugate with DTT restored the native OVA peak at 30-31 min 
(figure 4a). SDS-PAGE on collected fractions confirmed that the peak at 28-29 min contained 
TMC-OVA conjugate (figure 4b lane 7,8), as only under reducing conditions a band at 45 kDa 
was visible. Although the shoulder in the TMC-OMV conjugate peak in GPC indicates the 
presence of a small fraction of free OVA in the conjugate sample (figure 4a), SDS-PAGE was 
unable to detect OVA in this fraction (figure 4b lane 9,10).  
As a change in protein structure could adversely affect the immunogenicity of the antigen, 
the protein structure was investigated. Western blotting revealed that antigenic epitopes on 
OVA conjugated to TMC were still intact (figure 5), but does not give information on the 
overall conformation of OVA. Intrinsic fluorescence can be used to detect changes in the local 
environment of Trp residues inside a protein and UV spectroscopy gives information on Phe, 
Tyr and Trp. Therefore these techniques can give insight into the tertiary structure of the 
protein. As the individual UV spectra of Phe, Tyr and Trp strongly overlap, the 2nd derivative 
was used to enhance the resolution. The 2nd derivative spectra of native OVA and conjugated 
Figure 4: (a) GPC chromatograms based on fluorescence detection (ex 295 nm, em 340 
nm) of TMC-OVA conjugate (Conjugate), reduced TMC-OVA conjugate (Conjugate + 
DDT), OVA, and TMC. (b) SDS-PAGE under reducing (even lanes) and non-reducing (odd 
lanes) conditions of OVA (lane 1,2), TMC (lane 3,4), TMC-OVA conjugate fractions 25-27 




OVA practically overlapped (figure 6b), indicating no change in tertiary structure. Similarly, no 
shift in fluorescence emission maximum of the Trp residues was detected after excitation at 
295 nm (figure 6c), indicating that the polarity of the direct environment of the Trp residues 
had not changed after conjugation. The reduced fluorescence signal in conjugated OVA (figure 
6c) is likely due to the introduction of the S-S bonds, since both S-S and S-H groups have been 
reported to quench Trp fluorescence [34]. Indeed, the addition of TMC-PDP or TMC-SH to 





























Figure 5: Western blot of SDS-PAGE run 
under reducing conditions, using 
polyclonal anti-OVA IgG to detect the 
presence of intact epitopes. Lane 1: OVA; 
lane 2: OVA incubated for 16h at 40°C 
(equivalent conditions used for 
conjugation); lane 3: TMC; lane 4; TMC + 
OVA; lane 5: TMC-OVA. 
 
Figure 6: (a) UV 
absorption spectrum and 
(b) 2
nd
 derivate spectrum 
of 0.5 mg/ml OVA (grey 
line) and 2.5 mg/ml TMC-
OVA (corresponding to 0.5 
mg/ml OVA) conjugate 
(black line). c) 
Fluorescence emission 
spectra of OVA and TMC-
OVA conjugate. Spectra of 
a mixture of OVA and TMC 
(dashed grey line) and 
unfolded OVA (OVA + 6 M 
guanidine, dashed black 
line) are shown for 
comparison. Samples were 




Relatively monodisperse (polydispersity index 0.23) nano sized (280 ± 32 nm) TMC 
nanoparticles were produced. Particles carried a positive charge as indicated by their positive 
zeta potential, 21 ± 4.3 mV. 
 
Dendritic cell studies 
As uptake of the antigen by DCs is a critical step in the initiation of an adaptive immune 
response [4, 5], the extent to which the TMC-OVA conjugate was internalized by DCs was 
quantified in vitro. Concentration dependent association of OVA with DCs was observed, 
which was significantly enhanced by conjugation to TMC as well as encapsulation in TMC 
nanoparticles (p<0.001), but not by coadministration of TMC (figure 7a). Moreover, TMC-OVA 
conjugate was taken up actively, as at 4°C DC association was limited (p<0.001, figure 7b). 
TMC-OVA conjugate induced maturation of DC from antigen capturing to an antigen 
presenting (dendritic) phenotype (figure 8). Untreated immature DCs have a more or less 
round appearance, which was not notably changed after incubation with OVA (figure 8a) or 
OVA mixed with TMC (figure 8c), whereas DCs treated with LPS (figure 8b) or the conjugate 
(figure 8d) showed a dendritic phenotype. Expression of maturation marker CD86 was 
markedly increased after exposure of DCs to TMC-OVA conjugate as compared to a mixture of 
TMC and OVA or TMC/OVA nanoparticles (figure 9). Endotoxin levels were determined with a 
LAL assay (GenScript, Piscataway, NJ) and found to be similarly low for TMC and TMC-OVA 




An immunization study in mice was performed to investigate the immunogenicity of the 
TMC-OVA conjugate compared to a solution of OVA, a mixture of OVA and TMC, and 
TMC/OVA nanoparticles. The addition of TMC to OVA caused a significantly increased 
antibody production, compared to administration of OVA alone (p<0.05, figure 10). 
Conjugation of TMC and OVA, however drastically improves IgG production compared to both 
of these groups (p<0.001). The average IgG titer in mice immunized with TMC-OVA conjugate 
was slightly higher than that of mice immunized with TMC/OVA nanoparticles, although the 







































Figure 7: (a) Dose dependent association of OVA, a mixture of OVA and TMC, 
TMC-OVA conjugate and TMC/OVA nanoparticles by DCs incubated at 37°C for 4 
h. Conjugate as well nanoparticles showed a significant increase in uptake 
compared to OVA and TMC+OVA (*** = p<0.0001). (b) Active uptake versus 
passive association was investigated by exposing DC to TMC-OVA conjugate at 
37°C and 4°C. Data are a representative example of 4 different monocyte donors. 
Bars represent mean +/- SD (n=3). 
 

































Figure 8: Representative example of micrographs of DCs treated for 4 h with (a) 0.2 
µg/ml OVA, (b) 100 ng/ml LPS, (c) 0.2 µg/ml OVA + 1 µg/ml TMC and (d) 1 µg/ml TMC-
OVA conjugate (corresponding to 0.2 µg/ml OVA). Magnification 20x. 
 
Figure 9: CD86 expression as a measure for 
DC maturation. Immature DCs were pulsed 
with increasing amounts of TMC/OVA 
mixture (open circles), conjugate (closed 
squares), or TMC/OVA nanoparticles 
(closed triangles) for 4 h, after which 
medium was replaced and CD86 expression 




















Subunit vaccines are notorious for the fact that they are safer, but less immunogenic than 
live attenuated or whole inactivated vaccines. One way of overcoming this decreased 
immunogenicity is the use of adjuvants. Although the practice of using adjuvants has been 
known for more than a century (e.g. the use of alum), only recently a few new adjuvants have 
been approved for human administration [35]. The main pitfall for an adjuvant still remains 
the potential health risk associated with its use as an immune stimulating compound [36]. 
Here we report on a method to increase the efficiency of the adjuvant, which could permit 
lowering the adjuvant dose. 
The proteinaceous antigen, OVA, was coupled to polymeric adjuvant, TMC, using the SPDP 
method. This method, first described by Carlsson et al [37], has been developed to covalently 
link proteins with each other, but has also been used to synthesize protein-polymer 
conjugates [26, 38, 39] with the important advantage of introducing a disulfide bond, which is 
reversible under reducing conditions [22]. Detachment of the polymer from the protein, once 
the conjugate has been taken up by a DC, is a requisite for unaltered processing of the 
antigen, making the SPDP method an interesting approach. Free amine moieties on OVA and 
TMC were functionalized with protected thiol groups. The functionalization of TMC and OVA 
could be controlled, but reaction efficiencies were low compared to other reports [26]. 
Moreover, the total conjugation yield (25%) was lower than expected, as previous studies 
Figure 10: OVA specific serum 
IgG titers after a single dose of 
20 µg OVA, OVA mixed with 
TMC, TMC-OVA conjugate 
(conjugate) and TMC/OVA 
nanoparticles (TMC NP). * = 
p<0.05; ** = p<0.01; ***= 
p<0.001 Data represent mean 
+/- SD (n=5). 
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reported yields ranging from 50-90% [26, 38, 39]. This could be explained by aggregation of 
protein and polymer, which was getting more pronounced with higher degrees of PDP 
functionalization on TMC and OVA (data not shown). It is likely that the aggregation of the 
molecules interfered with the disulfide bond formation between the protein and the polymer, 
resulting in a loss of coupling efficiency.  
Nevertheless, the SPDP method proved to be a very useful way of covalently linking TMC 
and OVA, as the conjugation was reversible under reducing conditions and the epitopes on 
OVA were still intact. Moreover, we did not detect any changes in the structure of OVA using 
2nd derivative UV spectroscopy and intrinsic fluorescence spectroscopy. Protein conformation 
has not been regarded as essential with respect to the immunogenicity of its T-cell epitopes as 
these are mostly continuous or linear. B-cells epitopes however, have been reported to be 
discontinuous (conformational) [40]. The preservation of the protein structure makes the 
SPDP method an interesting strategy also to couple other protein-based antigens to an 
adjuvant carrying primary amine groups or free –SH groups. 
The TMC-OVA conjugate exerts interesting immunological properties. Besides the 
expected enhanced immune response by the TMC-OVA conjugate due to the simultaneous 
uptake by and maturation of APC, uptake studies with DCs also showed an increased antigen 
uptake compared to a mixture of TMC and OVA, similar to that observed for TMC/OVA 
nanoparticles. This suggests that TMC directly facilitates antigen uptake by DCs and not 
indirectly, for instance via upregulation of receptors on the DC’s surface, or by disrupting the 
cell membrane. Uptake-enhancing effects of cationic polymers have been reported before [12, 
41-43], which was attributed to non-specific interactions between the positively charged 
polymers and the negatively charged cell surfaces, followed by active uptake. A similar effect 
was observed here, as at 4°C a fraction of conjugated OVA was associated with DCs, indicating 
interaction on the cell surface or passive diffusion into the DCs. However, the amount of 
engulfed TMC-OVA conjugate by DC at 37°C greatly surpassed the amount engulfed at 4°C, 
pointing to an important role for active uptake of the conjugate and the TMC particles after 
adsorption to the cell membrane. The possibility of increasing antigen uptake via conjugation 
with a DC specific targeting ligand has been reported previously [44], however, TMC has not 
been described as a specific ligand for receptors on the DC cell surface. C-type lectins play a 
role in the recognition of carbohydrate residues of bacterial surfaces, and have been 
suggested to recognize chitosan via non-deacetylated units (N-acetylglucosamine residues) 
[45]. Due to the treatment with NaOH, the number of N-acetylglucosamine residues in TMC is 
low (an average of 6.5 N-acetyl residues per TMC molecule), but this may still be sufficient to 
contribute to the effective uptake of the conjugate.  
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Exposure of DCs to low concentrations of TMC-OVA conjugate was accompanied with a 
strong induction of DC maturation (Figure 8). Surprisingly, an equivalent amount of soluble 
TMC or TMC nanoparticles was unable to activate DCs. Only a >20 fold more concentrated 
TMC solution was capable of inducing similar CD83 (data not shown) and CD86 expression 
(figure 9), indicating that the conjugate had a more potent adjuvant effect compared to 
unconjugated TMC or TMC particles. Importantly, endotoxin levels of TMC and TMC-OVA 
conjugate were comparably low, indicating that the effect on DC maturation was not caused 
by LPS contamination. 
The in vitro findings were reflected in vivo as, in line with earlier reports about antigen-
adjuvant conjugates [44, 46-49], the overall immunogenicity of TMC-OVA conjugate was 
shown to exceed that of soluble OVA/TMC mixture. Moreover, immunization with the 
conjugate induced at least similar IgG titers as immunization with TMC-OVA nanoparticles, 
showing that concomitant delivery of antigen and adjuvant, without the need for a particulate 
carrier, is sufficient to obtain a potent immune response. These findings suggest that 
conjugation may be a sound strategy in the design of subunit vaccines. Here we focused on 
conjugation of a single adjuvant, but the SPDP method also allows the ligation of multiple 
adjuvants, which could be even more effective [50] and may in future even allow manipulation 





Conjugation of an antigen to an adjuvant is a promising strategy to enhance the 
immunogenicity of subunit vaccines. The SPDP crosslinker is well suited to covalently couple 
OVA to the polymeric adjuvant TMC, as the resulting linkage is reversible and protein 
conformation unchanged. TMC-OVA conjugates are efficiently taken up by DCs and the 
immunogenicity is superior to that of unconjugated OVA, even matching the immunogenicity 
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Entrapment of antigens in mucoadhesive nanoparticles prepared from N-trimethyl 
chitosan (TMC) has been shown to increase their immunogenicity. However, because of their 
large size compared to soluble antigens, particles poorly diffuse through the nasal epithelium. 
The aim of this work was to study whether nasal vaccination with a much smaller TMC-antigen 
nanoconjugate would result in higher antibody responses as compared to TMC nanoparticles.  
TMC was covalently linked to a model antigen, ovalbumin (OVA), using thiol chemistry. For 
comparison, TMC/OVA nanoparticles and solutions of OVA and a physical mixture of TMC and 
OVA were made. As shown previously for TMC-OVA nanoparticles, TMC-OVA conjugate 
prolonged the nasal residence time of the antigen. TMC-OVA conjugate diffused significantly 
better through a monolayer of lung carcinoma (Calu-3) cells than TMC/OVA nanoparticles did. 
Moreover, nasal immunization of mice with the conjugate resulted in significantly more OVA 
positive DCs in the cervical lymph nodes as compared to TMC/OVA nanoparticles. Mice nasally 
immunized with TMC-OVA conjugate produced high levels of secretory IgA in nasal washes 
and higher titers of OVA-specific IgG than mice immunized with any of the other formulations. 
Moreover, as compared to TMC/OVA nanoparticles, TMC-OVA conjugate induced a more 
balanced IgG1/IgG2a response.   
In conclusion, the TMC-antigen nanoconjugate improves nasal delivery and 
immunogenicity of the antigen. This suggests that efficient co-delivery of antigen and adjuvant 
to DCs, rather than a particulate form of the antigen/adjuvant combination, is decisive for the 



















The nasal mucosa is an attractive site for vaccination, as it is very accessible, low on 
proteolytic enzymes compared to the oral route, and presents a surface densely populated by 
immune cells, often referred to as the nasal associated lymphoid tissue (NALT). Various 
studies in rodents[1-4] and humans[5] have shown that the nasal epithelium not only can be 
the inductive site for the production of systemic (IgG) antibodies, but also can be the 
executive site for the secretion of local (sIgA) antibody responses. However, the amount of 
antigen that penetrates the nasal epithelium is limited and very large doses are necessary. 
Moreover, the tolerogenic nature of the nasal mucosa interferes with the induction of an 
adaptive immune response and makes the application of an adjuvant imperative for subunit 
vaccines[6].    
Encapsulation of antigens into particulate systems is a popular method to increase the 
immunogenicity, as particles can facilitate the uptake of the antigen by dendritic cells (DCs) 
and the multimerization of epitopes on the particle surface can increase the immune 
recognition by B-cells[7, 8]. Not surprisingly, the nanoparticle approach has also been applied 
to nasal vaccines[9, 10]. Mucoadhesive particles can prolong the antigens’ residence time in 
the nasal cavity[11] and can be supplied with adjuvants to break nasal tolerance. N-trimethyl 
chitosan (TMC) based nanoparticles combine mucoadhesiveness, adjuvant effect and even M-
cell targeting[12, 13]. Nasal administration of ovalbumin, tetanus toxoid or hemagglutinin 
loaded TMC nanoparticles (TMC NP) resulted in strong antibody against the encapsulated 
antigen[14-16].  
Although these advantages make the use of nanoparticles for nasal vaccination very 
appealing, a significant drawback is the increased size of the vaccine. Smaller entities have 
been associated with stronger immune responses[17, 18] as larger species evidently have 
more difficulties diffusing through the nasal epithelium[19]. M-cells present in the nasal 
epithelium have been reported to transport particulate structures from nano to micro scale, 
but the M-cell population is very small[20], probably making its contribution to the total 
amount of antigen reaching the subepithelium limited[18]. 
Recently we have reported on the synthesis and immunological properties of TMC-OVA 
conjugates[21]. After intramuscular administration, these nanoconjugates and TMC/OVA NP 
were equally effective at inducing systemic immune responses. We hypothesize that nasal 
vaccination with TMC-OVA conjugates results in higher antibody responses than 
administration of TMC/OVA NP as the conjugates may diffuse better through the nasal 




characteristics, because of the co-localization of adjuvant and antigen. Therefore we 
investigated TMC-OVA’s ability to diffuse through a mucosal epithelial monolayer in vitro, 
compared to TMC/OVA NP and plain OVA. Moreover, the nasal residence time of the 
nanoconjugates was studied in mice using a live imaging technique. To investigate the 
combined effect of nasal residence time, epithelial penetration capacity and ability of the 
nanoconjugate to be taken up by DC in vivo, the amount of OVA positive DCs in the draining 
lymph node was quantified 24 hour after nasal administration of the TMC-OVA conjugate. 
Finally, a nasal vacation study in mice was undertaken to measure the immunogenicity. 
 
 
Materials and Methods 
 
Materials 
N-trimethyl chitosan (TMC) with a degree of quaternization of 20% was synthesized 
starting from 92% deacetylated chitosan (MW 120 kDa; Primex, Siglufjordur, Iceland), as 
earlier described [22]. Endotoxin free OVA was purchased at Merck (Darmstadt, Germany). 
Phycoerythrin (PE)-Cy5 labeled anti-CD11c- and Matrigel were acquired from Becton Dickinson 
(Franklin Lakes, NJ, USA). Microtiterplates were purchased at NUNC (Roskilde, Denmark). 
Phosphate buffered saline (pH 7.4) was obtained from Braun (Oss, NL).  Normal 12-well plates 
as well as 12-well Transwell plates were obtained from Corning (Schiphol, NL), Invitrogen 
(Breda, NL) supplied fluorescein isothiocyanate labeled OVA (OVAFITC), AlexaFluor647 labeled 
OVA (OVAAF647), bovine serum albumin (BSA) and all cell culture products unless stated 
otherwise. LI-Cor (Lincoln, NE, USA) provided IRdye™ 800CW which was conjugated to OVA 
according to the manufacturer’s instructions. N-succinimidyl 3-(2-pyridyldithio) propionate 
(SPDP), dithiothreitol (DTT), pentasodium tripolyphosphate (TPP) and all other salts/chemicals 
were purchased at Sigma-Aldrich (Zwijndrecht, NL), unless stated otherwise. 
 
TMC-OVA nanoconjugate synthesis  
TMC-OVA nanoconjugates were synthesized and characterized as described before [21]. 
Briefly, 10 mg TMC and 5 mg OVA were separately exposed to a 10 fold molar excess of SPDP 
for 1 h at room temperature, resulting in approximately 2 functionalized groups per TMC and 
per OVA molecule. Functionalized TMC was treated with DTT for 30 min at room temperature 
to obtain thiolated TMC. Thiolated TMC and functionalized OVA were mixed at a 1:1 molar 
ratio to allow disulfide bond formation overnight. The conjugate’s hydrodynamic diameter 
TMC conjugates for nasal vaccination 
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was obtained by dynamic light scattering (ZetaSizer Nano, Malvern Instruments, UK) and 
determined to be 28 nm +/- 0.6. For determining the nasal residence time, transport over a 
Calu-3 monolayer and DC uptake in the lymph nodes, OVA was replaced by OVA-IR-dye 
800CW, OVAFITC and OVAAF647, respectively. 
 
TMC/OVA nanoparticles 
TMC/OVA NP were obtained by ionic complexation with TTP and OVA, as described 
before[12]. In short, OVA was added to a 0.2% w/v TMC solution in 5 mM Hepes (pH 7.4). 
Under continuous stirring (300 rpm) TPP was added to a weight ratio TMC:OVA:TPP of 
10:1.0:1.7. Particles were washed and collected by centrifugation on a glycerol bed for 15 min 
at 12000 g and resuspended in 5 mM Hepes (pH 7.4). The particle size of the obtained 
TMC/OVA NP as measured by dynamic light scattering was 312 ± 14 nm (polydispersity index 
0.22) and the zeta potential, determined by laser Doppler electrophoresis, was 19.2 ± 3.5 mV. 
TMC/OVAFITC and TMC/OVAAF647 NP with similar size and zeta potential were prepared by 
substituting OVA by its fluorescent counterpart. 
 
Calu-3 cell culture 
Calu-3 cells (ATCC, Washington, DC, USA) were maintained in Dulbecco’s Modified Eagles 
Medium (DMEM) supplemented with 10% v/v fetal bovine serum, 4.5 g/l glucose, 2 mM L-
glutamine, 1% v/v non essential amino acids and 500 U/ml Penicilline/Streptomycine at 37°C 
and 5% CO2.  
For transport experiments the inserts of 12-well Transwell plates were coated with 
Matrigel according to the manufacturer’s instructions. Calu-3 cells were seeded (5*105 per 
insert) and maintained for 14 days in supplemented DMEM. Medium at both the apical and 
the basolateral side was changed every other day. Integrity of the monolayer was assayed by 
measuring the transepithelial electrical resistance (TEER) using a home made dip stick 
electrode. 
 
In vitro transport 
Calu-3 monolayers were washed once with Hank’s Balanced Salt Solution (HBSS) and 
allowed to equilibrate in HBSS for 30 min at 37°C. TEER was determined used a home made 
dip stick electrode. Subsequently the apical medium was removed and the insert were 
transferred to a 12-well plate containing 1.2 ml HBSS per well. Formulations were diluted in 
HBSS to a final concentration of 100 µg/ml OVAFITC and 300 µl was added to the apical side. 




containing 1.5 ml HBSS and TEER was assessed. Basolateral compartments were collected and 
total fluorescence determined using fluorescence spectroscopy (excitation at 495 nm emission 
at 520 nm, Infinite M1000, TECAN, Mechelen, Belgium). 
 
Nasal residence time 
Nasal residence time measurements were performed in accordance to the protocol 
described by Hagenaars et al.[23]. Female Balb/c (nu/nu) mice between 8 and 10 weeks old 
(Charles River, L’Arbresle, France) were lightly anesthetized using isofluorane prior to the 
administration of 3 µg (10 µl) OVA labeled with IRdye™ 800CW. The nose was wiped clean 
with a paper towel and immediately fluorescence intensity (excitation 710 nm, emission 760; 
780; 800; 820 and 840 nm) was measured using an IVIS Spectrum® (Caliper Life Sciences 
(Hopkinton, MA, USA). Every 15 minutes, light anesthesia was applied again and fluorescence 
intensity was determined as described above. Between measurements, mice were conscious.  
To calculate the mean fluorescence in the nasal cavity, the IR-dye 800CW specific signal 
was separated from the background fluorescence by spectral unmixing using Living Image 3.1 
software (Caliper Life Sciences). Regions of interest (ROI) were set over the nasal cavity of the 
mice and the average pixel intensity within the ROI was quantified using the same software. 
Fluorescence intensity at t=0 was set as at 100%. 
   
Antigen uptake by DCs in the lymph nodes 
Eight weeks old female Balb/c mice were nasally administered 20 µg OVAAF647 in different 
formulations (in 10 µl PBS, 5 µl per nostril). After 24 h mice were sacrificed and cervical lymph 
nodes were collected. Single cell suspensions were obtained, by grinding the lymph nodes 
through 70 µm cell strainers. Lymphocytes were washed with PBS containing 1% w/v BSA and 
stained with 50x diluted anti-CD11c-PE-Cy7. Cells were analyzed with flow cytometry using a 
FACSCantoII (Becton Dickinson). DC population was determined based on the expression of 
CD11c and OVA+ cells in this population were quantified.  
 
Vaccination 
Eight week old female Balb/c mice nasally received formulations containing 20 µg OVA in a 
total volume of 10 µl PBS (5 µl per nostril). After 3 weeks, blood samples were drawn and mice 
received a similar nasal booster dose. After 6 weeks blood samples were taken from the femur 
artery and mice were sacrificed and nasal washes were performed. 
Animal experiments were approved by the Ethical Committee of the Leiden University 
Medical Centre in accordance to the Dutch Animal Protection Act. 




Determination of serum IgG, IgG1, IgG2a and secretory IgA 
Microtiter plates (96 wells) were coated with 100 ng OVA in 100 mM sodium carbonate 
buffer pH 9.4 for 24 h at 4°C. To reduce non specific binding, well surfaces were blocked by 
incubation with 1% w/v BSA in PBS for 1 hour at 37°C. After washing, serial dilutions of serum, 
ranging from 20 to 2*106, were applied for 1.5 hours at 37°C; nasal washes were added 
undiluted. After washing, OVA specific antibodies were detected by incubating HRP 
conjugated goat anti-mouse IgG, IgG1, IgG2a or IgA (1 h at 37°C) and, subsequently after 
extensive washing, with 50 µg tetramethylbenzidine (TMB)/ 1 µM H2O2 in sodium acetate 
buffer pH 5.5 for 15 min at room temperature. Reaction was stopped with 2 M H2SO4 and 
absorbance was determined at 450 nm with an EL808 micro plate reader (Bio-Tek 
Instruments, Bad Friedrichshall, Germany). 
 
Statistics 
All the data were analyzed with a one-way ANOVA with Bonferroni’s post-test, with the 
exception of the antibody titers, which were analyzed with a Kruskal-Wallis test with Dunns 





Nasal residence time 
Increasing the nasal residence time of the antigen is presumed to be one of the key 
features by which TMC NP augment the immune response10,[15]. In a recent study we showed 
that TMC NP indeed reduced the clearance rate of OVA from the nasal cavity with about 
50%[13]. It is therefore imperative to know whether TMC-OVA nanoconjugates also possess 
this characteristic. Monitoring the decay of fluorescence in the nasal cavity allowed an 
assessment of the effect of TMC conjugation on the clearance of OVA (Figure 1). Conjugation 
of OVA to TMC prolonged the nasal residence time compared to plain OVA. Whereas OVA was 
practically cleared from the nasal cavity within 2 h, the clearance of TMC-OVA conjugates was 
strongly delayed, with a residence time in the nasal cavity exceeding 2.5 h. Interestingly, no 
significant difference between TMC-OVA conjugate and a TMC+OVA physical mixture was 
observed, indicating that the increased residence time is caused by the presence of TMC and 





























Antigen transport in vitro 
Transport of the antigen through the nasal epithelium is a critical step in its delivery to 
antigen presenting cells (APCs). Calu-3 cells are lung cells that secrete mucus and form 
monolayers, making them an good in vitro model to study the transport of drugs and vaccines 
through respiratory epithelium[24],[25]. Coadministration of OVA with TMC enhanced the 
transport of OVA through a Calu-3 monolayer (p<0.01 Figure 2). This was accompanied by a 
decreased TEER, which was not observed for administration of OVA alone. Encapsulation of 
OVA into TMC/OVA NP resulted in a more than 10 fold reduction in the amount of transported 
OVA compared to plain OVA (p<0.001). TMC-OVA conjugates showed a significantly higher 
transport rate than TMC/OVA NP (p<0.05), although conjugation still reduced OVA transport 
through a Calu-3 monolayer compared to plain OVA (p<0.01). 
Figure 1: a) Nasal clearance of OVA after co-administration or conjugation with TMC. 
Emission spectra at 800 nm. b) Clearance derived from spectra. Circles OVA, squares 
OVA + TMC and triangles TMC-OVA conjugate. Error bars represent SD (n=3). 

























Antigen delivery to DCs in vivo 
After passing the epithelium, the antigen can either drain through the interstitum to the 
nearby cervical lymph nodes where it can be taken up by DCs, or it can first be taken up by 
local DCs that will subsequently transport the antigen to the lymph node[26]. One day after 
nasal administration the cumulative effect (direct or DC mediated antigen delivery) should be 
visible in the cervical lymph nodes. Analysis of the DCs isolated from the cervical lymph nodes 
showed that the delivery of OVA from the nasal cavity to the lymph nodes was significantly 
enhanced by conjugation of the antigen to or co-administration with TMC, compared to 
immunization with plain OVA or TMC/OVA NP (p<0.05, Figure 3). No significant differences 




Figure 2: Diffusion of OVA-FITC through a Calu-3 cell monolayer as a measure for 
mucosal epithelial permeability. Bars represent mean +/- SD (n=9). * p<0.05, ** p<0.01. 







































Figure 3: a) Representative flow cytometry histograms of single cell suspensions of cervical lymph 
nodes. 24 h after application of 20 µg OVAAF647. Cell were gated for  CD11c
+. Lymph nodes from non 
vaccinated mice were used as negative control (untreated), and those of mice vaccinated 
intranodally with 0.2 µg OVAAF647 as a positive control. Percentages indicate the number of DC 
within the OVA
+
 region b) Number of OVA
+
 DC in cervical lymph node 24 h after application of 20 µg 
OVAAF647.  n=4+/- SEM * p<0.05 compared to OVA. 




To investigate whether the observed differences in transport and delivery to DCs were 
reflected in the immunogenicity of the formulations, a nasal vaccination study was performed. 
To assess the effect on the systemic antibody response, OVA specific IgG titers were 
determined. As the delivery system has can also influence the quality of the immune 
response, IgG subclasses (IgG1 and IgG2a) were quantified and sIgA levels were measured in 
nasal washes. 
TMC-OVA nanoconjugates led to substantial OVA specific IgG titers already after a single 
nasal immunization (Figure 4), being significantly higher than titers of mice nasally vaccinated 
once with OVA alone, OVA/TMC mixture (p<0.001), TMC/OVA NP (p<0.05), or intramuscularly 
vaccinated with OVA (p<0.01). After a booster only TMC/OVA NP vaccination resulted in 
similar high titers as TMC-OVA nanoconjugates (p=0.29). Besides the more rapid onset of an 
immune response induced by the nanoconjugates than by TMC/OVA NP, the two formulations 
differed in the type of immune response elicited (Figure 5). Whereas vaccination with TMC-
OVA conjugate resulted in a rather balanced IgG1/IgG2a profile, immunization with a physical 
mixture of TMC and OVA or TMC/OVA NP resulted in antibody profile towards an IgG1 
(indicative of a Th2 type) response (p<0.05). 
TMC-OVA conjugates and TMC/OVA NP induced high levels of OVA-specific sIgA compared 












Figure 4: OVA specific serum IgG titers after 
nasal vaccination with a priming dose (white 
bars) or a booster dose (gray bars) of OVA. 
Mean +/- SD (n=8). *p<0.05  
Figure 5: IgG1/IgG2a ratio indicative of the 
quality of the immune response. Bar represent 




















A wide range of (nano)particulate systems have been shown to increase the 
immunogenicity of the encapsulated antigen when administered by injection[27]. Although 
these systems greatly differ in size, shape, charge and release profiles, the explanations for 
their immune potentiation are remarkably homogeneous. The adjuvant effect of particles has 
often been attributed to their ability to form slow release depots, to enhance antigen uptake 
and presentation by APCs or to enhance the activation of APCs. Moreover, the necessity of co-
localizing antigen and adjuvant in one entity to induce proper T-cell proliferation has been 
clearly shown[28] and may be the most important explanation why particles have an 
immunostimulatory effect[27, 29, 30].    
The benefit of using nanoparticulate formulations for nasal vaccination has become 
evident in the last decades[10, 31], as many studies have shown higher antibody responses 
towards encapsulated antigen than to soluble antigen[32]. Although nasal and parenteral 
vaccination share the fact that antigens have to be taken up by APCs and these APCs have to 
be activated, we recently demonstrated that the nasal delivery route requires a different 
nanoparticle design compared to the parenteral route[13]. Firstly, the residence time in the 
nasal cavity is limited due to mucociliary clearance, making a beneficial effect of a depot highly 
unlikely and favoring the use of mucoadhesive particles. Secondly, the need to pass the nasal 
epithelium may require an antigen-adjuvant construct to be as small as possible[17, 18]. 
TMC/OVA NP (diameter ca. 300 nm) are mucoadhesive and prolong the nasal residence time, 
Figure 6: OD450 
values reflecting sIgA 
levels in nasal washes 
retrieved from mice 
after having received 
two nasal doses. Bars 
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but are relatively large entities compared to soluble OVA (diameter ca. 5 nm). In this respect, 
TMC-OVA nanoconjugates (diameter ca. 28 nm) seem a logical design. We have shown before 
that TMC-OVA conjugates induce the uptake of OVA by DCs to a similar extent as TMC/OVA 
NP and also activate these DCs[21]. Here we show that they also prolong the nasal residence 
time (Figure 1), as earlier shown also for TMC/OVA NP[13], and seem to have an advantage 
over TMC/OVA NP as their transport over epithelial cells was higher (Figure 2). TMC is a known 
absorption enhancer[33, 34] by opening tight junctions between epithelial cells[35-37] and is 
not toxic for Calu-3 cells at concentrations similar to the ones used in the current study [37, 
38]. Indeed, the addition of TMC decreased the TEER of a Calu-3 cell monolayer and increased 
OVA transport. Encapsulation of OVA in TMC NP, however, dramatically decreased its 
transport, although the tight junctions were opened judging from a decrease in TEER (data not 
shown). This indicates that TMC/OVA NP are indeed too big for intercellular transport and 
would have to rely on transcellular transport (e.g. M-cell transport).  
TMC-OVA conjugates, being more bulky than OVA, did not penetrate the Calu-3 monolayer 
as efficiently as a physical mixture of TMC and OVA, but the conjugate’s transport was much 
better than that of TMC/OVA NP (Figure 2). This is likely the reason why more OVA+ DCs were 
detected in the cervical lymph nodes 24 h after nasal administration of TMC-OVA conjugates 
than after TMC/OVA NP (Figure 3). These results are in accordance with a study by Brooking et 
al.[19] who investigated the size dependent penetration of particles through the nasal 
epithelium and found that the smallest particles (20 nm) reached the highest peak 
concentration in the bloodstream. Unfortunately the particle disposition in the lymph nodes 
was not reported. However, in an earlier report, encapsulation of tetanus toxoid (TT) into 
poly-lactic acid (PLA) nanoparticles did not increase the TT concentration in cervical lymph 
nodes compared to the nasal application of TT solution[39]. Only when PLA particles were 
coated with poly-(ethylene glycol) the transport of encapsulated TT was enhanced[39, 40]. 
This indicates that particles can experience difficulties passing the nasal epithelium and their 
physicochemical characteristics affect the delivery of the encapsulated antigen to the draining 
lymph nodes.  
Interestingly, a similar number of OVA+ DCs was found after application of TMC-OVA 
conjugate and TMC/OVA mixture, whereas based on the in vitro transport one would expect 
more OVA+ DCs after administration of TMC/OVA mixture. This could be explained by the 
improved uptake of TMC-OVA by DCs due to the TMC-OVA co-localization as observed 
earlier[21], which might compensate for the inferior transport of the nanoconjugate 
compared to TMC/OVA mixture. A similar explanation could be applied to the difference 




more ease (Figure 2), the prolonged nasal residence time and superior delivery of TMC/OVA 
NP to cervical DCs compared to plain OVA make the total number of OVA+ DCs comparable 
(Figure 3).   
The nasal vaccination study reveals the cumulative effect of the formulation parameters 
(Table I). Only mice that received an adjuvanted (TMC-containing) formulation, developed 
OVA specific IgG titers after nasal administration (Figure 4). Secondly, mice that received TMC 
and OVA in co-localized form developed higher IgG titers as well as sIgA levels than mice that 
received TMC and OVA as a mixture, most likely because of improved antigen uptake by DCs in 
conjunction with improved DC maturation. Finally, from the two co-localized formulations 
TMC-OVA nanoconjugates outperformed TMC/OVA NP after the priming dose, probably 
because of superior uptake of the conjugates through the nasal epithelium. Although this 
explanation is very tempting and straightforward, a significant Th1 shift after vaccination with 
TMC-OVA conjugates compared TMC/OVA NP (Figure 5) could also indicate a more complex 
answer. TMC is generally associated with a strong IgG1 response[15, 41, 42], indicative of a 
Th2 bias, but also occasionally has been described to elicit substantial IgG2a antibody 
titers[12, 43]. Endotoxin determination with LAL-test showed no evidence of contamination of 
the nanoconjugate with endotoxin (<0.1EU/mg), suggesting the absence of immune 
stimulatory compounds other than TMC. However, parameters like the antigen dose, 
exposure time, interaction with pathogen recognition receptor and the mode of uptake by 
APCs can all influence the Th1/Th2 balance[44, 45]. Interestingly, it has been suggested that 
smaller particles may induce a more Th1 biased response, compared to larger particles with 
the same make up, as smaller particles resemble the dimensions of viruses [46], which could 
explain the Th1 shift observed here with the TMC-OVA nanoconjugate as compared to 
TMC/OVA NP. A Th1 shift could be beneficial in case of vaccination against intracellular 
bacteria or viruses. This, combined with the strong total antibody level makes it worthwhile to 




The co-localization of antigen and adjuvant seems to be the driving force behind the 
immune potentiating effect of TMC based nanoparticles after nasal administration, rather 
than the particulate antigen design. This makes nasal vaccination with TMC-antigen 
nanoconjugates a very promising strategy, as these conjugates are more easily take up by the 
nasal epithelium than larger nanostructures, while preserving the property of co-delivering 
the adjuvant (TMC) and antigen to APCs.  
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Table I: Summary of findings in this study. The extent of the immune response against OVA, in relation 
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Nasal vaccination is a promising, but challenging vaccination strategy. Poor absorption by 
the nasal epithelium and failure to break nasal tolerance are regarded as important reasons 
for poor efficacy of nasally applied vaccines. Formulation of the antigen into mucoadhesive 
nanoparticles, made of N-trimethyl chitosan (TMC) crosslinked with tripolyphosphate (TPP), 
has been shown to overcome these obstacles. However, although nasally administered 
antigen loaded TMC/TPP nanoparticles induce a strong humoral response, antibody subtyping 
indicates a Th2 bias. To design a nasal antigen delivery system capable of inducing stronger 
Th1 type responses, TPP as a crosslinking agent was replaced by unmethylated CpG DNA, a 
TLR-9 ligand and a potent inducer of Th1 responses, to prepare ovalbumin (OVA) loaded TMC 
nanoparticles (TMC/CpG/OVA). Several physicochemical characteristics of TMC/CpG/OVA 
(size, zetapotential, loading efficiency and antigen release profile) were assessed and 
compared to TMC nanoparticles prepared by crosslinking with TPP (TMC/TPP/OVA). Mice 
were nasally administered TMC/TPP/OVA and TMC/CpG/OVA after which antibody responses 
in serum and nasal washes were assessed and T-cell activation in the spleens determined. 
TMC/CpG/OVA showed similar physical properties as TMC/TPP/OVA in terms of particle 
size (380 nm), zetapotential (+21 mV) and antigen release characteristics. Nasal administration 
of TMC/CpG/OVA and TMC/TPP/OVA to mice resulted in comparable serum IgG levels (ca. 
1000 fold higher than those induced by unadjuvanted OVA) and local secretory IgA levels. 
Moreover, TMC/CpG/OVA induced a 10 fold higher IgG2a response than TMC/TPP/OVA and 
enhanced the number of OVA specific IFN-gamma-producing T-cells in the spleen.  
In conclusion, OVA loaded TMC nanoparticles, containing CpG as adjuvant and crosslinker, 
are capable of provoking strong humoral as well as Th1 type cellular immune responses after 
















Nasal vaccination has gained much interest over the past decades as it is non-invasive and 
thereby expected to increase patient compliance. Additionally, vaccination via the nose has 
been shown to induce, besides systemic humoral (IgG mediated) and cellular responses, local 
as well as distal secretory immune responses (secretory IgA (sIgA) mediated) [1-3], making the 
mucosal linings less vulnerable to infection. Moreover, the cross reactivity of sIgA is relatively 
high compared to IgG antibodies [4, 5], making the induction of local immune responses a 
promising strategy to target highly variable pathogens, like influenza viruses [6].  
Nonetheless, nasal immunization with subunit vaccines is challenging, as residence time in 
the nasal cavity is limited and therefore the uptake by the nasal epithelium is low. Moreover, 
the nasal epithelium is renowned for being a rather tolerogenic site [7, 8], making it difficult 
for subunit antigens to provoke an immune response. Vaccine formulation may be 
instrumental to successful nasal vaccination. Encapsulation of the antigen into particulate 
carrier systems has been explored extensively in recent years [9] and holds great promise as 
particles can be specifically designed to meet the challenges nasal vaccination provide [10]. 
Among the large variety of particles that can be found in the literature, chitosan based 
particles are among the most studied ones [11]. Chitosan is a cheap, biodegradable, 
mucoadhesive polymer. In rodents, particles prepared from chitosan have been shown to 
effectively induce systemic antibody responses against ovalbumin (OVA) and cholera toxin 
[12], Hepatitis B surface antigen  [13], and Meningococcal C oligosaccharides [14]. More 
recently chitosan derivatives have been developed, like thiolated chitosans [15] to enhance its 
mucoadhesiveness and trimethylated chitosans (TMC) [16] to improve its solubility at 
physiological pH. Especially TMC has been shown to be a very promising nasal vaccine carrier. 
Nanoparticles prepared from TMC by ionic crosslinking with tripolyphosphate (TPP) increase 
the nasal residence time of the encapsulated antigen [17], improve the uptake of the antigen 
by M-cells [18] and additionally promote maturation of dendritic cells (DCs) [9-11]. 
Consequently, TMC particles loaded with antigens, e.g. tetanus toxoid [12], meningococcal C 
oligosaccharides [19] or hemagglutinin [20] induce strong systemic as well local antibody 
responses. Moreover, intranasally administered TMC-coated whole inactivated influenza virus 
resulted in protection of mice against a challenge with a lethal dose of influenza virus [21]. 
Nonetheless, a significant drawback of TMC is its tendency to promote a humoral (Th2 type) 
rather than a Th1 type immune response [20, 22]. Strong Th1 type responses are important 
for many vaccines that we do not have [23], such as HIV/AIDS and tuberculosis vaccines, 




responses. The bias of TMC’s adjuvant effect toward a Th2 response is not restricted to the 
nasal administration route, as it is also observed after intradermal [24] and intramuscular 
administration of TMC-adjuvanted antigen (unpublished data). However, different types of 
immune responses have been reported after nasal vaccination [25-28], depending on the 
adjuvant used. As TPP does not act as an adjuvant but solely services as a crosslinking agent to 
promote TMC nanoparticle formation, we propose it should be possible to substitute TPP with 
a crosslinking agent that does have an adjuvant effect. Unmethylated CpG DNA is a Toll like 
receptor 9 ligand and described as a Th1 response-inducing adjuvant, also after nasal 
administration [23]. Furthermore, phosphate groups on CpG render it negatively charged, 
which could make CpG a possible crosslinking agent to prepare TMC nanoparticles.  
The aim of this paper was to study whether CpG can replace TPP as a crosslinker to 
prepare ovalbumin (OVA)-containing TMC nanoparticles and whether these new carrier 
systems are capable of redirecting the TMC-induced Th2 type response towards a more Th1 
type response, while maintaining strong systemic and local antibody responses. The 
TMC/CpG/OVA nanoparticles were compared to TMC/TPP/OVA nanoparticles with respect to 
their physicochemical characteristics and immunogenicity after nasal administration in mice. 
 
 
Material and Methods 
 
Materials 
Ovalbumin (OVA) was purchased from Calbiochem (Beeston, UK) and CpG DNA (ODN 
2006) as well as fluorescein isothiocyanate coupled CpG (CpG-FITC) from InvivoGen (Toulouse, 
France). N-trimethyl chitosan with a degree of quaternization of 15% was synthesized from 
92% deacetylated (MW 120 kDa) chitosan (Primex, Avaldsnes, Norway) and characterized by 
NMR, as described by Bal et al. [29]. KCl, NaCl, HNa2PO4, KH2PO4 and bovine serum albumin 
(BSA) were purchased from Merck (Amsterdam, The Netherlands). Pentasodium 
tripolyphosphate (TPP), 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES), Tween 
20 and 2-mercapto ethanol were obtained from Sigma-Aldrich (Steinheim, Germany). Goat 
anti-mouse IgG, IgG1, IgG2a and IgA conjugated with horseradish peroxidase was purchased 
from Southern Biotech (Birmingham, AL). BDOpteia IFN-γ ELISA kit was bought from Becton 
Dickinson (Breda, The Netherlands). RPMI 1640, fetal bovine serum (FBS), penicillin-
streptomycin (P/S) solution, L-glutamine, sodium pyruvate and fluorescein isothiocyanate 
coupled OVA (OVA-FITC) were acquired from Invitrogen (Breda, The Netherlands), and 70-µm 
cell strainers from VWR (Amsterdam, The Netherlands). 




OVA loaded TMC/TPP (TMC/TPP/OVA) nanoparticles were prepared as described before 
[18]. Briefly, 20 mg TMC and 1 mg OVA were dissolved in 8.3 ml 5 mM Hepes pH 7.4. Under 
continuous stirring 3.4 ml 0.1% w/v TPP was added to induce ionic complexation into 
nanoparticles. Particles were collected by centrifugation (10 min, 12000 g), resuspended and 
washed once with water. OVA loaded TMC/CpG (TMC/CpG/OVA) nanoparticles were prepared 
in the same way as TMC/TPP/OVA, replacing TPP by CpG. A total amount of 0.9 mg CpG was 
added to 20 mg TMC and 1 mg of OVA; the addition of more CpG caused aggregation and a 
dramatic increase of the polydispersity index (PDI), whereas the addition of less CpG reduced 
the number of particles formed (data not shown). Supernatants were stored for determining 
the loading efficiency and nanoparticles were stored at 4°C until further analysis. OVA-FITC 
loaded nanoparticles were prepared by substituting OVA-FITC for OVA. 
 
Size and zetapotential 
Particle suspensions were diluted in 5 mM Hepes pH 7.4 until a slightly opalescent 
dispersion was achieved. Hydrodynamic diameter (average and PDI) and zetapotential were 
determined with a Nanosizer (Malvern Instruments, Malvern, UK) by dynamic light scattering 
and laser Doppler electrophoresis, respectively.  
 
Loading efficiency 
To determine the loading efficiency, the OVA content of the nanoparticles as well 
supernatants, was determined using micro bicinchoninic acid (mBCA) protein assay (Pierce, 
Etten Leur, The Netherlands) according to the manufacturer’s instructions. To determine the 
encapsulation efficiency of CpG, FITC-labeled CpG was included and the amount of CpG-FITC 
was determined in the supernatant as well as in the particle formulation using fluorescence 
spectroscopy (FS920 fluorimeter, Edinburgh Instruments, UK; excitation 495 nm, emission 520 
nm; band widths 5 nm). 
 
Particle stability and antigen release in vitro  
TMC/TPP/OVA-FITC and TMC/CpG/OVA-FITC were diluted to a final particle concentration 
of 1 mg/ml in 10 mM phosphate buffered saline (PBS) pH 7.4 containing 0.01% Tween 20 and 
stored in several aliquots at 37°C. At different time points nanoparticle size was determined 
with DLS after which the dispersions were centrifuged (10 min 14000 g) and supernatants 
were collected allowing quantification of the released OVA-FITC with fluorescence 





Female Balb/c mice (Harlan, Boxmeer, The Netherlands), 6-8 weeks old, received 3 nasal 
doses of 20 µg OVA or an equivalent dose encapsulated OVA with intervals of 3 weeks. Mice 
receiving CpG were nasally administered 20 µg (3.1 nmol) of the adjuvant, either as a CpG 
solution with OVA or as a suspension of TMC/CpG/OVA nanoparticles. Three OVA injections of 
20 µg OVA were administered intramuscularly as control. For nasal administration, 
formulations were applied in a volume of 10 µl PBS, 5 µl per nostril. For i.m. administration, 25 
µl of formulation in PBS was injected in the thigh muscle. Blood samples were taken 2 weeks 
after the final booster dose. After sacrificing the animals, spleens were harvested and nasal 
washes collected. 
 
Determination of serum IgG, IgG1, IgG2a and secretory IgA 
Micro titer plates (Nunc, Roskilde, Denmark) were coated with OVA, by incubation of 1 
µg/ml OVA in 40 mM sodium carbonate buffer pH 9.4 for 24 hours at 4°C. To reduce aspecific 
binding, wells were blocked with 1% (w/v) BSA in PBS for 1 hour at 37°C. After extensive 
washing with PBS serial dilutions of serum ranging from 20 to 2*106 were applied, whereas 
nasal washes were added undiluted. After incubation for 1.5 hours at 37°C and extensive 
washing, OVA specific antibodies were detected using HRP conjugated goat anti mouse IgG, 
IgG1, IgG2a or IgA (1 hour 37°C) and by incubating with 0.1 mg/ml TMB and 30 µg/ml H2O2 in 
110 mM sodium acetate buffer pH 5.5 for 15 min at room temperature. Reaction was stopped 
with 2 M H2SO4 and absorbance was determined at 450 nm with an EL808 microplate reader 
(Bio-Tek Instruments, Bad Friedrichshall, Germany). 
 
T-cell activation study 
T-cell activation was studied using a protocol described by Christensen et al. [30]. Single 
cell suspensions were prepared, by grinding spleens over 70 µm cell strainers and rinsing with 
spleen medium (RPMI 1640 supplemented with 10% v/v FBS, 1% v/v glutamine, 1% v/v P/S 
and 0.05 mM 2-mercaptoethanol). Splenocytes were restimulated with 20 µg/ml OVA and 
maintained for 5 days at 37 °C and 5% CO2. IFN-γ levels in culture supernatant were 
determined using a BDOpteia IFN-γ ELISA according to the manufacturer’s instructions. 
 
Statistics 
Serum antibody titers were analyzed with a Kruskal-Wallis test with Dunn’s post-test. 
Antibody levels in nasal washes as well as splenocyte responses were analyzed with a one-way 
ANOVA with Bonferroni post-test. Statistics were performed using GraphPad 5.0 for Windows. 
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Results and discussion 
 
Nanoparticle characterization 
The characteristics of the TMC/CpG/OVA nanoparticles and the TMC/TPP/OVA 
nanoparticles were comparable in size and zetapotential (Table 1). Both particle types showed 
an average hydrodynamic diameter of ca. 300 nm, were fairly monodisperse (PDI 0.1-0.2) and 
had a positive zetapotential of about +20 mV. Moreover, changing the crosslinker did not alter 
the loading efficiency (Table 1) and the release pattern (data not shown), as both particle 
showed a burst release followed by no release over 48 hours. TMC/CpG/OVA did show a 
significantly higher burst under physiological conditions (p<0.001 Student’s t-test). This may 
be related to the higher amount and charge density of TPP compared to CpG, allowing a 
stronger interaction with TMC. Similar large burst releases (>50%) have been observed for 
even less densely negatively charged polymers like dextran sulfate and hyaluronic acid 
(Verheul et al. unpublished results).  
These results indicate that ionic crosslinking of TMC is just as easily achieved with other 
phosphate group-bearing entities as with TPP and TMC/CpG/OVA nanoparticles appear to be 
physically very similar to TMC/TPP/OVA nanoparticles.  
 
Nasal vaccination 
Nasal vaccination with subunit antigen is challenging as only a very limited amount of 
soluble antigen will be taken up by the nasal epithelium and subsequently be processed by 
DCs. This is reflected in the observation that nasal administration of a solution of plain OVA 
Values represent mean of 3 individually prepared batches ± standard deviation. Burst release 






resulted in negligible antibody titers, whereas intramuscular injection of the same dose of 
OVA induced high IgG titers after a booster dose (Figure 1). Coadministration of OVA with 
TMC, positively affected the IgG response (p<0.001 compared to OVA after prime as well as 
booster dose), as reported before for TMC mixed with other antigens [20, 21]. TMC can 
enhance the uptake of antigens through the nasal epithelium [31, 32] as it opens tight junction 
[33, 34] and can prolong the disposition of antigen in the nasal cavity [35]. The addition of CpG 
as an adjuvant resulted in enhanced antibody titers (p<0.05), but to a significantly lesser 
extent as TMC (p<0.001). Possible reasons for the weaker adjuvant effect of soluble CpG as 
compared to TMC are: CpG probably does not prolong the nasal residence time of the antigen, 
the adjuvant itself resides in the nasal cavity for only a short period of time and it may not be 
taken up by the nasal epithelium as efficiently as TMC.  
An even better approach than the application of solutions seems a particulate delivery 
system comprising the antigen and TMC, as both TMC/TPP/OVA and TMC/CpG/OVA 
vaccinated mice showed significantly enhanced IgG titers compared to OVA alone or a mixture 
of soluble TMC and OVA (p<0.05 after a priming dose). As the size of these nanoparticles 
would inhibit rather than induce intercellular transport through the tight junctions between 
nasal epithelial cells, nanoparticles promote the immunogenicity of the antigen in a different 
way. The mere particulate structure could favor uptake by M-cells [18, 36-38], allowing 
antigen access to the subepithelial space. There, multimerization of epitopes of the particle’s 
surface could contribute to an improved uptake by DCs and B-cells [39, 40]. 
Besides a systemic antibody response, both TMC nanoparticles also induced a potent 
mucosal immune response, indicating effective uptake of OVA by local B-cells. Nasal washes of 
both TMC/TPP/OVA and TMC/CpG/OVA vaccinated mice contained comparable elevated 
levels of sIgA (p<0.05) (Figure 2), whereas no significant sIgA elevation was detected in nasal 
washes after vaccination with plain OVA solution. Solutions of OVA with adjuvant (TMC or 
CpG) also showed an increase in sIgA levels but significantly lower than the sIgA levels induced 
by TMC/CpG/OVA (p<0.05). Although local antibodies are not often used as a correlate of 
protection, the interest in sIgA is increasing. sIgA is recognized as an important factor in 
mucosal homeostasis [41] and is capable of inducing M-cell transport of neutralized antigen 
[42], thereby delivering the antigen to local DCs [43]. Antigen specific sIgA at mucosal surfaces 
could therefore protect the host from future infection by directly neutralizing the pathogen, 
but also by acting as an early warning signal for the immune system. Furthermore, sIgA 
production after nasal vaccination is not restricted to the upper airways, as via a system called 
the common mucosal immune system [44], sIgA antibodies can be detected also in other 
mucosal secretions.  


























The major important difference between the effects of TMC/TPP/OVA nanoparticles and 
TMC/CpG/OVA nanoparticles appeared to be the type of response elicited (Figure 3). 
TMC/TPP/OVA caused a predominant IgG1 response (p<0.05), whereas TMC/CpG/OVA 
vaccinated mice showed a decreased IgG1/IgG2a ratio, indicating that the inclusion of CpG 
into TMC nanoparticle promoted a Th1 response. Similarly, coadministration of TMC led to an 
increased IgG1/IgG2a ratio indicating a shift towards Th2, whereas the addition of CpG to OVA 
decreased the IgG1/IgG2a ratio. The Th1-inducing effect of nasally administered CpG has been 
observed before [45, 46] and TMC/CpG/OVA nanoparticles seem to exert a similar effect. This 
was confirmed by the T-cell activation study, showing that splenocytes from TMC/CpG/OVA 
immunized mice produced large quantities of IFN-γ after restimulation with OVA (Figure 4), 
even more than mice immunized with a solution of OVA and CpG. Splenocytes from mice 
vaccinated with a solution of OVA and TMC or TMC/TPP/OVA did not produce more IFN-γ than 
Figure 2: OVA specific IgA levels in nasal 
washes of nasally immunized Balb/c mice. 
Bars represent mean n=8 ± SEM. *p<0.05 
compared to TMC/CpG/OVA, **p<0.01 
compared to OVA ***p<0.001 compared 
to OVA. 
Figure 1: OVA specific serum IgG titers in 
serum after a priming (black bars) and a 
booster dose (white bars). Mice received 3 
doses of 20 µg OVA nasally or 
intramuscularly (OVA im). The 2
nd
 boost did 
not further increase IgG levels and is not 
shown for reasons of clarity. All formulations 
except for OVA im after priming were 
significantly higher than OVA (p<0.01). Bars 





splenocytes from naïve mice. So, changing the crosslinker from TPP to CpG strongly shifted the 
T-cell polarization towards the Th1 direction. 
Overall, TMC/CpG particles seem to be capable of eliciting strong humoral responses, both 
local (sIgA) and systemic (IgG, IgG1, IgG2a), as well as a Th1 type response, making them a 
promising vaccine carrier for nasally applied OVA and, most likely, a wide variety of other 





















TMC/TPP/OVA nanoparticles have previously been shown to be very effective nasal 
vaccine carriers. Replacing TPP by CpG as a crosslinking agent to obtain TMC/CpG/OVA 
nanoparticles modulated the immune response towards a Th1 response after nasal 
vaccination, while maintaining the strong systemic and local antibody responses observed 
with TMC/TPP nanoparticles. TMC/CpG nanoparticles therefore are an interesting nasal 




Figure 3: Serum IgG1/IgG2a levels 
normalized for the average OVA 
IgG1/IgG2a ratio. * p<0.05 compared to 
OVA. ‡ p<0.05. 
Figure 4: IFN-γ production by splenocytes 
restimulated with OVA. Values represent 
mean n=5 ± SEM. * p<0.05  
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N-trimethyl chitosan (TMC) nanoparticles have been shown to increase the 
immunogenicity of subunit antigens after nasal and intradermal administration. This work 
describes a second generation of TMC nanoparticles containing ovalbumin as a model antigen 
(TMC/OVA nanoparticles) and an adjuvant (TMC/adjuvant/OVA nanoparticles). The selection 
of adjuvants included Toll-like receptor (TLR) ligands lipopolysaccharide (LPS), PAM3CSK4 
(PAM), CpG DNA, the NOD-like receptor 2 ligand muramyl dipeptide (MDP) and the GM1 
ganglioside receptor ligand, cholera toxin B (CTB) subunit. The TMC/adjuvant/OVA 
nanoparticles were characterised physico-chemically and their immunogenicity was assessed 
by determining the serum IgG, IgG1, IgG2a titres and secretory IgA levels in nasal washes after 
intradermal and nasal vaccination in mice. 
After nasal vaccination, TMC/OVA nanoparticles containing LPS or MDP elicited higher IgG, 
IgG1 and sIgA levels than non adjuvanted TMC/OVA particles, whereas nanoparticles 
containing CTB, PAM or CpG did not. All nasally applied formulations induced only marginal 
IgG2a titres. After intradermal vaccination, the TMC/CpG/OVA and TMC/LPS/OVA 
nanoparticles provoked higher IgG titres than plain TMC/OVA particles. Additionally, the 
TMC/CpG/OVA nanoparticles were able to induce significant IgG2a levels. None of the 
intradermally applied vaccines induced measurable sIgA levels. 
Altogether, our results show that co-encapsulation of an adjuvant with the antigen in TMC 
nanoparticles can significantly increase the immunogenicity of the antigen. However, the 


















Most human vaccines are administered via injection into muscle or subcutaneous tissue. 
Notwithstanding the success of this approach, during the last decades it has also become 
apparent that muscle and subcutaneous tissue may not be the most ideal sites to induce an 
immune response. The skin and the mucosal linings for instance contain more immune cells 
capable of initiating an immune response [1, 2], which is most likely a consequence of the fact 
that pathogens generally invade the human body via these tissues. Various examples have 
shown that intradermal vaccination is more effective than intramuscular administration as the 
same level of protection is reached by injection of a smaller dose [3-5]. Moreover, applying 
the vaccine via the route through which the pathogen would normally invade could induce a 
type of immune response that provides better protection [6]. Nasal vaccination often induces 
the production of secretory IgA (sIgA) antibodies that can neutralise pathogens colonising the 
mucosal linings [7], whereas intramuscular administration does not induce sIgA. 
Currently there are several vaccines on the market that use a different administration 
route (e.g., oral, intradermal and nasal) and they are well perceived by the vaccinee [8]. 
However, many of these vaccines are of live-attenuated nature, which makes them unsuitable 
for administration to young children, elderly or immune-compromised patients. Replacement 
of these vaccines by subunit vaccines would be a great improvement for safety reasons and 
would make them suitable for administration to these groups. However, such vaccines are 
difficult to develop as plain subunit antigens are poorly immunogenic. To enhance their 
immunogenicity, subunit antigens can be formulated into particulate vaccine delivery systems. 
This improves the uptake by antigen presenting cells (APCs) and when adjuvants are included 
it can also enhance the activation of these APCs [9]. Especially approaches that combine 
antigen and adjuvant into a particle have been shown to result in a strong immune response 
[10, 11]. We have recently shown that N-trimethyl chitosan (TMC) nanoparticles loaded with 
ovalbumin (OVA) as a model subunit antigen increased the immune response after nasal [12] 
as well intradermal administration [13]. Inclusion of an adjuvant may further improve the 
immunogenicity of TMC nanoparticles. 
The aim of the present study was to co-encapsulate various adjuvants in OVA-loaded TMC 
(TMC/OVA) nanoparticles and to evaluate if these additional danger signals can further 
enhance the efficacy of the TMC/OVA nanoparticles when administered nasally or 
intradermally in mice. We selected 5 potential adjuvants based on their physical chemical 
properties and their reported adjuvant effect after intradermal and nasal administration: 




[19, 20] and the non-toxic beta subunit of cholera toxin (CTB) [21, 22]. These adjuvants were 
co-complexed with OVA into TMC nanoparticles, rather than co-administered, as co-
localization of antigen and adjuvant into one entity has been reported to be very beneficial for 
the resulting immune response [10, 11, 23]. The size and zetapotential was studied, to ensure 
that all particles had a similar physical form. The adjuvanted nanoparticles were administered 
nasally and intradermally to mice to assess the extent of the immune response (OVA specific 




Materials and methods 
 
Materials 
TMC with a degree of quaternisation of 15% was synthesised from 92% deacetylated 
chitosan (MW 120 kDa, Primex, Siglufjordur, Iceland) as described previously [24]. Endotoxin 
free OVA grade VII was obtained from Merck (Darmstadt, Germany). Lipopolysaccharide (LPS) 
from E.Coli 0111:B4, Pam3Cys-Ser-(Lys)4 (PAM), and CpG oligonucleotide 1826 were obtained 
from Invivogen (Toulouse, France). Horseradish peroxidase (HRP) conjugated goat anti-mouse 
IgA, IgG (γ chain specific), IgG1 (γ1 chain specific) and IgG2a (γ2a chain specific) were 
purchased from Southern Biotech (Birmingham, USA). Invitrogen (Breda, The Netherlands) 
supplied chromogen 3, 3', 5, 5'-tetramethylbenzidine (TMB) and the substrate buffer and all 
cell culture reagents. Nimatek® (100 mg/ml Ketamine, Eurovet Animal Health B.V., Bladel, The 
Netherlands), Oculentum Simplex (TEVA, Haarlem, The Netherlands) and Rompun® (20 mg/ml 
Xylazine, Bayer B.V., Mijdrecht, The Netherlands) were obtained from a local pharmacy. 
Phosphate buffered saline (PBS) pH 7.4 was obtained from Braun (Oss, The Netherlands). 
Cholera toxin B subunit (CTB), muramyl dipeptide (MDP) and all other salts/chemicals were 
purchased at Sigma-Aldrich (Zwijndrecht, The Netherlands), unless stated otherwise.   
 
Animals 
Female BALB/c mice, 8 weeks old at the start of the vaccination study were purchased 
from Charles River (Maastricht, The Netherlands) and maintained under standardised 
conditions in the animal facility of the Leiden/Amsterdam Center for Drug Research, Leiden 
University. The study was carried out under the guidelines compiled by the Animal Ethic 
Committee of the Netherlands. 
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Plain TMC/OVA nanoparticles 
TMC/OVA nanoparticles were prepared as described before [25]. Briefly, 1 mg OVA was 
dissolved in 10 ml 0.1% (w/v) TMC in 5 mM Hepes pH 7.4. Under continuous stirring 1.7 ml 
0.1% (w/v) TPP was added to obtain an opalescent dispersion. Nanoparticles were collected by 
centrifugation (10 min, 12000 g) and resuspended in water. For size and zetapotential 
measurements using a Nanosizer ZS apparatus (Malvern Instruments, Malvern, UK), 
nanoparticles were diluted in 5 mM Hepes pH7.4 until slightly opalescent dispersions was 
obtained. Supernatants were stored to determine the loading efficiency with a BCA assay 
following the manufacturer’s guidelines (Pierce, Perbio Science, Etten-Leur, The Netherlands).  
 
Adjuvanted TMC/OVA nanoparticles 
Adjuvanted nanoparticles were prepared in the same way as non-adjuvanted TMC 
nanoparticles, as the adjuvant was co-dissolved with OVA in the TMC solution. TMC/CpG 
nanoparticles were the only exception, and were prepared by replacing TPP with strongly 
negatively charged CpG (serving as physical crosslinker and adjuvant), as described previously 
[16]. To remove unencapsulated OVA or adjuvant, nanoparticles were collected by 
centrifugation (10 min, 12000 g) and resuspended in water. To determine the loading 
efficiencies of the adjuvants fluorescently labelled analogues were used and the amount of 
adjuvant in the supernatant was determined by fluorescence spectroscopy (FS920 fluorimeter, 
Edinburgh Instruments, Campus Livingston, UK).  
Based on the pre-determined loading efficiencies of each adjuvant (table 2), the initial 
amount of adjuvant was chosen in such a way (table 1) that TMC nanoparticles carrying OVA 
and adjuvant in a 1:1 weight/weight ratio were prepared. This, to ensured that each 
formulation contained the same amount of TMC, OVA and adjuvant for the vaccination study.   
 
Immunisation study 
Groups of 8 mice (nasal) or 5 mice (intradermal) were vaccinated with the above 
mentioned formulations. Nasally the mice received 10 µg antigen and 10 µg adjuvant in a 
volume of 10 µl PBS (5 µl/nostril) and intradermally 2 µg of each in a volume of 30 µl PBS was 
applied. Intradermal immunisations were carried out under anaesthesia by intraperitoneal 
injection of 150 mg/kg ketamine and 10 mg/kg xylazine with a 30G needle as described before 
[26]. After 3 weeks blood samples were drawn from the tail vein and the mice received a 
similar booster vaccination. After 6 weeks total blood was collected from the femur artery and 




one, Alphen a/d Rijn, The Netherlands) till clot formation and centrifuged for 10 minutes at 
10,000 g to obtain cell-free sera. The sera were stored at −80°C until further use. 
 









TMC/OVA 10 1.8 1.0 - 
TMC/CTB/OVA 10 2.0 1.0 0.83 
TMC/LPS/OVA 10 2.0 1.0 1.7 
TMC/PAM/OVA 10 2.0 1.0 5.0 
TMC/MDP/OVA 10 2.0 1.0 1.3 
TMC/CpG/OVA 10 - 1.0 0.5 
 
 
Detection of serum IgG, IgG1, IgG2a and secretory IgA 
OVA specific antibodies (IgG, IgG1 & IgG2a) in the sera and sIgA in the nasal washes were 
determined by sandwich ELISA as described previously [27]. Briefly, plates were coated 
overnight with 100 ng OVA. After blocking, two-fold serial dilutions of sera from individual 
mice were applied to the plates. HRP-conjugated antibodies against IgG, IgG1, IgG2a or IgA 
were added and detected by TMB. Absorbance was determined at 450 nm with an EL808 
micro plate reader (Bio-Tek Instruments, Bad Friedrichshall, Germany). Antibody titres were 
expressed as the reciprocal of the sample dilution that corresponds to half of the maximum 
absorbance at 450 nm of a complete s-shaped absorbance-log dilution curve.  
 
Statistics 
Statistical analysis was performed with Prism 5 for Windows (Graphpad, San Diego, USA). 
Statistical significance was determined either by a one way or a two way analysis of variance 








Characterisation of the nanoparticles 
Inclusion of adjuvants into TMC nanoparticles did not alter the physical nature of the 
particles substantially. All adjuvanted particle showed a similar average diameter (between 
300-400 nm) and all were modestly positively charged (+13-21 mV). The capacity to 
encapsulate OVA was only marginally affected by the inclusion of any of the adjuvants (table 
2). The loading efficiency of the adjuvant however, greatly differed depending on the 
characteristics of the adjuvant. The strongly negatively charged species CpG and CTB easily 
complexed with the nanoparticles, whereas the positively charged adjuvant PAM hardly 
associated with the positively charged TMC nanoparticles. The loading efficiency of the 
amphiphilic adjuvants LPS (weakly negatively charged) and MDP (neutral) was 35% and 42%, 
respectively. So, LPS and MDP were more efficiently encapsulated than the positively charged 












TMC/OVA 314 +/- 31 0.12 18.2 +/- 1.8 63 +/-6 - 
TMC/CTB/OVA 323 +/- 39 0.29 14.7 +/- 2.4 56 +/- 4 68-74 
TMC/LPS/OVA 365 +/- 46 0.33 13.3 +/- 2.9 52 +/- 
0.1 
32-37 
TMC/PAM/OVA 375 +/- 99 0.11 15.5 +/- 0.2 59 +/- 7 8.1-9.4 
TMC/MDP/OVA 418 +/- 89 0.15 13.6 +/- 1.7 60 +/- 1 41-43 
TMC/CpG/OVA 304 +/- 22 0.20 20.9 +/- 2.0 52 +/- 7 52-62 










Total serum IgG response after nasal and intradermal vaccination 
The differently adjuvanted TMC/OVA formulations were administered intradermally and 
nasally to study their adjuvanticity and the site-dependency thereof. After nasal and 
intradermal vaccination TMC/OVA nanoparticles increased the IgG titres compared to OVA 
alone (figure 1A, B). In some cases the inclusion of an adjuvant into the TMC/OVA particle 
increased the immunogenicity even further. 
Nasally, the LPS- and MDP-loaded TMC/OVA nanoparticles elicited higher IgG titres 
compared to TMC/OVA nanoparticles (p<0.05 figure 1A). Encapsulation of CTB, PAM or CpG 
into TMC/OVA nanoparticles did not affect the total serum IgG response compared to 
TMC/OVA nanoparticles. 
After intradermal injection, TMC/LPS/OVA nanoparticles elicited higher IgG levels than 
plain TMC/OVA nanoparticles after both a priming (p<0.05) and a booster dose (p<0.01). In 
contrast to nasal administration, after a priming dose intradermal administration of 
TMC/CpG/OVA nanoparticles significantly increased IgG titres compared to plain TMC/OVA 
nanoparticles (p<0.05 figure 1B) and co-encapsulation of MDP had no effect. Encapsulation of 
CTB and PAM into TMC/OVA nanoparticles did not lead to elevated IgG titres compared to 
non-adjuvanted TMC/OVA nanoparticles.  
 
IgG subtyping of the immune response   
Besides the IgG titres, the IgG1 and IgG2a antibody titres were measured to obtain insight 
into the type of immune response elicited by the different formulations. Compared to 
vaccination with OVA alone for both administration routes the main subtype produced after 
vaccination with TMC/OVA was IgG1, which followed a similar trend as the total IgG titres 
after the boost.  
Nasally administered LPS- or MDP loaded TMC/OVA nanoparticles elicited higher IgG1 
titres than plain TMC/OVA particles (figure 2A), whereas the other adjuvants did not show 
significant effects on the IgG1 response. None of the formulation induced substantial IgG2a 
levels. After intradermal immunisation, TMC/OVA nanoparticles induced the production of 
significantly more IgG1 compared to a solution of OVA, but no additional effect of the 
encapsulation of adjuvants was observed. However, TMC nanoparticles containing CpG 
significantly boosted the IgG2a production (p<0.001), causing a decrease in the IgG1/IgG2a 
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Production of sIgA 
Secretory IgA is an important mediator of mucosal immunity and can therefore provide 
protection against respiratory pathogens. Intradermal administration did not induce 
detectable sIgA levels in the nasal washes (data not shown). In contrast, nasal vaccination with 
TMC/OVA nanoparticles containing LPS, MDP or CpG did result in increased levels of sIgA in 
some mice (figure 3). The nasal application of plain TMC nanoparticles or nanoparticles 
adjuvanted with CTB or PAM did not trigger sIgA production.  
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Figure 2.OVA specific serum IgG1 (white bars) and IgG2a (black bars) titres 3 weeks after a 
booster dose nasally (A) and intradermally (B). Data are presented as mean ± SEM, ** 
p<0.01 ***p<0.001.  
 
Figure 3: Secretory IgA levels 
in nasal washes of individual 
mice 3 weeks after a nasal 
booster dose. Bar represents 
mean. 
 




The field of adjuvants is rapidly evolving. Whereas alum had been the only approved 
adjuvant for many years, recently squalene emulsions (MF-59) and monophosphoryl lipid A (a 
LPS derivate) have been licensed for use in Europe. Increased knowledge on the activation of 
the innate immune system has led to the identification of new adjuvants that activate APCs 
specifically via Toll-like receptors (TLRs) [28] or NOD-like receptors (NLRs). Moreover, 
detoxification of known adjuvants (MPL instead of LPS; CTB instead of cholera toxin) and the 
development of new adjuvants exploiting the increased knowledge on activation of the innate 
immune system (CpG, PAM3CSK4, MDP), will probably increase the arsenal of adjuvants for 
commercial human vaccines in the future. This progress is crucial for the development of 
subunit vaccines as the addition of an adjuvant seems inevitable in order to yield a strong 
immune response. The large number of DCs in the dermis and nasal epithelium potentially 
makes application of adjuvanted vaccines at these sites very attractive, as it can directly result 
in activation of DCs. Nonetheless, a delivery system to enhance the uptake of both the antigen 
and the adjuvant will be an important utensil, as generally physical mixtures of adjuvant and 
antigen are inferior to systems where both components are co-localised. TMC nanoparticles 
are excellent antigen carriers as they associate with DCs and, because of their intrinsic 
adjuvanticity, activate DCs [25, 26]. As a consequence, in direct comparison with other vaccine 
delivery systems TMC nanoparticle have shown to be a more effective carrier for mucosal or 
dermal administration than PLGA nanoparticles [12], positively charged liposomes 
(unpublished data) and chitosan nanoparticles [25]. The beneficial effect of TMC nanoparticles 
as a carrier system was clearly observed in this study. Even though the OVA dose chosen was 
twofold lower than in the previous studies [12, 16, 26] (to better detect the effect of the 
encapsulated adjuvant), OVA-loaded TMC nanoparticles enhanced the IgG1 titres compared to 
nasal or intradermal administration of OVA alone. 
Co-encapsulation of adjuvants have been reported to further increased the 
immunogenicity of the carrier system [10, 11, 23], however the activity of the adjuvants 
appeared to be administration site specific. Nasally, co-encapsulation of LPS and MDP in 
TMC/OVA nanoparticles elicited higher IgG titres than TMC/OVA nanoparticles, whereas 
intradermally LPS and CpG were the most effective adjuvants. It has been reported that the 
expression of TLRs and NLRs on DCs is dependent on the micro-environment of the DC and the 
DC subset [29-32], which may explain the differential effects of adjuvants when comparing the 
nasal and intradermal route. For instance, the effect of the NOD2 ligand MDP could be 




deficient mice are more susceptible to Listeria monocytogenes and Bacillus anthracis, two 
bacteria that cause infection via a mucosal site [35, 36]. Moreover, Bogefors et al. recently 
reported that different NLRs, including NOD2, are present in the nose [31]. This implicates an 
important role for the NOD2 receptor in mucosal immunity, which concurs with the positive 
effect found for MDP after nasal administration. Regarding intradermal vaccination, the 
receptors for LPS (TLR4) and CpG (TLR9), the two adjuvants that showed a strong effect after 
intradermal administration, are readily expressed on murine keratinocytes, Langerhans cells 
and DCs [30, 37]. Previous murine vaccination studies via the skin have shown the 
adjuvanticity of CpG [38, 39], which induced migration of Langerhans cells and DCs from the 
skin to the lymph nodes [40, 41]. 
In a previous nasal vaccination study the TMC/CpG/OVA nanoparticles were equally potent 
as non-adjuvanted TMC nanoparticles and particularly stimulated the IgG2a response [16]. 
However, since the applied dose in the present study was two times lower, this effect may 
have been masked. These results together with the elevated sIgA levels for 3 out of 8 mice 
indicate that whereas CpG can function as an adjuvant for nasal vaccination, the adjuvant 
dose may be crucial. 
For both the intradermal and nasal route, CTB was unable to further promote the antibody 
titres compared to non-adjuvanted TMC/OVA nanoparticles. We have shown before that CT is 
able to boost the immune response after intradermal administration [13] and for both 
vaccination via the skin and nose CT is a well known adjuvant [42]. However, the toxicity of CT 
is a concern for nasal and intradermal administration. Especially after a nasal vaccine 
containing heat-labile enterotoxin (LT, a potent mucosal adjuvant with ADP-ribosylating 
activity like CT) was withdrawn from the market [43], CT is not considered a promising 
adjuvant for human nasal use anymore. CTB is a less toxic CT analogue [44] and successful 
nasal administration of CTB as an adjuvant has been reported [20, 22, 45, 46]. However, in a 
few case it has also been linked to the induction of tolerance [47-49], the opposite of what is 
desired in the current vaccination study. Anjuère et al. compared the ability of CT and CTB to 
provoke an immune response after transcutaneous immunisation [50]. They reported CTB to 
be poorly efficient in inducing anti-OVA IgG levels, whereas CT provoked a strong humoral 
immune response. This shows that the adjuvant effect of CTB depends on the antigen, the 
formulation and the administration route. 
Besides the extent of the immune response, also the type of immune response is an 
important parameter to consider, when selecting an adjuvant. TMC nanoparticles appear to 
be a Th2-biasing carrier system, as described before [13, 16, 51], regardless of the 
administration route. Encapsulation of most of the adjuvants did not significantly change the 
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Th1/Th2 ratio. LPS and PAM have been reported to augment the Th1 response after 
intramuscular and intraperitoneal administration [52, 53], but do not appear to elicit this 
effect after nasal or intradermal immunisation when co-encapsulated with the antigen in TMC 
nanoparticles. Only intradermal administration of TMC/CpG/OVA nanoparticles was able to 
counter the Th2 bias and increase the IgG2a levels (indicative of a Th1 response). Nasally, this 
effect of CpG was not observed, whereas an earlier study using a CpG dose that was twice as 
high, reported a clear Th1 biasing effect of TMC/CpG/OVA nanoparticles [16], also indicating 
an important role for the adjuvant dose. Overall, the effect of an adjuvant seems to be greatly 
dependent the dose, the type of antigen, the way it is formulated and –last but not least– the 
site of administration. 
 
Conclusion  
Inclusion of an adjuvant into antigen loaded TMC nanoparticles for nasal and intradermal 
vaccine delivery can be good strategy to improve the immunogenicity of the antigen. The 
success of this approach strongly depends on the selection of the adjuvant in conjunction with 
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Nasal vaccination is a promising alternative to classical vaccination via needle injections. 
The nasal epithelium is equipped with a large number of immune cells, capable of both 
initiating and providing a protective immune response. Moreover, the nasal cavity is very 
accessible, allowing simple administration (nasal spray or nose drops), and the proteolytic 
environment is relatively low (compared to oral) providing a less hostile environment for the 
administered vaccines. The licensing of the first nasal vaccine (Flumist®) has shown the 
possibilities nasal vaccination provides. However, the inability so far to develop an effective 
subunit vaccine that would, unlike Flumist®, also be suitable for young children and elderly has 
also shown the challenge this administration route comprises (Chapter 1).  
Vaccine formulation could be the key to successful nasal immunization as one can equip 
the antigen with the necessary tools to meet the challenges the nasal cavity offers. In order to 
rationally design nasal vaccine formulations, we will need to know the challenges the antigen 
will meet. Therefore this thesis has set out 3 aims:  
 
1. To identify the major physiological hurdles subunit antigens have to overcome to 
elicit an immune response after nasal administration. 
2. To develop methods in vivo or in vitro that allow these hurdles to be studied. 
3. To use the obtained knowledge to rationally design nasal vaccine formulations. 
 
The first aim is addressed in Chapter 2 where the nasal physiology is reviewed and a road 
map to successful nasal vaccination is presented.  
First of all, the nasal cavity has primarily evolved to keep substances out. A mucus layer 
covering the entire epithelium is replaced every 20 min, thereby removing all its constituents 
and thereby greatly limiting the time for the antigen to be taken up by epithelium. 
Formulation of the antigen with muco-adhesive substances like sodium alginate, carbopol, 
chitosan and N-trimethyl chitosan (TMC) can prolong the nasal residence time of antigen. A 
second hurdle identified is the passage through the nasal epithelium. Epithelial cells are 
closely stacked together by tight junctions, which leave little space for intercellular transport 
of large proteins. The inclusion of a tight junction opener like chitosan in a vaccine formulation 
can temporarily increase the permeability of the epithelium. The presence of M-cells in the 
epithelium offers the possibility of transcellular transport. As M-cells preferably transport 
particulate matter, the use of micro- or nanoparticle is advocated. Finally, when the antigen 




the proper response. Besides the use of particulate systems, the use DC targeting ligands can 
facilitate endocytosis by DCs. In order to be able to activate T-cells, DCs will have to mature. 
This can be promoted by the addition of an adjuvant in the formulation. The choice of 
adjuvant can greatly influence the extent and type of immune response elicited.  
The optimal nasal formulation will therefore be multifactorial and can be furnished with 
distinct functionalities such as mucoadhesive polymers, M-cell or DC targeting ligands and 
adjuvants. The opportunities in nasal vaccination ask for a concerted approach combining 
various targeting techniques is advocated. 
 
Methods to investigate the nasal residence time of the antigen, transport by M-cells, the 
uptake by DCs and the maturation of DCs are discussed in Chapters 3 and 4. 
An in vitro model for M-cells, based on intestinal epithelial cells co-cultured with a B-cell 
line, was assessed for its predictive value in the studies described in Chapter 3. Transport by 
M-cells of ovalbumin (OVA) loaded into TMC nanoparticles was higher than that of 
unencapsulated OVA or OVA loaded into chitosan nanoparticles. This was confirmed by ex vivo 
confocal fluorescent microscopic inspection of murine jejunum, showing that the M-cell 
model has predictive value. Moreover, an in vitro model for studying antigen uptake by DCs 
was introduced. Monocytes isolated from human volunteers were cultured into immature 
DCs, with which uptake of OVA in nanoparticles could be studied. TMC nanoparticles 
improved the association of OVA with DCs and induced activation of DCs. This correlated with 
the immunogenicity of OVA-loaded TMC nanoparticles after intraduodenal administration, 
which was significantly better than that of chitosan particles or a solution of OVA.  
In Chapter 4 a novel method of determining the nasal residence time of antigen using live 
imaging techniques is introduced. Three different types of nasal vaccine carriers PLGA, 
PLGA/TMC and TMC nanoparticles were investigated for their ability to decrease the clearance 
of OVA from the nasal cavity. Only TMC nanoparticles significantly prolonged the nasal 
residence time. Mice were nasally vaccinated with TMC nanoparticles and compared to the 2 
other classes of nanoparticles, which did not prolong the nasal residence time. Interestingly, 
only the TMC nanoparticles elicited high anti-OVA antibody responses, whereas after 
intramuscular administration all classes of particles enhanced the immune response.  
In contrast, nasal administration of OVA loaded PLGA nanoparticles appeared to result in 
tolerance rather than immunity (Chapter 5), as PLGA vaccinated mice showed a reduction in 
delayed type hypersensitivity against OVA. Vaccination with PLGA nanoparticles promoted the 
upregulation of the tolerogenic transcription factor FoxP3 in CD4+ T-cell and did not increase 
the number OVA specific B-cells, which is necessary for an antibody response. Nasal 
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immunization with OVA loaded TMC nanoparticles resulted in the opposite result, i.e. a large 
number of OVA specific B-cells was detected in the cervical lymph nodes and spleen. 
From the results presented in Chapters 4 and 5 it can be concluded that not only the 
ability to prolong the nasal residence time but also other characteristics of nanoparticles 
greatly influence (the quality of) the immune response elicited after nasal vaccination. Next to 
their mucoadhesiveness, TMC nanoparticles have other characteristics that make them a 
more suitable carrier system for nasal vaccination compared to PLGA or PLGA/TMC 
nanoparticles. Also the rapid release of the contained antigen (promotes uptake by B-cells) 
and immune stimulatory capacity (counteracting tolerance) are designated as the key 
characteristics that make TMC nanoparticles potentially successful nasal carrier systems when 
protective immunity is aimed for.  
In Chapter 6 studies are described in which the formulation of OVA with a delivery system 
and an adjuvant was investigated. A promising nasal delivery system, cationic liposomes, was 
used to investigate whether the antigen and adjuvant should be combined in one carrier. Mice 
were nasally immunized with solutions of OVA and the adjuvant CpG, or with OVA and CpG 
encapsulated in liposomes. The resulting immune response was measured by determination 
of anti-OVA antibodies in serum and compared to immunization via other administration 
routes (transcutaneous with microneedle pre-treatment, intradermal and intranodal). 
Encapsulation of the CpG and OVA in liposomes had a detrimental effect on the IgG titers after 
nasal (and transcutaenous) administration compared to co-administration of soluble OVA and 
CpG, whereas after intradermal or intranodal injection of OVA/CpG-liposomes the immune 
response was improved compared to soluble OVA and CpG. To gain more insight into the 
mechanism behind the differences between the responses elicited, the uptake of OVA and 
CpG by DCs in the draining lymph nodes was investigated after administration of the 
formulation via the different administration routes. This showed that encapsulation of OVA 
and CpG in liposomes reduced the amount of antigen and adjuvant reaching the DCs after 
nasal and transcutaneous administration, whereas after intranodal injection encapsulation 
had a positive effect on the number of OVA and CpG positive DCs. 
These data imply that co-encapsulation of the antigen and adjuvant into a cationic 
liposome can have a beneficial effect on the antibody response against OVA after parenteral 
injection. However, the concomitant size increment impairs proper transport of antigen and 
adjuvant to the lymph node when administered via the nasal or the  transcutaneous route.  
 
Whereas Chapters 3-5 describe TMC nanoparticles as a very promising nasal delivery 




penetrating the nasal epithelium, because of their relatively large size. This would imply that a 
smaller entity that still has the same characteristics as TMC nanoparticles would be an even 
better choice for nasal delivery. In Chapter 7 studies are presented in which such a possibility 
was investigated, as it introduces the conjugation of an antigen, OVA, to TMC as an alternative 
to nanoparticles for subunit vaccination. The size of these constructs was significantly smaller 
than that of TMC nanoparticles (30 nm vs. 300 nm). OVA was covalently linked to TMC using 
thiol chemistry (SPDP method [1]). It was found that with the SPDP method a reducible 
covalent bond between TMC and OVA could be introduced, without disrupting the protein’s 
antigenicity and structure. Moreover, TMC-OVA conjugates were shown to be very 
comparable to TMC nanoparticles regarding their co-localization of OVA and TMC and their 
interaction with DCs. Uptake of TMC-OVA conjugate by DCs was similar to the uptake of 
TMC/OVA nanoparticles, i.e. over 5-fold increase compared to a solution of OVA and TMC. 
Mice intramuscularly immunized with TMC-OVA conjugate produced about 1000-fold higher 
OVA specific IgG titers than mice immunized with OVA and about 100-fold higher than mice 
receiving a physical mixture of TMC and OVA. These antibody titers were even slightly 
elevated compared to the titers obtained with TMC/OVA nanoparticles.  
Just like TMC/TPP/OVA nanoparticles, TMC-OVA nanoconjugate prolonged the nasal 
residence time of the antigen (Chapter 8). The immunogenicity of TMC-OVA nanoconjugate 
was assessed after nasal vaccination and compared with that of TMC/TPP/OVA nanoparticles, 
solutions of OVA and a physical mixture of TMC and OVA. Mice nasally immunized with TMC-
OVA conjugate produced high levels of secretory IgA in nasal washes and higher titers of OVA-
specific IgG than mice immunized with any of the other formulations. The improved 
performance of TMC-OVA conjugates might be attributed to better penetration of the nasal 
epithelium. In vitro the conjugates diffused significantly better through a monolayer of lung 
carcinoma (Calu-3) cells than TMC/TPP/OVA nanoparticles did. Moreover, nasal immunization 
of mice with the conjugate resulted in significantly more OVA positive DCs in the cervical 
lymph nodes as compared to TMC/TPP/OVA nanoparticles. In conclusion, the TMC-antigen 
nanoconjugate improves nasal delivery and immunogenicity of the antigen. This suggests that 
efficient co-delivery of antigen and adjuvant to DCs, rather than a particulate form of the 
antigen/adjuvant combination, is decisive for the immunogenicity of the antigen.   
 
A second way to improve TMC nanoparticles as nasal delivery system is to combine it with 
an adjuvant, which is investigated in the studies described in Chapter 9 and 10. In previous 
chapters it has been shown that TMC/TPP nanoparticles effectively induce antibody 
responses. However, in some cases a strong cellular response is highly desirable, e.g. for 
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vaccination against intracellular bacteria (e.g. M. tuberculosis) or viruses (e.g. HIV, Influenza 
A). Therefore in Chapter 9 the composition of TMC nanoparticles has been altered. Whereas 
TMC was physically crosslinked with the strongly negatively charged molecule 
tripolyphosphate (TPP) in earlier chapters, here TMC was crosslinked with CpG DNA, an 
adjuvant known to provoke a cell mediated immune response. TMC/CpG/OVA nanoparticles 
showed similar physicochemical characteristics as TMC/TPP/OVA nanoparticles in terms of 
particle size (ca. 380 nm), zeta potential (+21 mV) and antigen release characteristics. Nasal 
administration of TMC/CpG/OVA and TMC/TPP/OVA nanoparticles to mice resulted in 
comparable serum IgG levels (ca. 1000 fold higher than those induced by unadjuvanted OVA) 
and local secretory IgA levels. Moreover, TMC/CpG/OVA nanoparticles induced a 10 fold 
higher IgG2a response than TMC/TPP/OVA nanoparticles and increased the number of OVA 
specific IFN-gamma-producing T-cells in the spleen. This shows that nasally administered OVA 
loaded TMC nanoparticles, containing CpG as adjuvant and crosslinker, are capable of 
provoking strong humoral and mucosal responses as well as Th1 type cellular immune 
responses and are therefore an all-round vaccine delivery system. 
Finally in Chapter 10, next to CpG various other adjuvants are described for inclusion in 
TMC nanoparticles. Toll like Receptor (TLR) ligands (including lipopolysaccharide (LPS), 
PAM3CSK4 and CpG DNA), a NOD-like receptor-2 ligand (muramyl dipeptide (MDP)) and a GM1 
ganglioside receptor ligand (cholera toxin B subunit) were encapsulated with OVA in TMC 
nanoparticles by ionic crosslinking with TPP. Physical characteristics like the nanoparticles’ 
size, zeta potential and loading efficiency were determined to ensure that  these parameters 
were similar between all particles. The effectiveness of the adjuvant loaded OVA-containing 
TMC particles was assessed in vivo by nasal vaccination of Balb/c mice using intradermal 
vaccination as a control. LPS loaded nanoparticles elicited the strongest IgG titers after nasal 
as well as intradermal vaccination. Moreover, LPS loaded nanoparticles induced higher sIgA 
levels than unadjuvanted TMC nanoparticles. Distinct differences between administration 
routes were observed: IgG titers after nasal immunization with MDP loaded particles were 
increased; nanoparticles with CpG showed decreased IgG levels compared to plain TMC 
particles; CpG loaded TMC particles after intradermal administration induced higher IgG and 
IgG2a titers; and MDP did not have an addition effect at all. This study shows that the 
inclusion of an adjuvant in OVA loaded TMC nanoparticles can significantly enhance the 
immune response. The selection of the adjuvant is not arbitrary and depends on the route of 







This thesis has set out to identify the limiting steps in nasal vaccination, study those 
limitations and find possible solutions to tackle the hurdles associated with these issues. In the 
next paragraphs several important aspects of nasal vaccine design are discussed and 
recommendations for future development are provided. 
 
The antigen determines the formulation  
The core of each vaccine formulation is the antigen. It is therefore not surprising that the 
rational design of a nasal vaccine should be based on the physicochemical and 
biological/immunological characteristics of the antigen, as well as the source (e.g. bacterium, 
tumor cell) from which it is derived. The model antigen in this thesis (OVA) is a water soluble 
negatively charged protein, with little mucoadhesive and immune stimulating properties. For 
instance, TMC nanoparticles were shown to be excellent nasal carriers for this antigen as the 
mucoadhesive and immunostimulatory characteristics of TMC compensated for the poor 
characteristics of OVA in this respect. Moreover, OVA easily complexes with the positively 
charged TMC polymers into nanoparticles, leading to a high encapsulation efficiency and, as 
shown in Chapter 10, adjuvants can be co-encapsulated to further increase and/or modulate 
the immune response. Notwithstanding these favorable characteristics of TMC as a nasal 
adjuvant for OVA, TMC may not be the ideal adjuvant for every antigen. Positively charged 
antigens are difficult to associate with TMC nanoparticles, leading to a lower encapsulation 
efficiency (unpublished results) and thus loss of costly antigen. Similarly, antigens with large 
lipophilic domains, such as hepatitis B surface antigen or hemagglutinin and neuraminidase, 
may profit more from formulation in liposomes as these membrane proteins can be 
incorporated in the liposomal bilayer, thereby mimicking more closely the natural way these 
antigens are presented to the immune system. 
In some cases the antigen itself already has mucoadhesive or immune stimulating 
properties. For instance, Hagenaars et al. [2] used whole inactivated influenza virus (WIV) and 
showed that co-administration with TMC did not prolong the nasal residence time of the 
antigen, as the plain antigen already resided in the nasal cavity for more than 4 hours. 
Although formulation of WIV with TMC did improve the immune response, one could argue 
that focusing on immune potentiation rather than mucoadhesion may be a better approach to 
improve the immune response to this antigen. 
Finally, each vaccine should elicit a tailored immune response that is strongly dependent 
on the pathogen (or disease) to be combated. To repel pathogens that reside in the bodies’ 
interstitial spaces, antibodies can be instrumental, making a humoral response desirable. 
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When intracellular bacteria or viruses are concerned, the help of cytotoxic T-lymphocytes 
(CTLs) and other leukocytes involved in the cellular immune response is required. A mucosal 
(sIgA mediated) response can prohibit pathogens that invade our bodies via mucosal surfaces 
from colonizing these epithelia and may therefore be very useful for the protective efficacy of 
a vaccine as well. This should be kept in mind when formulating an antigen for nasal 
administration. As can be concluded from this thesis, TMC increases sIgA production and 
causes a Th2 type response after nasal administration and may therefore be a good choice if a 
humoral immune response against respiratory or intestinal pathogens is required. This would 
make TMC based formulations potentially useful for future nasal vaccination against for 
instance diphtheria, influenza and polio. 
TMC is however not likely to be the “weapon of choice” if a cellular response is required, 
for instance against herpes, HIV, malaria or RSV infection. The use of a different antigen 
delivery system that is more capable of eliciting cellular response, like ISCOMs or the addition 
of an adjuvant that can enhance the T-cell mediated immunity should be considered.  
 
Nasal residence time, a critical parameter 
Nasally applying an antigen that is cleared from the nasal cavity within minutes seems a 
waste of vaccine if the antigen does not get a chance to be absorbed into the nasal 
epithelium. The pivotal role of a prolonged residence in the nasal cavity is supported by 
various studies that have shown increased antibody response after nasal administration of 
antigen with mucoadhesive substances. A recent study by Nochi et al. [3] even shows that 
when the antigen is present up to days after administration (using a mucoadhesive nanogel), 
no additional adjuvant is needed to boost the immune response, emphasizing the potential of 
a long nasal residence time. In this thesis the importance of delaying nasal clearance is 
underlined (Chapter 4). Moreover, it is not hard to accomplish, as simple co-administration of 
TMC already caused a significant increase in the nasal residence time of OVA (Chapter 8). 
Similarly, studies in which mucoadhesives like chitosan or carbopol were co-administered with 
the antigen describe a similar mode of action [4, 5]. Therefore, the inclusion of a 
mucoadhesive polymer in a vaccine formulation seems one of the simplest ways to improve 
the efficacy of a nasal vaccine. 
 
Small is beautiful 
Particulate antigens have been associated with higher immune responses as compared to 
soluble antigens [6]. Particles offer the distinct advantage of being efficiently phagocytosed by 




antigen specific uptake by B-cells. Indeed, particles can have a positive effect on the immune 
response after vaccination. However, careful consideration to the particle characteristics is 
recommended. As can be concluded from Chapter 6 the size of the particle is an important 
point to consider. Nanoparticles are generally more effective than microparticles, but small 
nanoparticles (100 nm) were not more effective than 500 nm particles. As the particles in this 
size range all greatly exceed the maximum diameter of a tight junction in the nasal epithelial, 
we can assume their transport to the subepithelium to be mainly dependent on active 
transport by M-cells. Therefore equipping particles with an M-cell targeting ligand or selection 
of particles that naturally have a strong affinity for M-cells is more likely to improve M-cell 
transport than further reduction in particle diameter. Alternatively, a drastic size reduction 
might improve the passive, intercellular uptake by the nasal epithelium. In Chapter 8 it is 
shown that TMC-OVA conjugates (size ca. 30 nm) cross the nasal epithelium more effectively 
than TMC/OVA nanoparticles and consequently induce a higher immune response. In 
conclusion, nasal vaccination could benefit from particulate formulations, however with 
respect to passing the epithelial barrier a diameter as small as possible is preferred to 
facilitate passive . 
 
Adjuvants 
The arsenal of adjuvants at our disposal is steadily growing. Whereas for more than a 
century alum was the only approved adjuvant for human use, recently new adjuvants like 
squalene emulsions (e.g., MF-59) and non toxic variants of LPS (e.g., MPL) were licensed for 
the European market. Increasing knowledge on the activation of the immune system 
(specifically the activation of APCs) has speeded up this process, as it has explained the mode 
action of several adjuvants from which the mechanism was unknown until recently (e.g., alum, 
MDP and LPS), which is a perquisite for approval by the American Food and Drug 
Administration. Moreover, the observation that APC maturation can be triggered via specific 
pathogen recognition receptors (PRRs, e.g. Toll-like receptors and NOD-like receptors) has led 
to the identification of new ligands that could act as adjuvants. As the signaling cascade 
resulting from activation of PRRs is becoming more clear, in the near future it may be possible 
to select the proper adjuvant according to the nature of the vaccine and the type of immune 
response required .  
As has been pointed out in Chapter 10, the use of adjuvants can be very beneficial for 
nasal vaccination, but not every adjuvant is a good nasal adjuvant. Whether or not an adjuvant 
is a good choice for nasal use, will depend on the type of response required (e.g. antibodies or 
cytotoxic T-lymphocytes) and on the dose of adjuvant required. In concurrence with the 
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“danger model” adjuvants are supposed to be dangerous goods and consequently there is 
only a small margin between immune potentiation and toxicity. Therefore not all adjuvants 
are suitable because their effective dose is a toxic one. For instance, heat labile enterotoxin 
(LT) was successfully used as an adjuvant with virosomes, but after nasal administration LT 
was presumably taken up by olfactory neurons, eventually leading to Bell’s palsy [7]. Whether 
an adjuvant will have a strong positive effect on the immune response raised by a nasal 
vaccine likely depends on how easily the adjuvant is absorbed into the nasal epithelium and 
on the expression of its complementary receptor on nasal DCs. For instance, in Chapter 9, CpG 
was a more effective as an adjuvant when formulated in the TMC nanoparticles as a delivery 
system. Interestingly, mice that received 2x 20 µg CpG in TMC nanoparticles elicited strong IgG 
and sIgA titers, whereas mice that received 2x 10 µg CpG (Chapter 10) in the same particle 
formulation did not develop an antibody response. This suggests that activation of the 
receptor for CpG (TLR-9) on DCs in the nose may not be that easy to establish. In this respect 
TLR-4 ligand (MPL) or MDP (a NOD-like receptor 2 ligand) in combination with TMC particles 
may be better candidates for nasal vaccination. Literature on PPR expression on nasal DCs is 
scarce, making it very difficult to select the right adjuvant a priori. However, the high dose of 
CpG was well tolerated by the mice, making CpG still a promising candidate adjuvant for nasal 
vaccination. Nonetheless, increasing knowledge on the expression pattern of PRR on nasal DCs 
would be very helpful for the rational design of nasal vaccination including the choice of ‘the 
right’ adjuvant. 
 
Combine and conquer 
The major challenge in formulation of nasal vaccine formulation is to manage the interplay 
between antigen, delivery vehicle and adjuvant in such a way that the optimal response is 
obtained. The research described in this thesis addressed this challenge and has identified 
some “must do’s”, if formulation with soluble antigens such as OVA is concerned. 
 
Must do’s: 
• Add a mucoadhesive to overcome the short residence time. 
• Use small entities, to improve penetration through the nasal epithelium. 
• Add an adjuvant to overcome nasal tolerance. 





In accordance with these 4 “must do’s”, also a certain “degree of freedom” was observed 
when OVA was formulated with TMC. This could be important, as it may simplify the design of 
the formulation. 
 
Degrees of freedom: 
• The mucoadhesive can be administered in conjunction with the delivery system or in a 
free form. 
• Co-localization of adjuvant and antigen does not necessarily have to be achieved 
through the use of particles but can also be effectuated by conjugation of antigen and 
adjuvant. 
 
Combining these rules of thumb, it seems that a small, co-localized antigen-adjuvant entity 
(like a conjugate or a nanoparticle <50nm) formulated in a solution with a mucoadhesive 
(mucoadhesive in a free form) could be a very promising approach. Based on the results in this 
thesis, in general a conjugate between an antigen with MPL, would be an interesting choice as 
LPS (of which MPL is a derivate) turned out to be the best adjuvant for OVA in Chapter 10. 
MPL is a less toxic variant of LPS and already licensed for human use. With the addition of 
TMC (as a mucoadhesive and additional adjuvant) antigen-LPS conjugates may provide 
effective future nasal subunit vaccines. 
 
Into the clinic, bears on the road 
Even if such nasal vaccine formulation with a relevant antigen is successful in a laboratory 
setting transferring it to the clinic successfully, will be large effort. The lack of correlation 
between mice and man is one of the first hurdles to take. Mice have been instrumental in the 
mechanistical aspects of nasal vaccination in this thesis, but will never be able to fully predict 
the immune response in humans. For instance, a very obvious difference between mice and 
man is the size of the nasal epithelium. Relatively the nasal epithelium of mice 4 times larger 
than the human epithelium, which could cause an overestimation of the absorbance and 
residence time of the antigen in mice compared to humans. Furthermore, the murine immune 
system is different than the human immune system, like the expression patterns of PRRs and 
the secretion of different antibody subtypes. Finally, many pathogens do not cause disease in 
mice. Mouse strains susceptible for these pathogens are being developed, but still these 
models have their limitations. Mice can be useful to test for local toxicity of the vaccine. TMC 
for instance was well tolerated by all mice in this study and has recently been applied to pigs 
with no resulting damage to the nasal epithelium (unpublished data). This, in combination 
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with the high antibody titers in mice, may be convincing enough to start a first small clinical 
trial.       
Furthermore it seems imperative to keep the formulation simple. From the experience 
with the one nasal vaccine on the market (Flumist) we know nasal administration is well 
perceived by the public and especially by children [8]. However, this positive perception is only 
sustained if the costs are low. The first year Flumist was introduced only 500,000 vaccines 
were sold, whereas a year later when the price was drastically lowered the sales quadrupled 
[9]. A formulation can therefore only be commercially interesting if the antigen and adjuvant 
are readily available and the formulation is cheap, reliable and scalable. Also in this respect, 
the addition of TMC to the formulation is very feasible. The material from which TMC is 
derived, chitin, is the second most abundant polymer on earth and therefore readily available. 
Although it is a very heterogeneous substance, synthesis routes to standardize the production 
of TMC have already been established [10]. TMC is therefore also in this respect a very 
promising vaccine adjuvant. 
Finally, the pharmaceutical form will be very important. A nasal spray seems an obvious 
choice, however this would require the vaccine to be in solution. Vaccine solutions are 
generally unstable and require cold storage and imply a short shelf life. A product in dry 
powder form is much more stable and could therefore be more easily distributed; also to 
countries were maintaining the cold chain is not self-evident. Lyophilization of OVA without 
damaging its antigenic epitopes has been shown in this thesis and for various other antigens 
this technique has also been successfully applied. If a simple and cheap delivery device can be 
developed to apply the vaccine as a powder or to reconstitute the vaccine just before 
application, nasal vaccination may become the new standard in vaccination. 
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Vaccinatie via de neus, verder te noemen nasale vaccinatie, is een veelbelovend alternatief 
voor de normale injecteerbare vaccines. De neusholte is heel toegankelijk, waardoor 
eenvoudige toediening van een vaccin, bijvoorbeeld als neusspray of neusdruppels, mogelijk 
is. Het neusepitheel is bovendien uitgerust met een groot aantal immuuncellen, waardoor het 
in staat is een beschermende immuunreactie te bewerkstelligen. Ook de enzymatische 
activiteit er relatief laag (in vergelijking met bijvoorbeeld de darmen) waardoor een vaccin in 
de neus minder snel afgebroken wordt.  
Er is inmiddels al een nasaal vaccin op de markt (griepvaccin, Flumist®), wat aantoont dat 
nasale vaccinatie zeker mogelijk is. Een nadeel van dit vaccin is echter dat het berust op een 
verzwakt griepvirus. Dit is weliswaar geen probleem voor gezonde mensen, maar bij ouderen, 
baby’s en mensen met een verzwakte afweer kan dit vaccin vervelende bijwerkingen hebben. 
Tot dusver is het nog niet gelukt om een veilig en effectief nasaal vaccin te ontwikkelen dat 
slechts uit een deel (een antigeen) van een virus bestaat (subunit vaccin). In tegenstelling tot 
Flumist® zou zo’n subunit vaccin ook geschikt kunnen zijn voor jonge kinderen en ouderen 
(Hoofdstuk 1). Dit proefschrift stelt zich dan ook ten doel de mogelijkheid van nasale 
vaccinatie met subunit antigenen te onderzoeken. 
De vaccinformulering kan de sleutel zijn tot succesvolle nasale vaccinatie. Het antigeen 
moet met de nodige hulpstoffen worden voorzien om de uitdagingen die de neusholte biedt 
aan te kunnen gaan. Voor het ontwerpen van nasale vaccinformuleringen, zullen we eerst 
moeten weten welke hindernissen het antigeen zal tegenkomen vanaf het moment van 
toedienen tot aan het bereiken van een beschermende immuunsrepons. Daarom zijn in dit 
proefschrift drie doelstellingen beschreven: 
 
1. Het identificeren van de belangrijkste barrières die subunit antigenen moeten 
overwinnen om een immuunreactie op te wekken na nasale toediening. 
2. Het ontwikkelen van methoden die het mogelijk maken deze hindernissen te 
onderzoeken. 
3. Het gebruiken van de verkregen kennis om nasale vaccinformuleringen te ontwerpen 
en te testen. 
 
Het eerste doel komt aan de orde in Hoofdstuk 2, waar de fysiologie van de neus wordt 
beschreven en een stappenplan voor een succesvolle nasale vaccin wordt geïntroduceerd.  




mucuslaag (snotlaag) welke het gehele epitheel overdekt wordt elke 20 minuten vervangen, 
waarmee alles wat in en op de mucus terechtgekomen is verwijderd wordt. Dit betekent dus 
dat een antigeen slechts kort in de neusholte zal verblijven en dus weinig kans krijgt om goed 
opgenomen te worden door het neusepitheel. Formuleren van het antigeen met plakkerige 
“muco-adhesieve” stoffen, zoals natriumalginaat, carbopol, chitosaan en N-trimethylchitosaan 
(TMC), zou de nasale verblijftijd van het antigeen kunnen verlengen.  
Een tweede hindernis is de doorgang door het neusepitheel. Epitheelcellen zijn nauw met 
elkaar verbonden door zogenaamde “tight junctions”, die weinig ruimte laten voor transport 
van grote eiwitten tussen de cellen door. Het toevoegen van “tight junction openers”, stoffen 
die deze nauwe doorgangen tussen de cellen verwijden, zoals het bio-polymeer chitosaan, kan 
een tijdelijke verhoging van de doorlaatbaarheid van het epitheel veroorzaken. De 
aanwezigheid van gespecialiseerde “transportcellen”, zogenaamde M-cellen, in het epitheel 
biedt de mogelijkheid voor transport door de cel zelf heen. Zulke M-cellen transporteren bij 
voorkeur hele kleine deeltjes (nano- of microdeeltjes). Van dit feit zou men gebruik kunnen 
maken, door het antigeen in zo’n deeltje te verpakken.  
Ten slotte, wanneer het antigeen het epitheel is gepasseerd, moet het worden opgenomen 
door dendritische cellen (DCs). Dit zijn de cellen die uiteindelijk de immuunreactie initiëren. 
Net als M-cellen zijn DCs in staat nanodeeltjes op te nemen. Door aan de met antigeen 
beladen deeltjes moleculen te koppelen die zich speciaal aan DCs binden (DC-liganden), kan 
de opname door DCs vergemakkelijkt worden. Om ervoor te zorgen dat de DCs vervolgens in 
staat zijn de uiteindelijke uitvoerders van de immuunreactie, T-cellen en B-cellen, aan te 
sturen, zullen de DCs geactiveerd moeten worden. Dit kan worden bevorderd door de 
toevoeging van een hulpstof (adjuvans) aan de formulering. De keuze van het adjuvans is 
belangrijk, want het kan sterke invloed hebben op de omvang en de aard van de 
immuunreactie.  
De optimale nasale vaccinformulering zal daarom vermoedelijk bestaan uit verschillende 
componenten, zoals mucoadhesieve polymeren, M-cel- of DC-liganden en adjuvantia. Een 
effectief nasaal vaccin vraagt dus om een gecoördineerde aanpak, gericht op het vernuftig 
combineren van de benodigde componenten. 
 
Methoden om de nasale verblijftijd van het antigeen, het transport door M-cellen, de opname 
door DCs en de activering van DCs te onderzoeken, worden besproken in de Hoofdstukken 3-
4. Een celkweekmodel voor de M-cellen, gebaseerd op darmepitheelcellen samen gekweekt 
met een B-cellijn, werd beoordeeld op zijn voorspellende waarde voor het transport van 
antigenen door het darmepitheel in levende muizen (Hoofdstuk 3). Uit een studie met deze 
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M-cellen bleek dat wanneer het subunit antigeen ovalbumine (OVA) werd verpakt in 
nanodeeltjes gemaakt van het polymeer TMC, OVA gemakkelijker werd getransporteerd dan 
wanneer OVA niet in nanodeeltjes was verpakt. Dit zelfde effect werd waargenomen in 
levende muizen, wat liet zien dat het M-cel-model voorspellende waarde heeft. Tevens is in 
dit hoofdstuk een kweekmodel van DCs beschreven. Witte bloedcellen geïsoleerd uit 
menselijke vrijwilligers werden gekweekt tot DCs, waarmee de opname van een model 
subunit antigen, OVA, kon worden onderzocht. Ook hier verbeterden TMC-nanodeeltjes de 
associatie van OVA met DCs en stimuleerden ook nog eens de activering van de DCs. Dit alles 
bleek te correleren met een beduidend sterkere immuunreactie na het toediening van met 
OVA beladen TMC-deeltjes dan na het toedienen van een oplossing van OVA.  
In Hoofdstuk 4 wordt een nieuwe methode voor het bepalen van de nasale verblijftijd van 
het antigeen met behulp van een beeldvormende techniek in levende muizen geïntroduceerd. 
Drie verschillende soorten potentiële nasale vaccinsystemen, PLGA-, PLGA/TMC- en TMC-
nanodeeltjes, werden onderzocht op hun vermogen om de verblijftijd van OVA in de 
neusholte te verlengen. Van de onderzochte deeltjes bleken alleen TMC-nanodeeltjes dit te 
doen. Muizen werden daarop nasaal gevaccineerd met de drie verschillende nanodeeltjes. 
Hierbij bleek dat alleen de TMC-nanodeeltjes hoge OVA antilichaamtiters opleverden, terwijl 
na intramusculaire toediening alle deeltjes een versterking van de immuunreactie gaven. 
Hieruit kan men concluderen dat het verlengen van de nasale verblijftijd een belangrijke factor 
voor succes is en TMC-nanodeeltjes daarom interessante vaccinformuleringen zijn. Dat laatste 
blijkt eens te meer uit Hoofdstuk 5. Hier wordt de aard van de immuunreactie die TMC en 
PLGA oproepen verder onderzocht. Analyse van de T-cellen en de B-cellen laat zien dat TMC-
deeltjes zorgen voor een actieve immuunrespons met productie van antistoffen tot gevolg, 
terwijl nasale vaccinatie met PLGA-deeltjes juist leidt tot tolerantie. Dit laatste kan echter heel 
erg interessant zijn, omdat in het geval van auto-immuunziekten (bijvoorbeeld reuma, 
multiple sclerose en de ziekte van Crohn), het induceren van tolerantie wellicht een goede 
therapie zou kunnen zijn. 
 
Zoals in het stappenplan aangegeven, is het toevoegen van een adjuvans ook een 
mogelijkheid om nasale vaccins te verbeteren. In Hoofdstuk 6 wordt onderzocht hoe een 
adjuvans dan moeten worden geformuleerd. Een antigeen en een adjuvans kunnen immers 
samen of apart worden toegediend en wellicht is het zelfs een goed idee (met de studies in 
Hoofdstuk 3-5 in het achterhoofd) om het antigeen met het adjuvans samen in een 
nanodeeltje te stoppen. Een veelbelovende nasale antigeendrager zijn positief geladen 




moeten worden gecombineerd in één transportsysteem. Liposomen zijn waterbolletjes met 
een buitenlaag van fosfolipiden (vetachtige moleculen die opgebouwd zijn uit o.a. verzuren en 
glycerol). In de liposomen kunnen moleculen zoals antigenen en adjuvantia ingebouwd 
worden. Muizen werden nasaal gevaccineerd met liposomen waar OVA en het bekende 
adjuvans CpG ingekapseld waren of met oplossingen van OVA en het adjuvans CpG (zonder 
liposomen). De resulterende immuunrespons werd vergeleken met vaccinatie via andere 
toedieningwijzen (op de huid, in de huid en rechtstreeks in een lymfeklier). Inkapseling van 
CpG in liposomen bleek een nadelig effect op de immuunreactie na toediening via de neus of 
op de huid ten opzichte van toediening van een mengsel van opgelost OVA en CpG. 
Interessant is overigens dat na injectie in de huid of in een lymfeknoop van in liposomen 
ingekapseld OVA en CpG de immuunreactie wel werd verbeterd. Uit verdere bestudering van 
de lymfeklieren na nasale toediening, bleek dat het inkapselen van OVA en CpG in liposomen 
leidde tot een verminderde hoeveelheid antigeen en adjuvant in de lymfeklieren. Deze 
gegevens duiden erop dat het inkapselen in een liposoom het vervoer van antigen en adjuvant 
door het neusepitheel nadelig beïnvloedt en daardoor bij nasale vaccinatie tot een 
verminderde immuunreactie leidt. 
 
Hoofdstukken 3-5 beschrijven TMC-nanodeeltjes als een veelbelovend systeem voor 
nasale toediening van subunit antigenen. Hoofdstuk 6 laat echter zien dat nanodeeltjes ook 
moeilijkheden kunnen ondervinden bij met het passeren van het neusepitheel, vanwege hun 
relatief grote omvang. Bij elkaar opgeteld, zou men kunnen veronderstellen dat een kleiner 
construct dat nog steeds dezelfde eigenschappen als TMC-nanodeeltjes heeft, een nog betere 
keuze voor nasale toediening zou zijn. In Hoofdstuk 7 wordt deze veronderstelling getoetst. 
OVA werd chemisch, via een disulfidebinding, aan een TMC-polymeer vastgekoppeld. De 
omvang van de verkregen TMC-OVA constructen (ca. 30 nm) is aanzienlijk kleiner dan die 
vanTMC-nanodeeltjes (ca. 300 nm). Er werd vastgesteld dat op deze manier een omkeerbare 
covalente binding tussen TMC en OVA kon worden ingevoerd, onder behoud van de structuur 
van het antigeen. Opname van TMC-OVA conjugaat door DCs was vergelijkbaar met die van 
TMC/OVA-nanodeeltjes, en ruim 5 maal hoger in vergelijking met een oplossing van OVA en 
TMC. Na intramusculaire (d.w.z. in een spier) vaccinatie met TMC-OVA conjugaat 
produceerden muizen ongeveer 1000- en 100-voudig hogere OVA specifieke IgG-titers dan 
muizen gevaccineerd met respectievelijk alleen OVA en een mengsel van TMC en OVA. Het 




Net als TMC/OVA nanodeeltjes, verlengen TMC-OVA conjugaten de nasale verblijftijd van 
het antigeen (Hoofdstuk 8). De immunogeniciteit van nasaal toegediende TMC-OVA 
conjugaten werd vergeleken met die van TMC/OVA-nanodeeltjes, een oplossing van OVA en 
een mengsel van TMC en OVA. Muizen die nasaal waren vaccineerd met TMC-OVA conjugaat 
produceerden antilichamen in hun long- en neusvocht en bovendien induceerde het conjugaat 
hogere antilichaamniveaus in het bloed dan de andere formuleringen. Deze uitstekende 
resultaten met de TMC-OVA conjugaten kunnen worden toegeschreven aan een betere 
penetratie door het neusepitheel. In een kweekmodel diffundeerden de conjugaten in 
vergelijking met TMC/OVA-nanodeeltjes beter door een laag van longepitheelcellen. 
Bovendien leidde nasale toediening van conjugaten aan muizen tot hogere opname van OVA 
in de lymfeklieren in vergelijking met nasale toediening van TMC/OVA-nanodeeltjes. Kortom, 
de TMC-OVA nanoconjugaten verbeteren de penetratie van OVA door het nasale epitheel en 
verhogen zo immunogeniciteit van het antigeen. Bovendien valt hieruit af te leiden dat het 
tegelijkertijd afleveren van antigeen en adjuvant aan DCs belangrijk is voor het uitlokken van 
een immuunreactie; wellicht belangrijker zelfs dan zorgen dat het antigeen in een deeltje 
verpakt zit. 
  
Een andere manier om TMC-nanodeeltjes als nasaal transportsysteem te verbeteren is ze 
te combineren met een adjuvans. Deze benadering wordt bestudeerd in de studies 
beschreven in Hoofdstuk 9 en 10. In de vorige hoofdstukken is aangetoond dat nasaal 
toegediende TMC-nanodeeltjes de antilichaamrespons tegen het ingekapselde antigeen 
bevorderen. Echter, in sommige gevallen is de aanmaak van antilichamen niet voldoende om 
een pathogeen te bestrijden en is er ook een sterke T-celreactie nodig, bijvoorbeeld bij 
vaccinatie tegen intracellulaire bacteriën (bijv. tuberculosebacillen) of virussen (bijv. HIV of 
griepvirus). In Hoofdstuk 9 is daarom de bereiding van de TMC-nanodeeltjes gewijzigd. Terwijl 
in eerdere hoofdstukken de positief geladen TMC-polymeren fysisch verknoopt werden door 
gebruikmaking van het negatief geladen molecuul tripolyfosfaat (TPP), werd hier TMC 
verknoopt met het eerder genoemde adjuvans CpG. Dit is een negatief geladen adjuvans dat 
bekend staat om het uitlokken van een T-celreactie. TMC/CPG/OVA-deeltjes hebben 
vergelijkbare fysisch-chemische eigenschappen als TMC/TPP/OVA-deeltjes; bijv. de 
deeltjesgrootte (ca. 350 nm) en de elektrische lading (+21 mV). Nasale toediening van 
TMC/CPG/OVA- en TMC/TPP/OVA-deeltjes aan muizen resulteerde in vergelijkbare 
antistofwaarden (ca. 1000 maal hoger dan die na nasale toediening van een oplossing van 
OVA). Echter, nasale toediening van TMC/CPG/OVA-deeltjes, in vergelijking met 




antistoffen en een toename van het aantal IFN-γ producerende T-cellen. Dit toont aan dat 
TMC/CpG/OVA-deeltjes veel beter de T-cel gemedieerde immuunreactie kunnen bevorderen 
dan TMC/TPP/OVA-deeltjes. Kortom, TMC/OVA nanodeeltjes, met CpG als adjuvans en 
crosslinker, is een “all-round” vaccindragersysteem, omdat het in staat is zowel 
antistofproductie als T-celactivering te bewerkstelligen. 
 
Uiteindelijk worden in Hoofdstuk 10 naast CpG diverse andere adjuvantia beschreven in 
combinatie met TMC-deeltjes. Verschillende receptoren op DCs kunnen worden aangezet om 
de DC te activeren. Zo zijn er de zogenaamde Toll like receptoren (TLR) en  NOD-like 
receptoren die kunnen worden geactiveerd door interactie met respectievelijk TLR- of NOD-
liganden. De onderzochte TLR-liganden, lipopolysaccharide (LPS), PAM3CSK4 en CpG, en de 
NOD-2-ligand muramyl dipeptide (MDP) hebben daarom de potentie om DCs te activeren. 
Deze liganden werden samen met OVA ingekapseld in TMC-nanodeeltjes door verknoping met 
TPP. De bereiding van de deeltjes was zodanig geoptimaliseerd dat hun fysieke kenmerken 
zoals grootte en lading vergelijkbaar waren. De effectiviteit van adjuvant geladen TMC deeltjes 
werd beoordeeld door de nasale vaccinatie in muizen, in vergelijking met vaccinatie in de 
huid. TMC/OVA-nanodeeltjes met LPS of MDP ontlokten de hoogste antistof titers na nasale 
vaccinatie. Niet alle adjuvantia waren echter even effectief en hun effectiviteit bleek 
afhankelijk te zijn van de toedieningsroute. Deze studie toont aan dat de combinatie van TMC-
nanodeeltjes als dragersysteem met een adjuvans, de immuunreactie aanzienlijk kan 
verbeteren. De selectie van het adjuvant is echter niet willekeurig en hangt af van de 
toedieningsroute. 
  
Met behulp van deze bevindingen kunnen we een aantal conclusies trekken (Hoofdstuk 
11). De belangrijkste obstakels voor nasale subunit vaccins zijn, (i) de korte verblijftijd van het 
antigeen in de neus, (ii) de beperkte opname van het antigeen door het neusepitheel, (iii) de 
gelimiteerde opname van het antigeen door DCs en (iv) inductie van tolerantie. 
Deze vier punten kunnen verholpen worden door het antigeen te combineren met 
hulpstoffen of te verpakken in nanodeeltjes, maar we hebben ook kunnen concluderen dat de 
ene maatregel de ander soms tegenwerkt. Zo kan het samen inpakken van antigeen en 
adjuvans in een nanodeeltje de opname door DCs verbeteren en tolerantie voorkomen, maar 
zorgt het voor een verminderde opname door het neusepitheel. Gelukkig geldt dat niet voor 
alle obstakels. Zo lijkt het toevoegen van een plakkerige “muco-adhesieve” stof aan de 
formulering om de nasale verblijftijd van het antigeen te verlengen een eenvoudige, effectieve 
maatregel. Het lijkt niet uit te maken of de muco-adhesieve stof los wordt toe gevoegd of in 
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de vorm van een nanodeeltje. Een adjuvans daarentegen lijkt bij voorkeur wel degelijk (fysisch 
of chemisch) aan het antigeen gekoppeld te moeten zijn. Op basis van hiervan zou een ideale 
nasale formulering er dus als volgt uit kunnen zien: 
Een antigeen gekoppeld aan een adjuvans, met daaraan een muco-adhesieve stof 
toegevoegd. 
 
De mucoadhesieve stof (bijvoorbeeld TMC) verlengt de nasale verblijftijd (i). Een antigeen 
gekoppeld aan een adjuvans kan de opname door DCs verbeteren (iii) en tolerantie 
voorkomen (iv) omdat het adjuvans de DCs activeert. Omdat zo’n antigeen-adjuvansconstruct 
vrij klein is, is het ook nog eens aannemelijk dat het (in vergelijking met nanodeeltjes) beter 
wordt opgenomen door het nasale epitheel (ii). 
 
Natuurlijk is dit nu nog slechts toekomstmuziek en betreffen de bevindingen die in dit 
proefschrift beschreven zijn slechts muizenstudies, die in de praktijk wel eens afwijken van 
studies in mensen. Verder onderzoek omtrent de werking en eventuele bijeffecten van 
bijvoorbeeld TMC en adjuvantia zal moeten uitwijzen in hoeverre deze voor bruikbaar zijn 
voor de ontwikkeling van veilige en effectieve nasale vaccins voor toepassing bij de mens. Ook 
zal het productieproces en de wijze van toediening zo goedkoop mogelijk gehouden moeten 


















































List of abbreviations 
 
ANOVA  Analysis of variance 
APC   Antigen presenting cell  
Caco-2  Colon carcinoma cell 
CBF   Ciliary beat frequency  
CpG  Unmethylated C-G motif 
CS   Chitosan  
CT   Cholera toxin 
CTB    Cholera toxin beta subunit 
CTL  Cytotoxic T-lymphocyte 
DC  Dendritic cells 
DCM  Dichloromethane  
DLS   Dynamic light scattering  
FAE   Follicle-associated epithelium  
FBS   Foetal Bovine Serum  
FITC  Fluorescein isothiocyanate 
HbsAg   Hepatitis B surface antigen  
IFN-γ  Interferon gamma 
IgG  Immunoglobulin G 
IgG1  Immunoglobulin G subtype 1 
IgG2a   Immunoglobulin G subtype 2a 
IgM  Immunoglobulin G 
IL  Interleukin 
i.n.  intranasal  
ISCOM  Immune stimulatory complex 
LC   Langerhans cells  
LE  Loading efficiency 
LN  Lymphnode 
LPS  Lipopolysaccharide 
LT  Escherichia coli heat labile toxin  
M-cell  Microfold cell 
MHC  Major histocompatibility complex 
MDP   muramyl dipeptide 




NLR  NOD like recepor  
NOD  Nucleotide-binding oligomerization domain containing 
NP   Nanoparticles  
OVA   Ovalbumin 
PAM  Palmitol 
PAMP   Pathogen associated molecular pattern  
PBS  Phosphate buffered saline 
PDI  Polydispersity index 
PLGA  poly(lactic-co-glycolic acid)  
PRR  Pathogen recognition receptor 
sIgA   secretory Immunoglobulin A 
SD  Standard deviation 
SEM  Standard error of the mean 
SPDP  N-succinimidyl 3-(2-pyridyldithio) propionate 
TEER  Transepithelial electrical resistance 
Th1  T helper 1  
Th2  T helper 2 
TMC   N-trimethyl chitosan  
TLR  Toll-like receptor 
TPP  Tripolyphosphate 
UEA-1  Ulex europaeus 1 lectin 
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